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Cancer is a common, complex, and oftentimes fatal disease. Despite extensive 
research in the field of cancer drug discovery, there are still improvements to be made in 
the design of effective anticancer agents. This project involved three separate but related 
studies that fall under the category of anticancer drug discovery as a whole. The overall 
goal of this project was to design and investigate the mechanisms of action of new 
antitumor agents to be used against solid tumors. First, we developed a series of 
anthracenyl isoxazole amides (AIMs) designed to bind to G-quadruplex DNA and inhibit 
telomerase. Results from this study demonstrated an alternative mitochondrial 
mechanism of action of the AIMs not yet fully described in the literature. Investigation of 
lead compound AIM 1 showed localization of the AIM in mitochondria with resulting 
induction of apoptosis, generation of mitochondrial superoxide, disruption of 
mitochondrial membrane potential, and activation of caspase-9. The second goal of this 
project was to assay a series of 4-isoxazolyl-1,4-dihydropyridines (IDHPs) that function 
as P-gp inhibitors to determine their contribution to enhanced cytotoxicity of the AIMs 
when co-dosed together in vitro. Because so many anticancer agents are substrates for P-
gp and are therefore limited in their ability to reach intended targets, the development of 
P-gp inhibitors is an important area of research. Results from this study indicate that 
IDHPs are a viable class of P-gp inhibitors that can be co-dosed with P-gp substrates to 
increase substrate cytotoxicity. The third goal of this study was to determine the NQO1 
substrate potential of a series of lavendamycin derivative quinolinequinones and assess 
their corresponding antitumor potential. Surprisingly, few of the quinolinequinones tested 
showed preferential specificity for NQO1-expressing cells compared to NQO1-null cells. 
However, in our series of aryl-substituted quinolinequinones, the active molecules appear 
to be the quinone derivatives and not derivatives of hydroquinones or semiquinones. 
These data suggest a mode of action that differs from that of previously studied 
lavendamycin analogues that are activated by NQO1 reduction. While this project 
focused on the general targeting of solid tumors, the type of tumor explicitly studied 
varied from brain cancer to breast cancer and encompassed multiple drug targets. 
Collectively the results of this study are expansive and offer much to the field of targeted 
drug discovery. 
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CHAPTER 1: INTRODUCTION 
Brain Cancer  
Overview 
  The National Cancer Institute estimates that approximately 23,000 people in the United 
States will be diagnosed with cancer of the brain and central nervous system in 2013 and of those 
diagnosed, it is predicted that over half will die from the disease. Primary brain tumors represent 
approximately 2% of adult cancers and 23% of childhood cancers (Marie and Shinjo, 2011). The 
most common and most aggressive primary brain tumor, glioblastoma multiforme, is particularly 
difficult to treat and patients diagnosed with this subset of brain cancer, have a median survival 
time of only 15 months (Bleeker and Molenaar, 2012). Despite poor prognoses, compared to 
other malignancies, there have been only small advancements made in the pharmacologic 
intervention and treatment of glioblastoma. The standard treatment has remained the same for 
many years—newly diagnosed cases of glioblastoma are managed with a combination of gross 
tumor removal or resection followed by radiation and the highly cytotoxic DNA methylating 
agent temozolomide (Westermark, 2012). Treatment is most often ineffective due to failure to 
completely resect the tumor on account of poor cellular differentiation and invasiveness, drug 
resistance, and subsequent aggressive tumor metastasis to other areas of the body (Candolfi et 
al., 2011).  
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Glioblastoma classification and development 
  Similar to other cancers, glioblastoma results from accumulated genetic and epigenetic 
alterations, characterized by genetic instability and complex alterations in both chromosome 
copy number and structure (Volgstein and Kinzler, 2004). Historically, glioblastoma treatment 
was based on histopathological classification of the tumor (cell type and morphology, presence 
of necrosis or microvascular proliferation), however, this type of diagnosis is quickly being 
supplemented with treatment strategies based on mutational and amplification characterization of 
the individual’s tumor (Dunn et al., 2012). Due largely to wide genomic studies of glioblastoma, 
common genetic alterations as well as molecular subclasses and commonly mutated biochemical 
and signaling pathways have been uncovered. To date, glioblastoma has been studied the most 
extensively under genomic profiling conditions and yet successful treatment options remain 
elusive. 
  Primary glioblastomas that arise de novo most often exhibit dysfunctions in the tumor 
suppressor proteins p53 and retinoblastoma protein (Rb), as well as abnormalities of the 
RTK/Ras/PI3K signaling pathway, allowing tumor growth to go cellularly unchecked and 
unregulated (Dunn et al., 2012). Another commonly mutated protein, epidermal growth factor 
receptor (EGFR) has been widely studied for its role in the development of glioblastoma. EGFR, 
a cell surface receptor responsible for intrinsic intracellular protein-kinase activation and 
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downstream signaling resulting in eventual DNA synthesis and cellular proliferation, is 
overexpressed in over 50% of primary glioblastoma and is associated with particularly poor 
prognosis in those patients presenting with EGFR mutations (Hurtt et al., 1999). Ligands 
associated with the platelet-derived growth factor (PDGF) receptor pathway are also commonly 
mutated, with over 30% of primary glioblastoma cases involving up-regulation of these proteins 
(Dunn et al., 2012). Alterations in the PDGF signaling pathway has been found to promote 
aggressive glioma growth and is attributed to tumor angiogenesis. Additionally the phosphatase 
and tensin homolog (PTEN) is one of the most frequently mutated genes in all cancers and is 
responsible for antagonizing PI3K signaling and the downstream effects responsible for halting 
cell division and driving cells into apoptosis. PTEN undergoes genomic loss, mutation or 
epigenetic inactivation in upwards of 50% of gliomas, resulting in increased cellular proliferation 
and reduced apoptosis (Koul, 2008). Although there are many biochemical alterations that occur 
and are yet to be discovered, the ability to describe and characterize glioblastoma tumors by their 
genetic makeup and molecular changes is a promising approach to the design of new therapeutic 
strategies. Induction of apoptosis is also an important factor in the targeting of glioblastoma and 
other tumors and is an effective means by which to eliminate cancer cells following 
administration of chemotherapeutic agents. 
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Apoptosis 
Overview 
  The term apoptosis, or programmed cell death, first appeared in the literature in 1972 as a 
means of describing a mode of cellular death morphologically distinct from the inflammatory 
and non-signal transduction pathway of cell death—necrosis (Kerr et al., 1972). Morphologic 
changes indicative of apoptosis include cell membrane blebbing, cell shrinkage, chromatin 
condensation and nucleosomal fragmentation (Ricci and Zong, 2006). Apoptosis is a vital and 
complex manner of cell death via programmed cell suicide and is the cornerstone in maintaining 
homeostasis during development. Apoptosis is also recognized as one of the major barriers that 
must be overcome by tumor cells that allow them to survive and thrive under hostile conditions.  
There are two major modes of initiating the apoptosis cascade: the intrinsic pathway and the 
extrinsic pathway; both result from activation of a series of proteins and enzymes belonging to 
the family of 14 cysteine proteases termed caspases. The intrinsic pathway of apoptosis involves 
mitochondrial dysfunction while the extrinsic pathway is associated with stimulation of cell 
membrane death receptors—both pathways converge at caspases-3 and from there follow a 
common activation process of executioner caspases (Mita et al., 2008). Intracellular stress, such 
as high levels of reactive oxygen species (ROS) or DNA damage, is a typical activator of the 
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intrinsic pathway of apoptosis. In contrast, the extrinsic pathway requires for activation the 
binding of extracellular ligands (such as TNF-α) to plasma membrane bound receptors (Figure 
1.1).  
  Apoptosis is a tightly regulated process involving both pro-apoptotic and anti-apoptotic 
factors for homeostatic balance. Under normal conditions, apoptosis functions as a protective 
means to remove genetically or otherwise damaged cells to prevent uncontrolled proliferation or 
tumorigenesis following unregulated mitogenic stimuli. A failure of cells to undergo apoptosis 
through evasion or acquired mutations, combined with maintenance of self-sufficient growth 
signals, insensitivity to anti-growth signals, tissue invasion and metastasis, limitless replicative 
capacity, and sustained angiogenesis, represents key features in the development and progression 
of cancer.  
The extrinsic apoptotic pathway 
  The extrinsic pathway of apoptosis is activated by two groups of proteins: the tumor 
necrosis factor family (TNF) and the receptors that bind them. Not all TNF ligands signal 
apoptosis—some proteins function solely to activate molecules associated with induction of 
proinflammatory signals. TNF ligands ultimately responsible for apoptosis include TNF-α, 
CD95L (or FasL), and TNF receptor apoptosis-inducing ligand (TRAIL, or Apo2L) (Peter and 
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Krammer, 2003). In the case of Fas or TNF, once ligand binds receptor, recruitment of the 
adaptor protein Fas-associated death domain-containing protein (FADD) occurs. Bound FADD 
in turn recruits initiator caspases (in this case pro-caspase-8) and this assembly of proteins 
becomes the death-inducing signaling complex, DISC (Ricci and Zong, 2006). Inhibitory anti-
apoptotic proteins can also block this process. 
The intrinsic apoptotic pathway: mitochondrial-mediated apoptosis 
  One of the key features of the intrinsic pathway of apoptosis is the release of cytochrome 
c from the mitochondrial intermembrane space into the cytosol. Cytosolic cytochrome c binds 
Apaf-1, a cytosolic protein containing a caspase-recruitment domain (CARD), creating 
oligomerization and formation of the apoptosome (Wang, 2001). The Apaf-1/cytochrome c 
complex subsequently recruits pro-caspases-9 (to be cleaved to its active form caspases-9) and 
downstream activation of the executioner pro-caspases-3 (to be cleaved to active caspases-3). 
Active caspases-3 (regardless of its activation via the external or intrinsic pathway of apoptosis) 
initiates end stages of the apoptotic cascade through the cleavage of substrates leading to the 
characteristic morphological cellular features of apoptosis, as well as externalization of 
phosphatidylserine, a classic feature of apoptosis. Important upstream regulators of cytochrome c 
include Bax, Bak, Bik, Bad, and Bid (inducers of cytochrome c release) and Bcl-2 and Bcl-xL, 
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(suppressors of cytochrome c release). These proteins make up the Bcl-2 family of proteins, 
important mediators of mitochondrial-mediated apoptosis. Tumor suppressor protein p53 directly 
interacts with members of the Bcl-2 family to regulate apoptosis (Hanahan and Weinberg, 2000). 
Although mitochondrial events of apoptosis commit a cell to die, as with the extrinsic pathway of 
apoptosis, these events can be blocked downstream by anti-apoptotic proteins that interfere with 
or inactivate caspases (Kasibhatla and Tseng, 2003).  
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Figure 1.1 
 
Figure 1.1. Extrinsic and intrinsic pathways of apoptosis. The two major apopotosis 
pathways. The extrinsic pathway is initiated by ligand binding to death receptors on the plasma 
membrane. The intrinsic pathway is activated by intracellular signals. Both pathways lead to 
activation of caspases (Li and Sheng, 2012). 
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Non-apoptotic methods of cell death 
 Although programmed cell death is vital to maintenance of normal cell functioning, non-
apoptotic mechanisms also exist and can contribute to tumorigenesis when processes are 
disrupted. As previously mentioned, necrosis is a non-apoptotic and less controlled mode of cell 
death characterized morphologically by cytoplasmic vacuolization, loss of membrane integrity 
and cellular swelling (De Bruin and Medema, 2008). Necrosis results in the activation of 
inflammatory responses due to the release of cellular components into the microenvironment. An 
increase in localized inflammation also occurs following the necrosis of malignant cells. In 
contrast to necrosis, another non-apoptotic process, autophagy, is the degradation of proteins and 
organelles by lysosomal proteases. The major characteristic of autophagy is the fusion of 
autophagasomes (double membrane vesicles containing cytosolic organelles) with lysosomes, 
providing not only a means of cellular degradation but also an alternative source of nutrients for 
cells (De Bruin and Medema, 2008).  In cancer, autophagy may prevent the malignancy of 
normal cells by degrading damaged organelles and reducing cellular stress, or by eliminating 
proteins that enhance tumor formation (Edinger and Thompson, 2003). Lastly, mitotic 
catastrophe is another means of cell death, distinctly different from those previously mentioned. 
Anomalous mitosis will cause mitotic catastrophe and results in deficient cell cycle checkpoints, 
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ultimately leading to enlarged and multinucleated cells, incomplete nuclear condensation, 
chromosome alignment defects, nondisjunction, or mitosis in the presence of DNA damage 
(Roninson et al., 2001). In tumorigenesis, mitotic catastrophe can function to effectively 
eliminate cells entering mitosis with damaged DNA to reduce the likelihood that these defective 
cells will divide or acquire additional mutations that allow them to become tumorigenic.  
Pharmacologic targeting of the apoptotic pathway as anticancer therapy 
Resistance to apoptosis is closely linked to the development of cancer as a failure of 
damaged or malignant cells to undergo apoptosis allows them to expand into the interstitium. 
Preventing cancer cells from evading apoptosis has led to the development of small molecule 
drugs designed to target a wide range of pathways involved in cell death and apoptosis. The 
challenge in developing anticancer agents lies in identifying and exploiting the differences 
between normal non-cancerous cells versus cancerous cells and targeting of the various 
components of apoptosis (or other means of cell death) represents a viable method to do this. 
First generation chemotherapeutic agents rather indiscriminately cause cancer cell death by 
interfering with cell division or DNA synthesis and cell function. These drugs include: alkylating 
agents (such as cisplatin or cyclophosphamide), which cause DNA damage and ultimately cell 
death, anti-metabolites (mercaptopurine) that interfere with cell cycle and division, vinca 
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alkaloids (such as vincristine or vinblastine) that inhibit normal tubulin formation to disrupt cell 
cycle, taxanes (paclitaxel) that disrupt anaphase, topoisomerase inhibitors (such as topotecan or 
etoposide) causing inhibition of topoisomerase I or II leading to DNA damage, and anticancer 
antibiotics (such as doxorubicin or bleomycin) that can cause DNA damage through a variety of 
mechanisms including intercalation and formation of DNA crosslinks. Drugs developed to 
induce cancer cell apoptosis are designed to overcome the abnormal evasion of apoptosis and can 
target potentially any component of the apoptosis cascade. Common approaches include: the use 
of inhibitors against Bcl-2 proteins (fenretinide), drugs aimed at destabilizing or restoring mutant 
p53, caspases activators (which may be used in conjunction with more traditional 
chemotherapies to increase drug sensitivity), and small molecule antagonists of apoptosis-
inhibitor proteins (Wong, 2011). While all of these methods have the potential to impact the 
viability of normal cells, the likelihood of inducing apoptosis in normal cells with therapy 
becomes less likely as more specific characteristics of cancer cells are identified and drugs are 
developed to only affect a specific component of the tumor cell. Although the targeting of 
apoptosis and apoptosis associated proteins represents a viable means of targeting cancer cells, 
there are other (and perhaps more specific) methods for anticancer drug therapies currently being 
investigated. 
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G-quadruplex 
Overview 
As mentioned previously, there are many chemotherapeutic agents currently being used 
to target DNA to damage and ultimately kill tumor cells. It is now recognized, however, that 
DNA structures exist outside of normal B-DNA that represent a feasible target for new 
anticancer drugs. Of particular interest are G-quadruplex (G4) DNA motifs, which adopt 
structures outside of normal Watson-Crick hydrogen bonding in duplex DNA formation. G-
quadruplex structures are higher order DNA and RNA structures formed from guanine-rich 
sequences that can adopt a non-canonical, four-stranded topology. These guanine rich DNA 
sequences form quadruplex structures stabilized by guanine tetrads (G-G-G-G repeats), 
monovalent cations (notably Na+ and K+), and Hoogsteen hydrogen bonding (Burge et al., 2006). 
Once a quadruplex is formed, it is very stable. Quadruplex can take on several different 
directionalities based on the arrangement of the backbone that constitutes the G-tetrad core 
(parallel versus antiparallel), by the syn or anti glycosidic bond arrangement of the guanines in 
the G-tetrad, the length and specifics of the G-G connecting loops, intra- or inter-molecular 
nature of the structure, and by the number of guanine tetrads (Sissi et al., 2011) (Figure 1.2). G-
quadruplex also function similarly to a molecular switch in that changes in the experimental 
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conditions or the introduction of G4 ligands into the environment can cause the quadruplex to 
fold or unfold. G-quadruplexes have been shown to form not only in humans, but other species 
as well, including yeast (Johnson et al., 2008). The properties of quadruplex structure and 
function are even more intriguing considering their biologic significance—G-rich sequences 
have been found in specific regions of the genome and are over-represented in cells under certain 
physiologic conditions and disease states, including cancer.  
In the context of cancer, it was first discovered that telomeres could form quadruplex and 
interfere with telomerase functioning, and more recently it has been found that there is 
disproportionately high expression of G-rich sequences in promoter regions of genes vital to cell 
signaling, especially proto-oncogenes (Balasubramanian et al., 2011). These findings provide 
reasonable basis for the study and development of small molecule inhibitors that recognize and 
stabilize quadruplex in tumor cells. 
Telomeric G-quadruplex 
Telomeres are specialized and complex ribonucleoprotein structures that cap the ends of 
eukaryotic chromosomes. Since 1941, it has been known that telomeric structures are necessary 
for maintaining the integrity of chromosomes (McClintock, 1941). Telomeres function to protect 
internal chromosome sequences by preventing the improper activation of DNA damage-response 
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pathways (Lipps and Rhodes, 2009). In humans, telomeres consist of tandem repeats of G-rich 
sequences (TTAGGG) with a total length of up to 12 kb (Gunaratnam and Neidle, 2010).  
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Figure 1.2 
 
Figure 1.2 G-quadruplex structure. A Chemical structure of the G-quartet, the base unit of a 
G-quadruplex with a monovalent cation at its core. B Multiple layers of G-quartets stack on top 
of each other to form a G-quadruplex with various arrangements (adapted from Oganesian and 
Bryan, 2007). 
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Telomeric DNA is normal duplex DNA except for the final 100-200 3’-terminal residues, which 
are single stranded (Gunaratnam and Neidle, 2010). These single stranded overhangs, containing 
G-repeats, have been shown to fold intramolecularly upon themselves to form G-quadruplexes 
(Tang et al., 2008). In normal somatic cells, telomeres progressively shorten at each round of cell 
division until reaching the Hayflick limit—the point at which cell division stops and cells can no 
longer replicate. Upon reaching the Hayflick limit, cells become senescent, a phase that under 
normal conditions precedes apoptosis. In over 80% of cancers, however, senescence is not 
achieved due to activation or up-regulation of the enzyme telomerase (Shay and Bacchetti, 
1997). 
Telomerase is a specialized reverse transcriptase enzyme that catalyzes the synthesis of 
TTAGGG repeats and adds these sequences to the end of chromosomes during replication to 
maintain telomeric DNA length. Telomerase is inactive in most somatic cells, but can be 
detected in germ cells and fetal tissue. In cancer cells, active telomerase prevents the progressive 
shortening of telomeres that would prime cells to enter apoptosis and instead enables these cells 
to replicate indefinitely. Because the single stranded overhang of telomeres is capable of forming 
G-quadruplex, small molecule inhibitors have been made to bind to and stabilize G-quadruplex 
in this region and prevent telomerase from extending or maintaining telomere length (Figure 
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1.3). The inhibition of telomerase by G-quadruplex inhibitors was first demonstrated in vivo 
using amidoanthraquinone analogues (Sun et al., 1997). Since the first use of 
amidoanthraquinone molecules as G-quadruplex stabilizers, a large number of small molecules 
have since been developed and tested for their telomerase inhibition efficacy. Results of these 
studies and additional experimentation with porphyrins, perylenes, various acridine derivatives 
and others have consistently shown that G-quadruplex stabilization can lock telomeric DNA in a 
G-quadruplex conformation and lead to inhibition of telomerase, resulting in telomere shortening 
and senescence in cell based assays (Monchaud and Teulade-Fichou, 2008).  
hTERT 
In the mid 1990s, the genes encoding the two major components of human telomerase 
were cloned—the RNA hTERC subunit and the catalytic functional portion hTERT (Feng et al., 
1995; Nakamura et al., 1997). Although the critical components of human telomerase are 
hTERC and hTERT, other subunits exist, including dyskerin and telomerase protein component I 
(Tep1). While the elements of telomerase such as dyskerin are important, only hTERT has been 
found to be essential in restoring telomerase activity in telomerase-negative normal cells, such as 
human fibroblasts (Artandi et al., 2002). Although telomerase expression and more specifically 
hTERT is correlated with almost all cancers, recent evidence suggests a non-telomeric role for 
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hTERT in tumorigenesis; hTERT has been found to be involved in extra-telomeric functions 
such as regulation of gene expression, growth factors, and cellular proliferation (Smith et al., 
2003; Li et al., 2005). Additionally, hTERT is capable of shuttling from the nucleus to the 
mitochondria upon exogenous stress (Santos et al., 2006; Haendeler et al., 2003). It appears as 
though hTERT translocation to the mitochondria is a protective mechanism–shuttling occurs 
following cellular stress (ROS generation, radiation) and confers resistance to apoptosis, 
although it may not be in and of itself the sole factor in determining entry into apoptosis.  
Instead, hTERT shuttling to the mitochondria may reduce overall cellular stress by aiding in the 
reduction of nuclear DNA damage and by decreasing oxidative stress within the mitochondria 
(Singhapol et al., 2013). In hTERT over-expressing cells (such as cancer cells), studies have 
shown that under conditions of stress, mitochondrial DNA (mtDNA) is protected, mitochondrial 
membrane potential is increased and mitochondrial superoxide production and cell peroxide 
levels are decreased, all indicating improved mitochondrial function in these cells (Ahmed et al., 
2008). Several oncogenes, including c-Myc and c-Jun, induce hTERT expression, while tumor 
suppressor proteins such as p53 reduce the expression of hTERT (Takakura et al., 2005; Xu et 
al., 2000). In this regard, hTERT mitochondrial translocation may be a factor in drug resistance, 
providing a means by which cancer cells evade apoptosis by protecting against nuclear DNA 
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damage and reducing mitochondrial stress following drug treatment (Singhapol et al., 2013).  
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Figure 1.3 
 
Figure 1.3. Structure and biological roles of telomeres. Repair mechanisms or telomerase 
reactivation is triggered by telomere shortening or damage. While repair or reactivation in excess 
would induce or trigger tumorigenesis, G4 ligands could induce or stabilize the G-quadruplex 
structure in this region and thus block telomerase from binding to the terminal single-stranded 
end of telomeres. (Ou et al., 2008). 
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Although the extra-nuclear non-telomeric functions of hTERT in the mitochondria 
remain controversial, if hTERT expression is higher in cancer cells compared to normal 
counterparts, and expression of hTERT confers survival advantage to these cells, then the 
targeting of hTERT by small molecule inhibitors represents a feasible anticancer therapeutic 
target. Indeed, inhibition of telomerase and hTERT can selectively trigger apoptosis in cancer 
cells and can also facilitate apoptosis by sensitizing cells to more traditional chemotherapies such 
as cisplatin, etoposide and mitomycin C (Massard et al., 2006). As previously mentioned, G-
quadruplex ligands can be designed to inhibit telomerase through the stabilization of G-
quadruplex within sections of the telomeres. Some telomeric directed G-quadruplex ligands, 
however, have been shown to induce cell senescence in the absence of telomere shortening, 
which suggests alternate mechanisms of actions in the presence of telomeric G-quadruplex 
stabilization (Pennarun et al., 2005; Zhou et al., 2009). In this regard, recent experimentation 
with two commercially available G-quadruplex ligands DODC and TMPyP4 induced hTERT 
translocation from the nucleus to the mitochondria, were capable of inhibiting telomerase and 
caused mitochondrial effects (reduced mitochondrial membrane potential, induction of 
apoptosis) consistent with disruption of mitochondrial function in cancer cell lines (Zhuang and 
Yao, 2013). Although these data are not necessarily G-quadruplex specific, they do support the 
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notion that hTERT functions in a more complex manner than just effecting telomerase in the 
nucleus, and also links G-quadruplex ligands to disruption of mitochondrial regulation as a 
mechanism of action. Additional research investigating G-quadruplex drug design should focus 
more broadly outside of just capacity for G-quadruplex stability and binding to include more 
finite molecular pathways leading to eventual apoptosis. 
G-quadruplex in gene promoters 
The most studied G-quadruplex forming region in a gene promoter is in that of the proto-
oncogene c-MYC. Up to 80% of all solid tumors overexpress c-MYC, including brain tumors 
(Eilers and Eisman, 2008; Lutz et al., 2002). Research has shown that transcriptional repression 
of c-MYC occurs by targeting a G-quadruplex in the nuclease hypersensitive element (NHE) 
within the promoter region (Siddiqui-Jain et al., 2002). As discussed earlier, G-quadruplex can 
be formed from four separate strands of DNA into a tetramolecular arrangement. However, 
arrangements can also include two separate strands of DNA (bimolecular) or a single strand of 
DNA (unimolecular)—the most common formation in gene promoters is a continuous stretch of 
G-quadruplex sequences with four or more G-tracts that fold unimolecularly (Balasubramanian 
et al., 2011). Of note structurally as well, in contrast to telomeric G-quadruplexes which can be 
formed from the single stranded overhang at the 3’ end of telomeres, G-quadruplex in gene 
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promoter regions are constrained by duplex DNA structure (Balasubramanian et al., 2011). 
Complexities in G-quadruplex structure and arrangement make modeling ligand/G-quadruplex 
binding a challenge, but also strengthen the hypothesis that many other G-quadruplex may exist 
in gene promoter regions. Indeed, in addition to c-MYC, proto-oncogene KIT has received 
attention for the discovery of regions within the gene that have been identified as forming G-
quadruplex. KIT encodes a receptor tyrosine kinase that once activated stimulates cellular 
proliferation and differentiation and promotes cell survival (Yarden et al., 1987). Because high 
activity of the protein KIT has been implicated in cancers, notably gastrointestinal stromal 
tumors, KIT has been the target of specific kinase inhibitors such as imatinib and sunitinib 
(Balasubramanian et al., 2011). Upon discovery of G-quadruplex forming regions within 
promoter areas of KIT, research began to focus on the design of small molecule G-quadruplex 
stabilizers to target these regions. An advantage to the targeting of KIT in terms of G-quadruplex 
research is that KIT is already the focus of clinically relevant and established chemotherapy. 
Additional research in the area of KIT and other oncogenes is vital to understanding binding and 
stabilization of G-quadruplex in gene promoter regions and furthering drug design in this area. 
G-quadruplex ligand features and druggability 
As previously discussed, G-quadruplex can form varying structures depending on the 
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cellular location and features of the microenvironment, such as presence and type of cation 
within the central channel. Despite the vast array of conformations possible, there are common 
features among G-quadruplex structures that allow for specific design of ligands. A structural 
element that is conserved through all G-quadruplex is the large planar surface of the terminal G-
quartet. This characteristic of G-quadruplex has led to the development of small molecules 
containing a heteroaromatic system that complements the G-quartet platform and encourages 
proper orientation upon binding (Balasubramanian et al., 2011). The challenge in design of G-
quadruplex ligands is the development of small molecule drugs that will specifically recognize 
discrete G-quadruplex structures and bind with high affinity. G-quadruplex ligands can be 
promiscuous in nature and if not specific enough for their target, can recognize single stranded or 
duplex DNA in addition to interacting with G-quadruplex DNA. However, structural selectivity 
for known G-quadruplexes can be achieved for example, by exploiting the steric hindrance 
imposed on ligands by loops (such as the T-loop formation that is found in telomeric G-
quadruplex)—a result of ligand inaccessibility to the G-quartet platform. Identifying the location 
of grooves and loops within the G-quadruplex of interest provides an opportunity to model 
ligands to fit into specific binding pockets and increases the likelihood of specificity towards that 
G-quadruplex. Although creating specialized ligands is challenging, several drugs have recently 
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shown promise.  
Telomestatin, a natural product analog isolated from Streptomyces anulatus 3533-SV4, is 
a promising G-quadruplex ligand that has shown good specificity towards telomeric G-
quadruplex DNA (Shin-Ya et al., 2001). In vitro, telomestatin is a potent telomerase inhibitor 
and has an EC50 of 5nM.  Additionally, telomestatin is a very specific ligand for the human 
intramolecular basket-type G-quadruplex conformation and has approximately a 70-fold greater 
affinity for G-quadruplex DNA over single stranded or duplex DNA (Rezler et al., 2005). 
Another auspicious G-quadruplex ligand that has received scientific attention is quarfloxin. 
Quarfloxin reached Phase II clinical trials for the treatment of neuroendocrine carcinomas and is 
considered to be a relatively specific G-quadruplex ligand for c-MYC. Initial studies with 
quarfloxin demonstrated topoisomerase II interactions and consequently decreased specificity for 
G-quadruplex DNA. Cyclene Pharmaceuticals (San Diego, CA, USA) led the optimization of 
quarfloxin into the final drug design, which expanded a planar system to force better interactions 
with the tetrad in G-quadruplex DNA compared to duplex DNA. DNA groove binding arms 
were also added to the quarfloxin structure to decrease selectivity for topoisomerase II and 
increase specificity towards G-quadruplex within the promoter areas of c-MYC. Quarfloxin 
disrupts the interaction between the nucleolin protein and a G-quadruplex DNA structure located 
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within ribosomal DNA, causing inhibition of RNA polymerase I transcription leading to 
relocation of nucleolin to the nucleoplasm and subsequent inhibition of c-MYC through 
alterations in c-MYC expression. Tumor cells ultimately undergo apoptosis following treatment 
with quarfloxin (Balasubramanian et al., 2011).  
 
 
Barriers to effective drug treatment 
Overview 
All pharmacotherapy for treatment of brain and central nervous system cancers are 
limited by the blood-brain barrier (BBB). In glioblastoma for instance, in order for 
chemotherapeutic agents to gain access to the target tissue in the brain, the drug needs to be able 
to move across the BBB and overcome the physicality of the BBB in addition to export by 
transporters. The BBB serves to protect the brain from toxicants by providing a physical barrier 
between the brain and systemic circulation. The endothelial cells of the brain contain a wide 
array of transporters that regulate their movement across the BBB and into the brain. The ATP-
binding cassette (ABC) superfamily of efflux transporters is the main class of multidomain 
integral membrane proteins that are responsible for the efflux of many drugs out of the brain 
(Figure 1.4). ABC transporters expressed at the level of the BBB include p-glycoprotein 
(ABCB1 or P-gp), MRP1 (ABCC1), MRP2 (ABCC2), MRP3 (ABCC3), MRP4 (ABCC4), 
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MRP5 (ABCC5), MRP6 (ABCC6), and BCRP (ABCG2). Although each transporter is capable 
of exporting any drug that is a substrate for it, one of the most studied and frequently implicated 
in cancer is P-gp. 
P-glycoprotein 
 P-gp was first discovered in the 1970s and studied as the prototypical transporter 
involved in multidrug resistance in cancer cells (Juliano and Ling, 1976). There are two types of 
human P-gp: Type I (MDR 1 P-gp, herein denoted as P-gp) encoded by the MDR1 gene, that 
confers the drug resistance phenotype at the BBB and Type II, encoded by the MDR2 gene, that 
is present not at the BBB, but in the canalicular membrane of hepatocytes and that functions as a 
phosphatidylcholine translocase (Demeule et al., 2002). P-gp, like other members of the ABC 
transporter family, uses the energy of ATP hydrolysis to translocate solutes across the cellular 
membrane. The molecular structure of P-gp includes four domains: two nucleotide-binding 
domains and two transmembrane domains. The cytosolic nucleotide-binding domains bind to and 
hydrolyze ATP, whereas each of the transmembrane domains consist of six transmembrane 
helices that together form the substrate or drug binding sites (Sauna and Ambudkar, 2007). 
It has been suggested that the following are the minimum events that occur in regards to P-gp 
function: initial binding of ATP and/or substrate, conformational changes at the nucleotide-
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binding domains following ATP binding and/or hydrolysis, transmission of the conformational 
changes at the nucleotide-binding domains to the transmembrane domains to effect an affinity 
switch (low or high) at the drug binding site, and then the subsequent resetting of the transporter 
back to the original conformation (Sauna and Ambudkar, 2007). At the subcellular level, P-gp is 
expressed at the apical membrane of brain capillary endothelial cells in humans—drugs that are 
substrates for P-gp enter the endothelial cells from circulation and are immediately pumped back 
into the blood, preventing them from reaching their site of action in the brain.  
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Figure 1.4 
 
Figure 1.4. Efflux transporters. Localization of selected drug efflux proteins on brain capillary 
endothelial cells that form the blood-brain barrier. Only transporters that are localized on the 
apical (luminal) side of the brain capillary endothelium would be in a position to restrict brain 
uptake of xenobiotics (adapted from Loscher and Potschka, 2005). 
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There are many anticancer drugs that are P-gp substrates, notably doxorubicin, paclitaxel, 
methotrexate, vincristine, and etoposide (Loscher and Potschka, 2005). Therefore, using these 
drugs in clinical practice can be problematic because the efflux properties of P-gp at the BBB for 
P-gp Type II dramatically reduces the net penetration of these drugs at their site of action. Also, 
aside from their normal functioning as efflux transporters under physiologic conditions, ABC 
transporters, especially P-gp, have been found to be overexpressed in a variety of human 
diseases, including cancer (Leonard et al., 2003). This overexpression can lead to the drug 
resistance encountered upon treatment with anticancer agents and leads to ineffective 
chemotherapy treatment. P-gp inhibitors are now being designed to prevent drug resistance and 
increase drug absorption at the designated site of action. 
P-glycoprotein inhibitors 
The development of P-gp inhibitors (or multidrug resistance, MDR, modulators) is a 
viable means to block the function of P-gp and encourage drug accumulation at the drug target 
sites of action. First generation P-gp inhibitors were found to have inhibition activity after 
already being used clinically for other conditions and include the calcium ionic channel blockers 
verapamil and diltiazem, the immunosuppressive agent cyclosporine, and tamoxifen, an estrogen 
receptor antagonist. When these drugs were examined in vitro for their inhibitory properties, 
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some produced almost complete P-gp inhibition and reversed the multidrug resistant effects, 
however, all of the first generation P-gp inhibitors were deemed minimally effective, non-
specific and toxic when used in vivo. The issues of promiscuous binding and toxicity have 
plagued the progression of the field of P-gp inhibitors to be used clinically, but several 
pharmacophore models have provided insight into properties required for drug resistance 
reversal and complete P-gp inhibition. These include: liposolubility with hydrophobic centers, 
cationic species or a basic center in the physiologic range for pH, at least two coplanar aromatic 
rings and hydrophobic substituted aromatic rings to increase activity, and appropriate hydrogen 
bond acceptors (oxygen or nitrogen) and/or hydrogen bond donors (OH or NH groups) with 
appropriate spacial separation (Yang et al., 2008). The development of P-gp inhibitors for 
concomitant use with anticancer agents is an important field of study with potential to create 
comprehensive cancer treatment that is effective and minimally toxic systemically. 
Alternative anticancer drug targets 
As mentioned previously, anticancer drugs are designed to be cytotoxic only to cancer 
cells, while exerting minimally toxic effects to normal healthy tissue. In order to develop 
effective anticancer therapies, it is necessary to identify differences between normal cells and 
cancer cells to target these metabolic or biologic alterations and exploit them for therapeutic 
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purposes. In regards to the design of new drugs, if the crystal structure of a potential drug target 
has been elucidated then structure-based ligand design is an effective approach to drug 
development. 
NQO1 
Overview 
 NAD(P)H:quinone oxidoreductase 1 (NQO1 or previously DT-diaphorase) is an enzyme 
responsible for the detoxification of toxicants or quinone-based compounds that are substrates 
for the enzyme. Early research suggested that NQO1 enzymatic activity is protective upon 
carcinogen exposure—NQO1 expression was induced following carcinogen treatments and 
reduced accumulated harmful effects following repeat exposure (Huggins, 1979). It is also 
known however, that some quinone substrates are inactive until they are reduced by NQO1 and 
then become toxic. This effect—in which an inactive or essentially nontoxic compound functions 
as a prodrug that gains activity only upon enzymatic reduction—is an important feature in the 
field of enzyme-directed bioreductive drug design. In the 1970s, bioreductive activation was 
hypothesized to occur because of the location of hypoxic cells proximal to necrotic cores of solid 
tumors that would potentiate reductive metabolism based drug activation in these cells 
selectively over normal aerobic cells (Lin et al., 1972). Agents that undergo bioreductive 
activation can generate ROS through redox cycling or be reduced by one and two-electron 
	  
	  
  
33	  
reductases to alkylating agents capable of cross-linking DNA (bioreductive alkylation). The 
other important component to bioreductive activation is the identification of enzymes that are 
overexpressed in tumor tissue (and not in normal tissue) and can thus drive the design of 
substrates that can be bioactivated by these enzymes and used as anticancer therapies. NQO1 has 
been widely studied as an enzyme capable of bioreductive activation due to its marked 
overexpression in tumor tissue (Ross et al., 1994; Workman, 1994). 
NQO1 structure and function 
 NQO1 is a two-electron reductase that is characterized by its utilization of either NADH 
or NADPH as reducing cofactors and by its inhibition by dicoumarol (Ernster, 1979). NQO1 is a 
homodimer containing one molecule of cofactor FAD for each monomer, that is required for 
catalytic activity (Danson, 2004; Lind, 1990). Found almost exclusively in the cytosol, NQO1 is 
responsible for the reduction of many quinone-based compounds. Quinone reduction occurs via 
an obligatory single-step two-electron reduction, which bypasses the reactive and toxic formation 
of semiquinone intermediates (Dinkova-Kostova and Talalay, 2000). The enzymatic functions of 
NQO1 are described as ping pong kinetics whereby NAD(P)H binds to the active site of NQO1, 
reduces FAD cofactor to FADH2, and is then released prior to substrate binding and complete 
reduction by hydride transfer (Li et al., 1995). Under conditions of oxidative stress, NQO1 
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expression is induced to protect the microenvironment; this upregulation is also accompanied by 
an increase in antioxidant enzymes (Nioi and Hayes, 2004). NQO1 functions to metabolize 
endogenous ubiquinone, which can lead to the scavenging of free radicals and the more 
traditional route of detoxification for which it was first implicated. It has also been suggested that 
NQO1 can stabilize p53 either by inhibiting its degradation or by a direct protein-protein 
interaction, leading to increased tumor suppression response (Ross and Siegel, 2004). In humans, 
NQO1 is also overexpressed in a variety of solid tumors, including those of the adrenal gland, 
bladder, breast, colon, liver, lung, ovaries and thyroid (Schlager and Powis, 1990; Malkinson et 
al., 1992; Siegel and Ross, 2000). Aside from normal detoxification function, the overexpression 
of NQO1 in tumor tissue combined with properties of bioreductive activation make NQO1 a 
selective drug target in the treatment of solid tumors. 
Quinones as NQO1 substrates 
Quinones are a large group of natural products that are substrates for NQO1. Many 
quinones, such as doxorubicin and mitomycin c, have anticancer properties as well and are 
therefore good candidates to examine for their ability to be reduced to more active cytotoxic 
agents. One of the first NQO1 substrates to be studied was streptonigrin (SN), a natural product 
isolated from Streptomyces flocculus (Rao and Cullen, 1959). SN has shown to have broad-
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spectrum antitumor activity and is cytotoxic against tumors of the lung, breast, head and neck, as 
well as lymphomas and melanoma; however, SN is toxic when used as treatment in vivo and has 
never been approved for use in the clinic (Bolzan and Bianchi, 2001). 
Other NQO1 substrates that have reached clinical trials or have been in use 
therapeutically include mitomycin c, EO9, and diaziquone (AZQ) (Beall and Winski, 2000) 
(Figure 1.5). Mitomycin c is considered the prototypical bioreductive drug and has antitumor 
activity against tumors of the stomach, pancreas, colon and breast; it was also the first quinone-
containing alkylating agent to be used successfully in the clinic alone and in combination therapy 
(Teicher, 1997). Mitomycin c, like SN, is potent and toxic and is limited by causative 
myelosuppression, which is directly related to cumulative administration of the drug. Mitomycin 
c is a relatively weak NQO1 substrate—newer analogues have been designed to increase enzyme 
specificity with limited bone marrow suppression. EO9 was designed as a mitomycin c analog 
and is a synthetic indolequinone. EO9 reached clinical trials for use in tumors of the breast, 
colon, pancreas and stomach, but was withdrawn, presumably due to poor pharmacokinetics 
(Phillips, 1998; Dirix et al., 1996). AZQ, an aziridinylbenzoquinone designed for tumors of the 
central nervous system, has shown effectiveness towards primary brain tumors, but similar to 
other quinones, is also a potent bone marrow suppressive agent (Teicher, 1997; Chou et al., 
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1976). In an effort to probe for the minimum structural components needed for NQO1 substrate 
activity, lavendamycin analogues have been developed for examination of antitumor potential. 
Lavendamycin was isolated from Streptomyces lavendulae and is structurally and 
biosynthetically similar to SN (Balitz et al., 1982; Doyle et al., 1981). Lavendamycin activity is 
comparable and less potent than SN and investigation into structural properties explaining the 
activities have been important in continuing the research into the development of lavendamycin 
analogues (Boger et al., 1987). Lavendamycin contains a pentacyclic ring structure, whereby any 
of the ring constituents may be modified to improve cytotoxicity and affinity for NQO1 (Fang et 
al., 2003). Further investigation into the structure of lavendamycin has shown that although 
lavendamycin may be limited clinically due to toxicity and poor pharmacokinetics, structurally 
similar indolequinones and quinolinequinones are good NQO1 substrates. Structural 
modification of these compounds has the potential to lead to structure-activity relationship 
(SAR) studies and better substrates with increased specificity and tumor cytotoxicity (Hassani et 
al., 2005; Fryatt et al., 2004; Beall et al., 1998; Swann, 2001; Hassani et al., 2008; Cai et al., 
2008). Continued experimentation in the field of NQO1-directed antitumor quinones will provide 
important information on the structural components needed for NQO1 activity and has the 
potential to lead to the discovery of more specific antitumor agents.  
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Figure 1.5 
 
                                                 
Figure 1.5. Selected antitumor quinone structures. 
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Conclusions 
 Cancer is a common and often fatal disease. It is important to continue to research the 
mechanisms of tumor development and identify the characteristics of cancer cells that make 
them cellularly distinct from normal cells, in an effort to exploit these differences with new 
anticancer therapies. The goal of the proposed studies is to examine the cytotoxicity and 
therapeutic potential of new anticancer agents in an effort to better understand the mechanisms of 
cancer development. The results of this project will aid in the development of new and 
alternative approaches to selectively target and eliminate tumor cells.   
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Cytotoxicity and therapeutic potential of novel anticancer agents: 
Hypothesis and Specific Aims: 
 
(1) We hypothesize that small molecule anthracenyl isoxazole amides (AIMs) selectively bind 
within mitochondria in cancer cells and induce apoptosis via the mitochondrial pathway 
of apoptosis.  
(2) We hypothesize that small substituents at the R1 position and small heterocyclic 
substitutions at the R2 position of our lavendamycin quinolinequinone derivatives will be 
preferentially cytotoxic to NQO1-expressing human breast cancer cells. 
 
Specific Aim 1: Assess degree of AIM toxicity to human glioblastoma cell line SNB-19. 
Determine whether compounds are cytotoxic to SNB-19 human glioblastoma cells and to what 
degree, using IC50 values as a measure of toxicity. 
Specific Aim 2: Evaluate the AIMs effects on the mitochondria of SNB-19 human 
glioblastoma cells 
Using an in vitro cell culture model, examine AIMs potential to interact with mitochondria and 
induce apoptosis via the mitochondrial-regulated pathway of apoptosis 
Specific Aim 3: Determine if AIMs have increased selective toxicity to P-gp expressing and 
non-P-gp expressing MDCK canine kidney cells when used in conjunction with novel P-gp 
inhibitors 
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Using an in vitro cell culture model, examine selective toxicity of AIMs used in conjunction with 
novel dihydropyridine compounds at the level of export protein interactions in brain tumor cells. 
Specific Aim 4: Investigate the effect of aryl-substitutions on quinolinequinone analogues of 
lavendamycin derivatives 
Using an in vitro cell culture model of NQO1 expressing and non-expressing human breast 
cancer cells, determine the NQO1 substrate efficiency and selective toxicity of structurally 
modified quinolinequinones. 
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ABSTRACT 
 The design and synthesis of G-quadruplex ligands as selective anticancer agents is a 
rapidly emerging scientific field of study. Recently, we have developed a series of anthracenyl 
isoxazole amides (AIMs) that function as G-quadruplex ligands and possess unique fluorescent 
and intracellular characteristics. In this study, we evaluate several AIM analogues for their 
cytotoxic potential, fluorescent properties, and preliminary mechanism of action. In contrast to 
published studies, we show that our AIMs preferentially localize to cellular structures outside of 
the nucleus—the generally accepted site of action of G-quadruplex ligands. Our results 
demonstrate an intriguing extra-nuclear mechanism of action and implicate a mitochondrial role 
in the function of our compounds. Due to this unexpected finding, further investigation into the 
mechanisms of action of our AIMs is warranted.  
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INTRODUCTION 
 Classic chemotherapy used in the treatment of solid tumors includes the administration of 
small molecule drugs that target DNA. While these agents are effective, there is an inherent lack 
of selectivity in targeting DNA, as well as issues with toxicity to normal tissue when these drugs 
are used clinically. New anticancer agents have been developed that are more specifically 
designed to interrupt abnormal cell signaling and interfere with cellular processes that are 
implicated in the development and progression of cancer. Recently, the discovery of higher order 
secondary DNA structures, G-quadruplexes, has led to investigation into new anticancer agents 
that bind to and stabilize G-quadruplex DNA and selectively induce apoptosis in cancer cells that 
overexpress G-quadruplex structures. This approach to drug design is a viable option in creating 
selective anticancer agents because of the features of G-quadruplex within cells, and within 
cancer cells more specifically. Although G-quadruplex structures exist in normal non-cancerous 
cells, G-quadruplex structures have been found to be overexpressed in cancer cells within the 
promoter region of oncogenes (Siddiqui-Jain et al., 2002). G-quadruplexes also exist in 
telomeres, a finding that has sparked interest in investigating methods of G-quadruplex 
stabilization that prevent the elongation and maintenance of telomeres that is characteristic of 
	  
	  
  
52	  
cancer cells (Sen and Gilbert, 1988). The ability to maintain telomere length and continue 
cellular replication and avoid reaching the Hayflick limit is advantageous to cancer cells in that it 
promotes excessive cell growth and can lead to cellular immortality, as cells are not instructed to 
die by normal apoptotic stimuli. One way by which cancer cells evade apoptosis in this regard is 
by overexpressing telomerase, the enzyme responsible for maintaining telomere length. By 
stabilizing G-quadruplex structures within the telomeres, G-quadruplex ligands function to 
inhibit the ability of telomerase to add the DNA sequence repeats TTAGGG to the 3’ ends of 
chromosomes and maintain telomere length. When this process is interrupted, cells become 
senescent or enter apoptosis and are eventually eliminated. Telomerase inhibition by G-
quadruplex stabilization is an important area of drug discovery research, however, as is the case 
with all new drugs, it is not without problems. One of the most prominent barriers to G-
quadruplex ligand synthesis is the issue of binding promiscuity and problems with lack of 
selectivity for G-rich sequences. For example, Quarfloxin, a G-quadruplex ligand that reached 
clinical trials for use as anticancer therapy, issues with binding promiscuity led to interactions 
with single stranded or B-DNA and limited its use in the clinic (Drygin et al., 2009; Bates et al., 
2009).  
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In this regard, we have developed a series of novel anthracenyl isoxazole amide 
compounds (AIMs) that exert toxic effects on a SNB-19 human glioblastoma cell line and 
preferentially interact with telomeric G-quadruplex DNA sequences. Our AIMs were originally 
developed for use as anti-HIV agents, but when evaluated showed no activity for this target. 
Surprisingly, follow up studies revealed antitumor potential. Data from the NCI-DTP 60 cell line 
screen indicated that the AIMs possess antitumor activity against central nervous system (CNS) 
SNB cell lines (Han et al., 2009). Upon further investigation, several structural themes emerged 
that were consistent with G-quadruplex binding capability (Gajewski et al., 2009; Han et al., 
2009). For example, the planar isoxazole component of the AIMs encourages proper 
perpendicular spatial orientation to allow G-quadruplex binding and the nitrogens at each tail 
increase solubility. The tails of the AIMs (single or double) presumably anchor to the phosphate 
backbone of the quadruplex and aid in binding as well. Additionally, one of the more 
experimentally useful properties of our AIMs comes from the aromatic anthracene moiety that 
leads to autofluorescence—that is, under appropriate excitation, our compounds emit 
fluorescence that allows for the careful examination of the AIMs without the use of additional 
fluorescent tags. 
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In this study we assess the cytotoxicity and antitumor potential, as well as perform 
preliminary experimentation into the mechanisms of action of our lead compound. In developing 
the AIMs, we had several hypotheses: first, we believe that the C10 position of the AIMs is the 
site of potential cationic interactions that are essential for proper G-quadruplex interaction; 
therefore, synthesis proceeded with modifying this site, with the goal being to add small 
substituents that would overall make the AIMs more cytotoxic (and presumably better G-
quadruplex binders). Second, the AIMs were synthesized with either one or two tails bearing 
either two or three nitrogens, respectively. Based on initial molecular modeling, we believe that 
the tails serve to anchor the ligand to the phosphate backbone of the quadruplex. We hypothesize 
that the addition of two tails will allow for stronger binding and that this will be reflected in a 
more cytotoxic ligand. Taken together, we believe that customization of the AIMs with 
modifications to the tails and to the C10 position will increase their selectivity for G-quadruplex 
DNA and will result in enhanced toxicity to brain cancer cells. 
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MATERIALS AND METHODS 
Chemicals. AIMs were obtained from the University of Montana (Missoula, MT). We are 
appreciative of the efforts Matthew J. Weaver and the Natale laboratory for contribution to the 
synthesis of the AIM compounds.  
 
Cell Culture. SNB-19 human glioblastoma cells (American Type Cell Culture Cat No. CRL-
2266) were grown in RPMI 1640 medium with L-glutamine and penicillin/streptomycin, 
supplemented with 10% fetal bovine serum (FBS). Cell culture medium and supplements were 
obtained from Invitrogen (Carlsbad, CA). The cells were incubated at 37 °C under a humidified 
atmosphere containing 5% CO2 and allowed to achieve confluence prior to experimentation.  
 
Cell Viability Assay. Cell survival was measured by the [3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. MTT was obtained from Sigma-
Aldrich (St. Louis, MO). As previously described, cells were plated in 96-well plates at a density 
of 10,000 cells/mL and allowed to attach overnight (16 h). AIM solutions were applied in 
medium for 24 h, removed, and replaced with fresh medium, and the plates were incubated at 
37°C under a humidified atmosphere containing 5% CO2 for 3−5 days. MTT (50 µg) was added 
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and the cells were incubated for another 4 h. Medium/MTT solutions were removed carefully by 
aspiration, the MTT formazan crystals were dissolved in 100 µL of DMSO, and absorbance was 
recorded on a spectrophotometer at 560 nm. IC50 values (concentration at which cell survival 
equals 50% of control) were determined from semilog plots of percent of control versus 
concentration. Each experiment was performed in triplicate. Average IC50 values are reported 
from triplicate results.  
 
Confocal Microscopy. SNB-19 cells were plated on cover slips in 6-well plates at a density of 1 
x 103/well, allowed to adhere, and incubated overnight at 37oC in 5% CO2 to achieve adherence. 
AIM solutions (1 µM) were added to cells and incubated overnight. After incubation, medium 
was aspirated, cells were washed twice with PBS and fixed in 4% paraformaldehyde/PBS (on 
ice; 10 min).  Following three additional washes in PBS, cells were washed once with de-ionized 
water, and fluorescent images were taken with an Olympus FV1000 confocal laser scanning 
microscope using selective laser excitation at 405 nm (40X objective with an optical 
magnification lens of 10X and oil immersion objective of 40X [NA, 1.35]).  Images were 
processed with Nuance 1.6.2.368 alpha software (Cambridge Research Institute).  
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Laser Scanning Cytometry with Propidium Iodide. SNB-19 cells were plated at a density of 
2000 cells/mL on cover slips in medium. The cells were incubated at 37 °C under a humidified 
atmosphere containing 5% CO2 and allowed to adhere. Media was aspirated and replaced with 1 
µM AIM in medium. Drug was removed and cells were washed twice with phosphate buffered 
saline (PBS). Cells were fixed in 4% paraformaldehye (10 minutes, RT) and washed once with 
PBS. To determine nuclear localization, samples were permeabilized with 0.2% Saponin and 
exposed to propidium iodide (Invitrogen, Carlsbad, CA). Following washes, cover slips were 
inverted to microscope slides and sealed using FluoroSave Reagent (Calbiochem). Light 
absorption was measured to produce a DIC-like image for cell morphology and each signal was 
given a pseudo-color.  
 
Laser Scanning Cytometry with MitoTracker Red and HCS Nuclear Mask. As described, 
SNB-19 cells were plated at a density of 2000 cells/mL on cover slips in medium. The cells were 
incubated at 37 °C under a humidified atmosphere containing 5% CO2 and allowed to adhere. 
Media was aspirated and replaced with 1 µM AIM in medium. Drug was removed and cells were 
washed twice with phosphate buffered saline (PBS). Cells were fixed in 4% paraformaldehye (10 
minutes, RT) and washed once with PBS. To determine cellular localization, HCS NuclearMask 
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Deep Red stain and MitoTracker Red stain (Invitrogen, Carlsbad, CA) were added directly to 
cells and incubated following manufacturer’s directions. Following two additional washes, slides 
were inverted to microscope slides and sealed using FluorSave Reagent (Calbiochem). Images 
were generated from scans from a CompuCyte iCys Laser Scanning Cytometer (CompuCyte, 
Westwood, MA). Cells were scanned sequentially and light absorption was also measured to 
produce a DIC-like image for cell morphology as necessary.  Each signal was given a pseudo-
color and overlaid to produce images. Untreated samples were run as negative controls. 
 
Bioavailability Estimates. Parameters relating to oral bioavailability were calculated using the 
Symyx Draw v3.1 program. The pentagonal plot takes into consideration: log P (the oil water 
partition coefficient), PSA (polar surface area), nRotb (number of rotatable bonds), MW 
(molecular weight) and WS (water solubility). The color of the pentagon corresponds to the best 
fit in relation to the Lipinski guidelines for oral bioavailability. Green = 0-1 violations, Yellow  = 
2 violations, Orange = 3-4 violations, Red = 5 violations. The Symyx Draw Log P calculation is 
based on Ghose’s AlogP method (Ghose et al., 1998). The Polar Surface area computation is 
based on Ertl’s method (Ertle et al., 2000). 
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NMR Spectroscopy. DNA oligonucleotides were purchased from Integrated DNA Technologies. 
For analysis, we followed the methods of Dai et al. (2011), as well as those of Wang and Patell 
(2003; with modifications). Briefly, NMR samples were prepared containing oligonucleotide 
(0.1-1.0 mM) in 90% H20/10% D20 buffer at pH 6.0 with 100 mM or 200 mM K+ ions. Ion 
concentrations were obtained with KH2PO4 25 mM/KCl 75 mM or 50 mM/150 mM. Samples 
were re-annealed prior to each round of data collection and those containing AIM 1 ligand (1 
equivalent) were subjected to a subsequent round of re-annealing after the addition of ligand. 
Experiments were performed on a Varian 500 MHz spectrophotometer at 25°C. Following 
Watergate and Wet 1D water suppression techniques, data was transformed using the squared 
shifted sine bell function. 
 
Flow Cytometry Annexin V Apoptosis. Apoptosis levels of SNB-19 cells treated with AIM 
solutions (1 µM, 2.5 µM, 5 µM) were determined by Annexin-V staining and propidium iodide 
(PI) exclusion using the FITC Annexin-V Apoptosis Detection Kit I (BD Pharmingen, San 
Diego, CA, USA) following manufacturer’s instructions. Cells were treated with each 
concentration of AIM and plated in 6-well culture dishes for exposure period. Samples were 
carefully trypsinized and transferred to flow cytometry tubes for processing, following the 
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protocol for Annexin V for adherent cells indicated by the manufacturer. Untreated samples were 
run as negative control. Staurosporine treated samples were run as positive control.  
 
Statistics. All statistical analyses were performed using GraphPad Prism 4.0 for 
Macintosh (GraphPad Software, San Diego, CA). Student’s t-test was used to compare untreated 
and treated samples. Mean and standard deviation were used to calculate IC50 values. Values 
p≤0.05 were determined to be significant. 
 
RESULTS 
AIMs are cytotoxic at single digit micromolar levels. Five AIMs were examined for this study 
(Figure 2.1). Results from MTT analysis showed that all AIMs produced growth inhibition in 
SNB-19 cells at doses no higher than 8µM for a 24 hour treatment period (Figure 2.2). The first 
AIM that was synthesized in this series, AIM 2, had good toxicity towards SNB-19 cells, which 
was somewhat surprising considering its large molecular weight that would presumably limit 
solubility. However, in the original development of the AIMs, AIM 2 was synthesized as a dimer 
due to the hypothesis that this structure would allow for multiple G-quadruplex binding at a time 
and result in more potent telomerase inhibition downstream. Overall, results indicate that AIMs 
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bearing double tails (AIM 1 and AIM 4) were more cytotoxic to SNB-19 cells compared to their 
single tail counterparts (AIM 3 and AIM 5).  
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Figure 2.1 
 
 
AIM 1 
 
AIM 2 
 
AIM 3 
 
AIM 4 
 
AIM 5 
 
Figure 2.1. AIM structures. AIMs 1-5 and corresponding structures.  
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Figure 2.2 
  A. 
	  
	   	   B. 
	   	   	  
    
    
    
    
     
 
 
Figure 2.2. AIMs toxicity testing. MTT viability assay results reveal all AIMs have single digit 
micromolar IC50 values and are cytotoxic to a SNB-19 human glioblastoma cell line.  
 
 
 
 
 
 
 
AIM 
Molecular Weight 
(g/mol) 
IC50 (µM) 
1 629.19 3.13 + 0.45 
2 1028.97 4.75 + 0.27 
3 585.69 7.66 + 0.73 
4 673.64 3.16 + 0.25 
5 544.04 6.27 + 0.23 
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AIM 1 and AIM 2 penetrate cell membranes and can be observed fluorescently within the cell. 
Initial fluorescent experimentation was performed to determine ability of AIMs to be visualized 
without additional fluorescent labeling. The effect of double tail structure versus dimer 
configuration on AIMs localization within cells was selected as the initial investigation (Figure 
2.3). Confocal microscopy revealed that both AIM 1 and AIM 2 appeared to be localized outside 
the nucleus. These findings were surprising given that telomeres, the target of G-quadruplex 
ligands, are located within the nuclei of cells. To investigate the localization of AIM 1 and AIM 
2 further, we performed LSC imaging with the nuclear indicator propidium iodide (PI) (Figure 
2.4). These results seem to indicate that both AIMs were in fact inside the nucleus, as 
demonstrated by the overlapping fluorescence of both the AIMs and PI. Due to the conflicting 
microscopy showing first that the AIMs were extra-nuclear and then that with the addition of a 
counterstain appeared to be nuclear, we could not decisively confirm the location. This led us to 
modify our microscopy procedures and alter sample preparation to ensure the effects of the 
AIMs on SNB-19 cells were only due to inherent cytotoxicity and not due to the way in which 
we processed samples.  
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Figure 2.3 
 
Figure 2.3. Confocal microscopy indicates differences in cellular distribution of AIM dimer 
vs. double tail structures. Fluorescent imaging of SNB-19 cells exposed to 1 µM of each AIM 
reveal that AIM 2, with a high molecular weight of 1028.97 g/mol appears to penetrate cells, but 
it is unclear as to what cellular structure it is localized. In contrast, AIM 1 (molecular weight 
629.19 g/mol) appears to permeate the membrane of the human glioma cells, and punctate 
binding is observed.  
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Figure 2.4 
 
Figure 2.4. Laser Scanning Cytometry with PI counterstaining. DIC-like images were 
produced to allow for visualization of cell morphology. AIMs (shown in green) appear to 
localize within the nucleus of SNB-19 cells (nucleus stained in red). When the fluorescence 
overlaps substantially, areas of AIM in the nucleus appear yellow in color. 
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AIM 1 possesses a better bioavailability profile than AIM 2. Due to the fluorescent imaging 
results that showed both AIM 1 and AIM 2 enter SNB-19 cells, we performed analysis of 
bioavailability parameters to better understand the effect that double tail vs dimer structure has 
on solubility. Radar plots (Figure 2.5) indicate that based on all parameters assessed, AIM 1 is a 
more suitable drug for continued evaluation. Due in part to the large molecular weight of AIM 2, 
these results are not altogether surprising.  
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Figure 2.5 
 
Figure. 2.5. AIM 1 possesses better bioavailability properties compared to AIM 2.  Radar 
graphs summarizing properties of AIM 1 (green) and AIM 2 (orange). AIM 1 lies within the 
acceptable parameters for bioavailability with acceptable cLogP and AlogD values. AIM 2 lies 
outside of the optimum parameters for bioavailability in almost all respects.  
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Lead compound AIM 1 localizes to the mitochondria of cells. Due to the fluorescent imaging 
results, MTT viability assay and solubility properties, AIM 1 was selected as our lead compound 
for further investigation. Because results from our preliminary microscopy were conflicting in 
terms of the cellular location of AIM 1, we performed additional fluorescence experimentation. 
Initial confocal microscopy appeared to indicate AIM 1’s location outside of the nucleus; 
however, LSC imaging demonstrated that AIM 1 was nuclear. To address this disparity, changes 
were made in the experimental protocol to omit the permeabilization step discussed previously 
with images shown in Figure 2.4. We hypothesized that the permeabilization required for 
propidium iodide counterstaining might be impacting the true cellular location of the AIMs; 
therefore, nuclear counterstaining was performed with HCS Nuclear Mask, which does not 
require permeabilization. Results revealed that as shown by confocal microscopy, AIM 1 
localized outside of the nucleus (Figure 2.6a). Because of these results and the punctate staining 
profile observed both with confocal microscopy and LSC imaging with HCS Nuclear Mask, we 
believed AIM 1 may be localized in the mitochondria of SNB-19 cells. With the addition of a 
mitochondrial marker, AIM 1 was confirmed to be concentrated within the mitochondria of 
SNB-19 cells (Figure 2.6b). 
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Figure 2.6 
A. 
  
 
B. 
 
	  
Figure 2.6. Laser scanning cytometry of AIM 1 in SNB-19 cells with counterstaining. HCS 
nuclear mask (blue), a nuclear indicator, was used to confirm AIM 1 distribution (green) outside 
of the nucleus (A). Additional imaging with a mitochondrial marker, MitoTracker Red (red), 
revealed AIM 1 localized to the mitochondria (B).  
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AIM 1 binds the human telomeric G-quadruplex sequence as determined by NMR 
spectroscopy. In order to determine if AIM 1 functions as a G-quadruplex ligand, we performed 
NMR spectrophotometry using a commercially available human telomeric G-quadruplex 
sequence (Figure 2.7). Results indicated that AIM 1 binds G-quadruplex sequences within 
telomeres. 
 
AIM 1 induces apoptosis. To investigate the mechanism of action for AIM 1, Annexin V flow 
cytometry was performed at three doses: 1 µM, 2.5 µM, 5 µM for a 24 h exposure period (Figure 
2.8). Annexin V analysis was performed using PI exclusion to determine the stages of apoptosis 
that occur at each dose: Annexin V+/PI- corresponds to early apoptosis, Annexin V+/PI+ 
indicates late stage apoptosis and Annexin V-/PI+ are those samples that are showing signs of 
necrosis. Results for AIM 1 show a significant induction of apoptosis at the highest 
concentration as compared to untreated control. 
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Figure 2.7 
 
Figure 2.7. NMR spectra with AIM 1. NMR of oligonucleotide 5’-(T2AG3)4-3’ with 1 Eq of 
AIM 1 (top) and with DNA only (bottom) showing upfield shift of guanine imino protons. 
Chemical shift scale is from 9.7-12.4 ppm. Guanine imino proton signals are between 10.5 and 
12.5 ppm; upfield shifts occur due to ligand binding to G4 DNA. (The authors wish to 
acknowledge the contributions of Dr. Nicholas R. Natale and Matthew J. Weaver for NMR 
spectroscopy). 
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Figure 2.8 
 A. 
	  
 B. 
 
 
Figure 2.8. AIM 1 induces apoptosis in SNB-19 cells. Flow cytometry indicates AIM 1 induces 
apoptosis in a dose dependent trend (A). Analysis of Annexin V staining details the overall 
amount of apoptosis induction by AIM 1 at varying doses (B). *indicates significance of p≤0.05, 
and ***indicates significance of p≤0.0001. 
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Single tailed AIMs are able to penetrate cells and be visualized within the cells. To evaluate if 
small structural changes on single tail structures effect the localization and fluorescent properties 
of the AIMs, laser scanning cytometry was performed (Figure 2.9). Fluorescent microscopy of 
single tail structures revealed that while both AIMs are able to enter cells, they bear different 
fluorescent properties. That is, AIM 3, which contains a phenyl group at the C10 position, is 
more fluorescent compared to AIM 5, when both AIMs are excited at the same wavelength. 
These results are consistent with the notion that aromatic groups, such as phenyl groups, 
contribute structural fluorescence due to the ability to excite the electrons within the aromatic 
ring. Results from fluorescent microscopy demonstrated that single tail AIMs can be visualized 
within cells.  
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Figure 2.9 
 
Figure 2.9. Laser scanning cytometry of single tail AIM structures. AIM 3 and 5 (highlighted 
in blue) visualized by laser scanning cytometry. AIMs are minimally punctate in nature and 
appear diffuse within SNB-19 cells. AIM 5 produces a dimmer fluorescent compared to other 
single tail structures; therefore DIC images were acquired to more clearly show cellular 
morphology and AIM location within cells (Mirzaei et al., 2012). 
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DISCUSSION 
 The purpose of this study was to develop a library of potential G-quadruplex ligands, 
determine their cytotoxicity to SNB-19 human glioblastoma cells and identify lead compounds 
for additional experimentation. Overall, studies indicated that one of the most important 
structural features of the AIMs was the addition of a double tail that resulted in AIMs that were 
more cytotoxic than their single tailed counterparts. This supports our original hypothesis that the 
addition of a double tail can anchor more effectively than a single tail on to the phosphate 
backbone of the G-quadruplex and that this would make these compounds better drugs (and 
result in a more cytotoxic drug). In addition, AIMs synthesized with two tails bear three 
nitrogens that are ionizable at physiologic pH, giving these AIMs better solubility properties as 
well. In regards to substituents at the C10 position of the AIMs, it appears as though smaller 
groups (for example Cl vs Br in the double tail AIMs) lead to a more cytotoxic compound, 
however, the differences in IC50 values are subtle. Regardless, these effects are likely due to a 
smaller molecular weight—large groups at C10 will results in a larger compound that may not as 
efficiently enter cells to exert activity. Additionally, AIM 2, a structural dimer, was able to 
penetrate cell membranes despite its large size and poor bioavailability. Based on initial 
molecular modeling results performed during the genesis of this project, the C10 position of the 
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AIMs was believed to be the site of cationic interactions of ligands within the central channel of 
the G-quadruplex—an essential feature of G-quadruplex stabilization. While this hypothesis was 
not tested directly, we believe that if these interactions were occurring, the results would be more 
potent AIMs that are able to bind to G-quadruplex efficiently. The results of this study indicate 
modifications at the C10 position alters the fluorescence of the AIMs as well as changes the 
overall cytotoxicity (as indicated by IC50 values), although the results were subtle in this regard.  
To summarize the results of investigation of lead compound AIM 1, NMR experiments 
indicated AIM 1 interacts with telomeric G-quadruplex DNA and MTT analysis demonstrated 
that AIM 1 had good cytotoxicity, but fluorescent microscopy was intriguing as results showed 
extra-nuclear localization—traditional G-quadruplex ligands are designed to target G-quadruplex 
structures within the nucleus (Casagrande et al., 2011; Ou et al., 2008). In this regard, contrary to 
what was expected, AIM 1 was highly concentrated in the mitochondria of cells. We believe that 
the original LSC experiments with AIM 1 and AIM 2 and the nuclear indicator PI were 
somewhat misleading. First, after repeating several experiments with PI, permeabilization was 
determined to be a factor leading to fluorescent quenching which may also explain why PI 
appears to not only stain the nucleus but also almost the entire SNB-19 cells. Second, in these 
early experiments sequential laser scanning was not performed—meaning that it is possible that 
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AIM 1 and AIM 2 in the nucleus were actually a result of excitation by the fluorescence of PI 
and were therefore falsely staining positive in the nucleus. Third, in respect to AIM 1 even when 
the HCS Nuclear Mask nuclear indicator was used, there is a small subset of cells (always <10% 
of the entire population sampled) that appear morphologically distinct from the majority and 
appear to stain positive for AIM 1 in the nucleus. Due to the fact that SNB-19 cells are 
heterogeneous at the time of sampling (at different stages of cell cycle), we believe this explains 
these somewhat varying microscopy results; some cells are naturally more apoptotic at the time 
of drug exposure and take up AIM 1 through damaged membranes, resulting in AIM 1 in the 
nucleus when these samples are visualized.  
 There are several points worth considering in regards to the data that indicate AIM 1 is 
localized in the mitochondria. First, the effect of telomeric G-quadruplex DNA stabilization by 
ligands has been experimentally shown to be caused by the inhibition of telomerase and the 
consequent interference with telomere length leading to apoptosis or senescence (Neidle and 
Parkinson, 2002). However, some unexpected research findings have also demonstrated that G-
quadruplex ligands interact with telomeric G-quadruplex DNA but induce cell death in the 
absence of telomere shortening (Pennarun et al., 2005; Zhou et al., 2009). These results 
contradict the original theory that G-quadruplex ligands function only to interfere with telomere 
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length and support our research findings that another mechanism of action may exist outside of 
telomerase inhibition in the nucleus (Kelland, 2007). Research is also emerging that implicates 
the mitochondria in the role of G-quadruplex stabilization and indicates that some G-quadruplex 
ligands, once bound to quadruplex, cause mitochondrial dysfunction and mitochondrial-
dependent apoptosis (Zhuang and Yao, 2013). While the research showing that G-quadruplex 
ligands affect the mitochondria do not include fluorescent studies indicating cellular localization 
of these G-quadruplex ligands within the mitochondria, we believe that collectively, our data 
with AIM 1 indicates that our AIMs may also possess properties leading to mitochondrial-
specific effects. We propose that, based on our results that AIM 1 functions as a G-quadruplex 
DNA binder and is highly concentrated outside of the nucleus within the mitochondria of cells, 
that AIM 1 is causing mitochondrial-specific intracellular effects following or coinciding with 
the binding to and stabilization of telomeric G-quadruplex structures. Data showing AIM 1 in the 
mitochondria of cells supports the emerging hypothesis that the mitochondria may be implicated 
in ways that are yet undiscovered in the field of G-quadruplex.  
This series of AIMs targeting G-quadruplex is the first of their kind to possess fluorescent 
properties that do not require additional labeling to be visualized while also being preferentially 
localized outside of the nucleus and in the mitochondria. We have demonstrated that lead 
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compound AIM 1 induces apoptosis at single digit micromolar doses in SNB-19 human 
glioblastoma cells and additionally, is concentrated in the mitochondria of these cells. The 
investigation into the role of the mitochondria in the functioning of the AIM compounds is 
imperative to determining to what extent G-quadruplex ligands might impact the mitochondria. 
Also, in light of recent findings that demonstrate a mitochondrial-based extra-telomeric 
mechanism of action of G-quadruplex ligands, a further detailed investigation into the cellular 
pathways involved in the stabilization of G-quadruplex structures is warranted. Additional 
studies examining the mechanisms of action of G-quadruplex ligands outside of solely testing for 
binding affinity is a crucial component in the design of more specific G-quadruplex ligands as 
anticancer agents. 
 
ACKNOWLEDGEMENTS 
 The authors wish to thank Dr. Nick Natale and lab members for their contributions to the 
synthetic chemistry of the AIMs. Also, we would like to acknowledge Matthew J. Weaver for his 
work in regards to the NMR spectroscopy. 
 
 
	  
	  
  
81	  
 
REFERENCES 
 
Ahmed, S., Passos, J. F., Birket, M. J., Beckman, T., Brings, S., Peters, H., Birch- 
Machin, M. A., Von Zglinicki, T., Saretzki, G. (2008). Telomerase does not counteract 
telomere shortening but protects mitochondrial function under oxidative stress. J Cell Sci 
7, 1046-1053. 
Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D., and Trent, J. O. (2009). 
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment 
for cancer. Mol Pathol 86, 151-164. 
Casagrande, V., Salvati, E., Alvino, A., Bianco, A., Ciammaichella, A., D’Angelo, C., 
Ginnari-Satriani, L., Serrilli, A. M., Iachettini, S., Leonetti, C., Neidle, S., Ortaggi, G., 
Porru, M., Rizzo, A., Franceschin, M., and Biroccio, A. (2011). N-cyclic bay-substituted 
perylene G-quadruplex ligands have selective antiproliferative effects on cancer cells and 
induce telomere damage. J med Chem 54, 1140-1156. 
Dai, J., Carver, M., Hurley, L. H, and Yang, D., (2011). Solution structure of a 2:1 
quindoline c-MYC G-Quadruplex: Insights into G-Quadruplex-Interactive small 
molecule drug design. J Am Chem Soc 133, 17673-17680. 
Drygin, D., Siddiqui-Jain, A., O’Brien, S., Schwaebe, M., Lin, A., Bliesath, J., Ho, C. B., 
Profitt, C., Trent, K., Whitten, J. P., Lim, J. K., Von Hoff, D., Anderes, K., and Rice, W. 
G. (2009). Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer 
Res 69, 7653-7661. 
Ertl, P., Rohde, B., and Selzer, P. (2000). Fast calculation of molecular polar surface area 
as a sum of fragment-based contributions and its application to the prediction of drug 
transport properties. J Med Chem 43, 3714–3717. 
Gajewski, M. P., Beall, H., Schnieder, M., Stranahan, S. M., Mosher, M. D., Rider, K. C., 
and Natale, N. R. (2009). Bis-anthracenyl isoxazolyl amides have enhanced anticancer 
activity. Bioorg Med Chem Lett 19, 4067–4069. 
Ghose, A. K., Viswanadhan, V. N., and Wendoloski, J. J. (1998). Prediction of 
hydrophobic (lipophilic) properties of small organic molecules using fragmental 
methods:  An analysis of ALOGP and CLOGP methods. J Phys Che. A 102, 3762–3772. 
Haendeler, J., Drose, S., Buchner, N., Jakob, S., Altschmied, J., Goy, C., Spyridopoulas, 
I., Zeiher, A. M., Brandt, U., and Dimmeler, S. (2009). Mitochondrial telomerase reverse 
transcriptase binds to and protects mitochondrial DNA and function from damage. 
	  
	  
  
82	  
Arterioscler Thromb Vasc Biol 29, 929-935. 
Han, X., Li, C. L., Mosher, M. D., Rider, K. C., Zhou, P., Crawford, R. L., Fusco, W., 
Paszczynski, A., and Natale, N. R. (2009). Design, synthesis and biological evaluation of 
a novel class of anticancer agents:Anthracenylisoxazole lexitropsin conjugates. Bioorg 
Med Chem 17, 1671-1680. 
Kelland, L. (2007). Targeting the limitless replicative potential of cancer: the 
telomerase/telomere pathway. Clin Cancer Res 13, 4960-4963. 
Masutomi, K., Possemato, R., Wong, J. M. Y., Currier, J. L., Tothova, Z., Manola, J. B., 
Ganesan, S., Lansdorp, P. M., Collins, K., and Hahn, W. C. (2005). Proc Natl Acad Sci 
102, 8222-8227.  
Mirzaei, Y. R., Weaver, M. J., Steiger, S. A., Kearns, A. K., Gajewski, M. P., Rider, K. 
C., Beall, H. D., and Natale, N. R. (2012). Improved synthesis of 3-aryl isoxazole 
containing fused aromatic rings. Tetrahedron 68, 10360-10364. 
Neidle, S., and Parkinson, G. (2002). Telomere maintenance as a target for anticancer 
drug discovery. Nat Rev Drug Disc 1, 383-393. 
Ou, T-M., Lu, Y-J., Tan, J-H., Huang, Z-S., Wong, K-Y., and Gu, L-Q. (2008). G- 
quadruplexes: Targets in anticancer drug design. Chem Med Chem 3, 690-713. 
Pennarun, G., Granotier, C., Gauthier, L. R., Gomez, D., Hoffschir, F., Mandine, E., 
Riou, J-F., Mergny, J-L., Mailliet, P., and Boussin, F. (2005). Apoptosis related to 
telomere instability and cell cycle alterations in human glioma cells treated by new highly 
selective G-quadruplex ligands. Oncogene 24, 2917-2928. 
Sen, D., and Gilbert, W. (1988). Formation of parallel four stranded complexes by 
guanine rich motifs in DNA and its implications for meiosis. Nature 334, 364-366. 
Siddiqui-Jain, A., Grand, C. L., Bearss, D. L., and Hurley, L. H. (2002). Direct evidence 
for a G-quadruplex in a promoter region and its targeting with a small molecule to repress 
c-MYC transcription. Proc Natl Acad Sci 99, 11593-11598. 
Wang, Y., and Patell, D. (1993). Solution structure of the human telomeric repeat 
d[AG3(T2AG3)3] G tetraplex. Structure 1, 4. 
Zhou, W. J., Deng, R., Zhang, X-Y., Feng, G-K., Gu, L-Q., and Zhu, X-F. (2009). G- 
quadruplex ligand SYUIQ-5 induces autophagy by telomere damage and TRF2 
delocalization in cancer cells. Mol Cancer Ther 8, 3203-3213. 
Zhuang, X-Y., and Yao, Y-G. (2013). Mitochondrial dysfunction and nuclear- 
mitochondrial shuttling of TERT are involved in cell proliferation arrest by G-quadruplex 
ligands. FEBS Lett 11, 1656-1662. 
	  
	  
  
83	  
 
CHAPTER 3 
Investigation of novel antitumor agent anthracenyl isoxazole amide (AIM) 1 as a 
mitochondrial modulator of apoptosis 
 
Authors 
Alison K. Kearns and Howard D. Beall 
 
Corresponding Author 
Dr. Howard D. Beall 
Address: University of Montana 
Department of Biomedical and Pharmaceutical Sciences 
32 Campus Drive, Skaggs 
Missoula, MT 59812 
Telephone: 406-243-5112 
Fax: 406-243-2807 
Email: Howard.Beall@umontana.edu 
	  
	  
  
84	  
ABSTRACT 
 Development of G-quadruplex ligands for the treatment of solid tumors is an emerging 
field of research. The site of G-quadruplex structures within the nucleus of cells has been the 
target of these ligands, with the goal of inhibiting telomerase and causing replicative senescence 
or selective apoptosis of tumor cells. We have shown previously that an anthracenyl isoxazole 
amide, AIM 1, is a good candidate for further investigation into the mechanisms of G-quadruplex 
ligand functions due to its cytotoxicity and ability to induce apoptosis in a human glioblastoma 
cell line. Our initial research curiously showed that AIM 1 was localized within the mitochondria 
of cells—a finding that differs from the believed site of action of G-quadruplex ligands within 
the nucleus. Several parameters of mitochondrial function are assessed and detailed in this study. 
Our results indicate AIM 1 induces mitochondrial-specific apoptosis and that exposure results in 
mitochondrial dysfunction. Additionally, we were interested in investigating the potential of 
AIM 1 to actuate hTERT shuttling. hTERT nuclear export is an advancing field of telomerase 
research, that has potential to impact the way in which investigators view the site of action of G-
quadruplex ligands and other telomerase inhibitors. Collectively, the results of our investigation 
into the mechanisms of AIM 1 demonstrate that G-quadruplex ligands may function in ways 
more complex than previously thought.  
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INTRODUCTION 
 Mitochondrial research is an active discipline in pharmaceutical research. Mitochondria 
have long been accepted as the ‘power house of the cell’, but it is the revelation that 
mitochondria also represent the ‘motor of cell death’, that is most intriguing in mitochondrial 
medicine (Brown et al., 1999). The mitochondria are crucial regulators of the intrinsic pathway 
of apoptosis and control the activation of apoptosis by regulating the translocation of pro-
apoptotic proteins from the mitochondrial intermembrane space to the cytosol (Fulda et al., 
2010). In this regard, mitochondrial-targeted anticancer agents represent a promising approach to 
the treatment of cancer for three reasons: mitochondria are key regulators of cell death, altered 
mitochondrial functions are a hallmark of cancer, and cancer cell mitochondria are structurally 
and functionally different from mitochondria in normal cells; the latter which allows for the 
selective targeting of cancer cell mitochondria (Gogvadze et al., 2008; Modica-Napolitano and 
Singh, 2004). Additionally, an increasing number of xenobiotics and pharmaceutics are being 
recognized as agents capable of manifesting toxicity through interference with mitochondrial 
functions (Wallace and Starkov, 2000). There are several means by which to target the 
mitochondria including the use of ROS regulators, modulators of BCL-2, metabolic inhibitors, 
and agents that deplete mitochondrial DNA (Fulda et al., 2010). One of the advantages of 
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mitochondria-targeted drugs in the context of cancer is the potential to induce apoptosis in the 
absence of the apoptosis-resistance that often plagues traditional anticancer agents (Weissig et 
al., 2004). 
Aside from changes in the mitochondria, cancer cells are also distinct from normal cells 
due to telomerase activation. Telomerase, the enzyme responsible for adding the telomeric 
repeats TTAGGG on to the 3’ ends of chromosomes, is overexpressed in >85% of all cancer and 
enzyme activation results in the maintenance of telomere length and enhanced replicative 
capacity (Shay and Bacchetti, 1997). The guanine-rich sequence in telomeres have been shown 
to form 4-stranded G-quadruplex DNA structures that can be stabilized with small molecules and 
effectively interfere with the functioning of telomerase, leading to telomere shortening, cellular 
senescence and apoptosis (Burge et al., 2006; Neidle et al., 2002). The development of 
telomerase inhibitors such as G-quadruplex ligands is a viable therapy to treat malignancy; 
however, new research is emerging in the field of telomeres that is changing the way researchers 
view telomerase targeted anticancer therapies. 
 The catalytic subunit of human telomerase, hTERT, is the major determinant and the 
rate-limiting factor of telomerase activity (Cong et al., 2002; Poole et al., 2001). The 
conventional oncogenic role of hTERT has been linked to cellular immortalization, but evidence 
	  
	  
  
87	  
to support non-canonical activities of hTERT is emerging. In examining the extra-nuclear 
functions of hTERT, it is important to first consider the role of the mitochondria in cellular 
homeostasis. The mitochondria are an inherent source of reactive oxygen species (ROS) due in 
part to close proximity to the electron transport chain (ETC). In situations where the 
mitochondria or the anti-oxidant defense systems are impaired or inefficient, cells may become 
exposed to the damaging effects of ROS and accumulate mitochondrial DNA damage or amass 
excessive ROS within the mitochondria; damage to the mitochondria through extensive oxidative 
stress leads to eventual cell death and apoptosis. Similar to the way in which cellular outcomes 
are affected by redox states within the mitochondria, hTERT expression is also regulated by 
many redox-sensitive transcriptional factors (Akiyama et al., 2003; Cong and Shay, 2008). In 
addition to ROS-mediated transcriptional consequences, ROS is also a determinant of hTERT 
intracellular location and therefore, cellular function.  
Following periods of oxidative stress, hTERT shuttles from the nucleus to the 
mitochondria; however, once in the mitochondria, the role of hTERT is not fully understood 
(Ahmed et al., 2008; Massard et al., 2006; Passos et al., 2006). At the cytosol, hTERT interacts 
with mitochondrial import proteins that facilitate transport into the mitochondria (Indran et al., 
2010). Following cellular stress, hTERT localization from the nucleus to the mitochondria is 
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correlated with increased mitochondrial DNA damage (Santos et al., 2006). Conversely, under 
some experimental conditions after inducing cellular stress, hTERT in the mitochondria has also 
been associated with improved mitochondrial function, presumably due to reinforcement of 
cellular anti-oxidant systems following the initial period of cellular stress (Massard et al., 2006). 
These contrasting effects may be drug and dose specific, but taken together, they highlight a role 
for hTERT as a toggle switch whereby the cellular balance can be tipped to favor either cell 
survival or cell death.  
In the past, it has been generally accepted that G-quadruplex ligands interfere with 
telomerase functioning in the nucleus of cancer cells (Biffi et al., 2013). Our recent data with a 
new G-quadruplex ligand anthracenyl isoxazole amide 1 (referred to hereon as AIM 1) 
demonstrated an alternate site of functioning as fluorescent microscopy consistently revealed 
AIM 1 localization to the mitochondria of human glioblastoma cells (described in Chapter 2). 
While performing studies investigating the mechanism of action of AIM 1, reports emerged 
regarding the role of two commercially available G-quadruplex ligands on the mitochondria of 
cells (Zhuang and Yao, 2013). These data were the first of its kind to show alternate activities for 
G-quadruplex ligands that include effects on the mitochondria and examine the functions of 
hTERT shuttling. Although our results are consistent with the findings from these experiments, 
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the advantage to our studies is the use of a novel G-quadruplex ligand created in conjunction 
with our laboratory, as well as the additional benefit of inherent fluorescence of compound AIM 
1—both of which are lacking from the results published from this group. The results detailed in 
this study indicate AIM 1 is preferentially located in the mitochondria of cells, induces 
mitochondrial apoptosis and mitochondrial dysfunction, and leads to shuttling of hTERT out of 
the nucleus. These data provide essential insight into the specific mechanisms of action of small 
molecule G-quadruplex inhibitors. 
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MATERIALS AND METHODS 
Chemicals. AIM 1 was obtained from the University of Montana (Missoula, MT). We are 
appreciative of the efforts Matthew J. Weaver and the Natale laboratory for contribution to the 
synthesis of the AIM compounds.  
 
Cell Culture. SNB-19 human glioblastoma cells (American Type Cell Culture Cat No. CRL-
2266) were grown in RPMI 1640 medium with L-glutamine and penicillin/streptomycin, 
supplemented with 10% fetal bovine serum (FBS). Cell culture medium and supplements were 
obtained from Invitrogen (Carlsbad, CA). The cells were incubated at 37 °C under a 
humidified atmosphere containing 5% CO2 and allowed to achieve confluence prior to 
experimentation.  
 
AIM Localization Studies. SNB-19 cells were plated on cover slips in 6-well plates at a density 
of 1 x 103/well, allowed to adhere, and incubated overnight at 37oC in 5% CO2 to achieve 
adherence. AIM solutions (1 µM) were added to cells and incubated overnight. After incubation, 
medium was aspirated, cells were washed twice with phosphate buffered saline (PBS) and fixed 
in 4% paraformaldehyde/PBS (on ice; 10 min). To determine mitochondrial co-localization 
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MitoTracker Red stain at a concentration of 250 nM (Invitrogen, Carlsbad, CA) was added 
directly to cells and incubated following manufacturer’s directions. Following washes in PBS, 
cells were washed once with de-ionized water, and fluorescent images were taken with an 
Olympus FV1000 confocal laser scanning microscope using selective laser excitation at 405 nm. 
Images were processed with Nuance 1.6.2.368 alpha software (Cambridge Research Institute).  
 
Mitochondrial Superoxide Determination. MitoSox Red selectively and rapidly targets the 
mitochondria of live cells and allows for the visualization of mitochondrial superoxide. SNB-19 
cells were plated on sterile coverslips in 6-well culture dishes and treated with 1 µM AIM 1 
overnight and 5 µM MitoSox Red (Invitrogen, Carlsbad, CA) for 10 min at 37 °C immediately 
prior to imaging, following manufacturer’s directions for use. For this experiment, modifications 
to manufacturer’s protocol included a fixation step immediately before analysis (4% 
paraformaldehyde for 10 minutes, RT). Hydrogen peroxide was used as a positive control. After 
exposure to MitoSox Red, samples were washed with PBS and inverted to microscope slides and 
sealed using FluorSave Reagent (Calbiochem, Billerica, MA, USA). Images and histograms 
were generated from scans from a CompuCyte iCys Laser Scanning Cytometer (CompuCyte, 
Westwood, MA). 
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Mitochondrial Membrane Potential Analysis. Mitochondrial membrane potential was 
determined using a JC-1 for flow cytometry kit (Invitrogen, Carlsbad, CA). JC-1 has advantages 
over other cationic dyes in that it can selectively enter into mitochondria and reversibly change 
color from red to green as the membrane potential decreases. For these experiments, 
manufacturer’s protocol was followed and 2 µM JC-1 was added to SNB-19 as described in the 
protocol. Samples with CCCP (m-chlorophenylhydrazone) served as a positive control. CCCP 
was included in the JC-1 for flow cytometry kit and causes rapid mitochondrial dysfunction and 
mitochondrial membrane depolarization. SNB-19 cells were treated with AIM 1 for a 24 h 
exposure period at concentrations of 1 µM, 2.5 µM, 5 µM and fluorescent data from cells were 
acquired using a BD FACSAria flow cytometer and analyzed using BD FACSDiva 4.0 Software 
(BD Biosciences San Jose, CA). 
 
FLICA Caspase-9 Detection. Green FLICA for Caspase 9 kit (ImmunoChemistry Technologies, 
Bloomington, MN) was used to probe for active caspase-9. FLICA assays allow for whole cell 
detection of caspase activity in apoptotic or caspase-positive cells. FLICA is advantageous 
because it is membrane-permeant and the dye forms covalent bonds with activated caspase 
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enzymes and is retained only in cells with active caspases. FLICA caspase probes are not 
retained in non-apoptotic cells following a simple wash process. For this experiment, SNB-19 
cells were plated in 6 well tissue culture dishes and treated with AIM 1 for 24 h at doses of 1 
µM, 2.5 µM, 5 µM. After exposure, the staining protocol for adherent cells was followed for the 
FLICA kit. Propidium Iodide (PI) exclusion was also performed, as suggested by manufacturer. 
Hydrogen peroxide was used as a positive control to ensure kit accuracy and samples were 
acquired using BD FACSAria flow cytometer and analyzed using BD FACSDiva 4.0 Software.  
 
hTERT Shuttling. To determine the effects of AIM exposure on hTERT shuttling out of the 
nucleus the methods of Wu, et al., were followed with modifications. Briefly, fixed SNB-19 cells 
incubated with 1 µM AIM 1 (16 h) were permeabilized with 0.1% Triton X, blocked with normal 
goat serum supplemented with PBS, bovine serum albumin (BSA), and sodium azide, and 
incubated with a 1:2000 dilution of rabbit anti-hTERT antibody (Rockland Immunochemicals, 
Gilbertsville, PA). Following several washes, AlexaFluor 594 anti-rabbit 2° antibody 
(Invitrogen, Carlsbad, CA) diluted to 1:1000 was added for 1 h and samples were washed 
thoroughly. HCS NuclearMask Deep Red stain (Invitrogen, Carlsbad, CA) was added following 
manufacturer instructions to counterstain organelles. Untreated samples were also included in 
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this experiment to visualize baseline hTERT expression in SNB-19 cells. Samples were acquired 
with an Olympus FV1000 confocal laser scanning microscope at 60X objective. Images were 
additionally magnified for optimal visualization and processed with Nuance 1.6.2.368 alpha 
software (Cambridge Research Institute). 
 
Statistics. All statistical analyses were performed using GraphPad Prism 4.0 for Macintosh 
(GraphPad Software, San Diego, CA). Student’s t-test was used to compare untreated and treated 
samples. Values p≤0.05 were determined to be significant. 
 
RESULTS 
AIM 1 is localized in the mitochondria of SNB-19 human glioblastoma cells. We have shown 
previously using iCys Laser Scanning Cytometry that AIM 1 (Figure 3.1) appears to distribute 
outside of the nucleus, within the mitochondria of cells. To confirm our finding, we performed 
confocal imaging. Samples were counterstained using the dye MitoTracker Red to visualize the 
mitochondria (Figure 3.2). A time course evaluation was also performed to determine the 
staining profile of AIM 1 following short-term exposure (Figure 3.3A). SNB-19 cells treated 
only with MitoTracker Red are shown for comparison. (Figure 3.3B) This experiment revealed 
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AIM 1 staining profile consistent with all other microscopy and with our previous findings from 
Laser Scanning Cytometry (detailed in Chapter 2). 
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Figure 3.1 
 
 
	  
 
 
 
IC50 3.13µM + 0.45  
 
MW 629.19 g/mol	  
  
Figure 3.1. Structure and corresponding toxicity data of AIM 1 in SNB-19 human 
glioblastoma cells. AIM 1 is cytotoxic to SNB-19 cells at the single digit micromolar level. 
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Figure 3.2 
 
 
Figure 3.2. AIM 1 location within SNB-19 cells. Confocal microscopy (60X, additionally 
magnified images) allow for visualization of AIM 1 (top, shown in green) with the addition of 
MitoTracker Red mitochondrial indicator in SNB-19 cells (bottom, images overlaid). Center 
images indicate MitoTracker localization within the mitochondria of AIM 1 treated cells. 
Overlay images clearly show AIM within mitochondria of cells. 
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Figure 3.3 
A. 
 
B.  
 
Figure 3.3. AIM 1 short-term exposure shows immediate localization to the mitochondria. 
Confocal microscopy shows staining of AIM 1 (green) in SNB-19 cells at various time points. 
For comparison, MitoTracker Red stained untreated SNB-19 cells (red) were examined. Results 
indicate AIM 1 is located in mitochondria at all exposures. 
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AIM 1 induces mitochondrial reactive oxygen species generation. Following results indicating 
that AIM 1 is preferentially located in the mitochondria of SNB-19 cells and that AIM 1 induces 
apoptosis, we hypothesized that AIM 1 was also causing mitochondrial dysfunction and stress. 
To test this theory, the mitochondrial superoxide indicator MitoSox Red was used. MitoSox Red 
will only be observed when mitochondrial ROS is present within the cell and will fluoresce 
brighter when there is a greater amount of superoxide. Results from these experiments 
demonstrated a visual and quantitative change in the amount of mitochondrial superoxide in 
samples treated with AIM 1 as compared to untreated groups (Figure 3.4). Histograms indicating 
the mean fluorescence intensity (MFI) of MitoSox Red in both untreated and AIM 1 treated 
groups are also shown. Fluorescence intensity is proportional to superoxide concentrations.   
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Figure 3.4 
A. 
 
B. 
 
Figure 3.4. AIM 1 induces mitochondrial superoxide production. Laser Scanning Cytometry 
shows MitoSox Red staining (shown in red), an indicator of mitochondrial ROS. SNB-19 
untreated samples (A) show positive MitoSox Red staining as expected of cancer cells, however, 
mean fluorescence intensity (MFI) values for this sample were determined to be less than half 
that of treated samples. SNB-19 cells treated with only 1 µM of AIM 1 (B) show much brighter 
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MitoSox Red flourescence. This is also reflected in a MFI for MitoSox Red that was two-fold 
higher than untreated samples.  
AIM 1 exposure results in a reduction in mitochondrial membrane potential. Following results 
from mitochondrial superoxide analysis, we sought to examine in more detail AIM 1 induced 
effects on the mitochondria. Apoptosis and ROS experiments led us to speculate that AIM 1 
exposure to SNB-19 cells was disrupting the mitochondrial membrane potential leading to the 
excessive ROS accumulation observed in MitoSox Red mitochondrial superoxide experiments. 
To evaluate this hypotheses, experiments to assess the mitochondrial membrane potential using 
JC-1 staining for flow cytometry were performed. As shown in Figure 3.5 (A and B), results 
indicate a significant reduction in the mitochondrial membrane potential following a 24 h 
exposure to 5 µM AIM 1. A dose dependent trend towards mitochondrial membrane 
depolarization above untreated control at each increasing dose of 1 µM, 2.5 µM, 5 µM of AIM 1 
was also observed. Additionally, it should be noted that exposure to the highest dose of AIM 1 
produced mitochondrial depolarizing effects that were even greater than the positive control 
using the protonophore m-chlorophenylhydrazone, CCCP. 
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Figure 3.5  
 
A. 
 
 
B. 
 
 
Figure 3.5. Assessment of mitochondrial dysfunction. Flow cytometry was performed using 
JC-1 staining to highlight the effects of AIM 1 on mitochondrial membrane potential (A). Green 
fluorescence indicates mitochondrial membrane depolarization. Statistical analysis demonstrated 
a dose dependent trend in mitochondrial membrane depolarization with increasing doses of AIM 
1 (B). ***indicates significance of p≤0.0001. 
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AIM 1 exposure results in activation of caspase-9. Following AIM 1 exposure, mitochondrial 
dysfunction observed in JC-1 experiments was speculated to coincide with activation of 
caspases—specifically caspases-9, which is responsible for mitochondrial-mediated apoptosis. 
Flow cytometry was performed to assess induction of apoptosis and caspases-9 activation by 
application of FLICA. As demonstrated in Figure 3.6, SNB-19 cells exposed to 5 µM AIM 1 for 
24 h resulted in a statistically significant increase in induction of activated caspase as compared 
to untreated control. It is of importance to note also that these results are consistent with previous 
Annexin V apoptosis analysis that showed similar values for each stage of apoptosis (Chapter 2).  
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Figure 3.6 
 
 
 
 Figure 3.6. AIM 1 exposure leads to activated caspase-9. FLICA binding indicates an 
induction of activated caspase 9 following exposure to AIM 1. FLICA+ groups indicate positive 
staining for active caspases-9. PI exclusion was used to identify the various stages of apoptosis 
coinciding with caspases-9 activation: early (FLICA+/PI-), late (FLICA+/PI+) and necrotic 
(FLICA-/PI+).  ***indicates significance of p≤0.0001. 
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hTERT shuttles out of the nucleus following AIM 1 exposure. We tested whether overnight 
treatment (16 h) at 1µM AIM 1 was a sufficient exposure period to cause hTERT shuttling from 
the nucleus to the mitochondria. For these experiments, we treated SNB-19 cells with the nuclear 
indicator HCS Nuclear Mask to visualize the nucleus, shown in Figure 3.7. As expected, in 
untreated cells, hTERT is primarily nuclear. However, following exposure to AIM 1, it is clear 
that hTERT moves out of the nucleus (Figure 3.8). Once again, in these images we are also able 
to visualize AIM 1 cellular location. Although it is clear that hTERT has shuttled out of the 
nucleus upon AIM 1 treatment, we are unable to determine if the location following exposure is 
mitochondrial or cytoplasmic. However, both extra-nuclear cellular locations have been observed 
in the literature following cellular stress (Chung et al., 2012; Zhuang and Yao, 2013). 
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Figure 3.7  
 
 
 
Figure 3.7. hTERT staining in untreated cells. Confocal microscopy (60X, magnified) shows 
untreated SNB-19 cells with hTERT (red). Nuclear counterstaining is highlighted in blue. 
Overlaid images are also indicated. 
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Figure 3.8 
 
 
 
Figure 3.8. Shuttling of hTERT following AIM 1 treatment. Confocal images (60X, 
magnified) show hTERT (red), AIM 1 (green) and nuclear counterstain (blue). Each frame is 
shown independently with overlaid images indicated (merge). 
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DISCUSSION 
Conventional chemotherapy for advanced malignant tumors is many times ineffective 
and there remains a need for new drugs that specifically target cancers and possess minimal 
toxicity to other tissues in the body. G-quadruplex ligands are promising anticancer agents that 
have potential to enhance current therapies and improve patient outcomes. We have examined 
here some of the characteristics of the apoptotic pathway induced by AIM 1 and conclude that 
the AIM 1 G-quadruplex ligand exerts effects beyond what was traditionally believed to be 
limited to telomere specific roles within the nucleus of cells. Indeed, studies are beginning to 
investigate the detailed mechanisms of toxicity of G-quadruplex ligands and evidence is 
emerging that the effects of stabilizing G-quadruplex structures are much more complex than 
originally thought (Tatuchi et al., 2003; Dourre et al., 2005; Li et al., 2004; Zhuang and Yao 
2013).   
The traditional approach to studying potential G-quadruplex ligands included 
experimental design that, once G-quadruplex interaction was confirmed, focused on basic 
toxicity testing and general apoptotic analysis. It is only recently becoming more common to 
include detailed microscopy highlighting the cellular localization of G-quadruplex ligands, as 
demonstrated by the comprehensive article in Nature Chemistry, which includes not only 
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visualization using fluorescent microscopy, but quantification of their G-quadruplex ligand 
within chromosomes as well (Biffi et al., 2013). In this regard, our research is a vital component 
in the progression of G-quadruplex study and moreover, the use of AIM 1 that already possesses 
inherent fluorescent properties, is incredibly advantageous to detailed microscopy 
experimentation. 
To ensure that the localization of AIM 1 was indeed a true event and not an artifact of a 
downstream site of action, a time course experiment was performed that demonstrated AIM 1 in 
the same cellular location during all short time periods of exposure. A mitochondrial counterstain 
was not included in these AIM 1-treated SNB-19 cells to rule out the possibility that the 
localization of AIM 1 to the mitochondria was being induced or being caused by the addition of 
a marker. To this end, untreated SNB-19 cells stained with a mitochondrial dye MitoTracker dye 
was included as a separate experiment to highlight the similar staining profiles between 
MitoTracker Red and AIM 1. What is clear is that the staining profile of AIM 1 is identical to all 
other experiments, including those performed with the additional MitoTracker dye in AIM 1-
treated cells. These conclusive results support the analysis that AIM 1 is binding somewhere 
within the mitochondria, immediately following exposure.  
At this time, the effects of hTERT shuttling from the nucleus are unknown. Based on 
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fluorescence staining of hTERT following AIM 1 exposure, it appears as though hTERT has 
moved out of the nucleus, as evidenced by the lack of red fluorescence in the nuclear region. 
Additionally, the exterior outline of untreated cells is visible in confocal microscopy (likely due 
to nonspecific staining) and highlights the stark contrast between the nuclear concentrated 
hTERT in untreated cells versus the very obvious increase in both hTERT fluorescence and 
location in AIM 1 exposed cells out of the nucleus. Due to fluorescence overlap and constraints 
relating to the available dyes, we were unable to confirm hTERT localization to the mitochondria 
and cytoplasm with counterstains. It has been reported that hTERT contains a mitochondrial 
targeting signal (MTS) and that hTERT import to the mitochondrial matrix is driven by changes 
in the mitochondrial membrane potential (Sharma et al., 2012). It is plausible that following AIM 
1 binding to G-quadruplex and the subsequent mitochondrial membrane depolarization reported 
in this study, hTERT shuttling out of the nucleus observed in confocal microscopy experiments 
is a consequence of intracellular stress. hTERT shuttling to the mitochondria is also speculated to 
occur to protect the mitochondria from DNA damage and apoptosis (Haendeler et al., 2009). 
Apoptosis and caspase activation are occurring in AIM 1 treated SNB-19 cells, which can 
explain extra-nuclear hTERT shuttling as an effect of cellular damaged caused by AIM 1.  
While the mitochondrial effects of AIM 1 are detailed in this study, what still remains 
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under investigation is the actual binding site of AIM 1 within the mitochondria. Initial NMR 
experiments showed an interaction with AIM 1 and a commercially available telomeric G-
quadruplex sequence (detailed in Chapter 2), but research suggests that G-quadruplex ligands do 
have some promiscuity for G-rich sequences in general, for which there are many. AIM 1 is not 
located within the nucleus, where telomeres are located; this suggests that AIM 1 is binding to a 
similar guanine-rich sequence and G-quadruplex structure in another cellular organelle. 
Currently, the data on G-quadruplex formation within mitochondrial DNA is not definitive, 
however, several groups suggest the presence of G-quadruplex structures within the 
mitochondria (Wanrooij et al., 2012; Capra et al., 2010; Ngo et al., 2013). If AIM 1 is binding to 
G-quadruplex in mitochondrial DNA, this may also explain the hTERT shuttling effects. Both 
mitochondrial DNA and mitochondrial hTERT are located within the mitochondrial matrix; the 
very presence of AIM 1 in the matrix could be enough to induce the export of hTERT out of the 
nucleus. Based on the fact that AIM 1 was designed as a G-quadruplex ligand, shows specificity 
for G-quadruplex structures (as demonstrated by NMR), the effects are not associated with any 
other known mechanism as detailed by COMPARE analysis (Han et al., 2009), and is localized 
in the mitochondria associated with the mitochondrial effects detailed in this study, we believe 
the likely binding of AIM 1 is to G-quadruplex within mitochondrial DNA. However, since this 
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is not definitive at this time, further investigation into the sub-mitochondrial location of AIM 1 
needs to be performed to determine if binding occurs in the mitochondrial matrix, where 
mitochondrial DNA is located, or somewhere along the membrane. Furthermore, it would be 
relevant to examine mitochondrial DNA following AIM 1 treatment in SNB-19 cells to 
determine the effects of exposure.  
Collectively, results of this study support an intriguing and alternate mechanism of action 
for the function of G-quadruplex ligands. Fluorescent microscopy and flow cytometric analyses 
support our hypothesis that AIM 1 acts as a mitochondrial modulator in addition to its role as a 
G-quadruplex stabilizer. Additionally, our data definitively demonstrating the mitochondrial 
location of AIM 1, combined with our NMR results indicating the G-quadruplex interaction 
potential of AIM 1, is supportive of the theory that G-quadruplex structures do exist within the 
mitochondria. Future work carefully examining the effects of AIM 1 on structures within the 
mitochondria as well as the mitochondrial DNA will be an exciting and necessary addition to the 
field of G-quadruplex. 
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CHAPTER 4 
A novel series of 4-isoxazolyl-1,4-dihydropyridines (IDHPs) P-gp inhibitors enhance the 
cytotoxicity of anthracenyl isoxazole amide (AIM) antitumor compounds when co-dosed 
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ABSTRACT 
The P-glycoprotein efflux pump is a major contributor to the failure of many anticancer 
agents that are substrates for the transporter. P-gp overexpression is also an important 
mechanism that is responsible for the multidrug resistance phenotype observed in many different 
types of cancers, including brain cancer. To this end, the development of inhibitors that function 
to block the efflux of anticancer agents out of the brain and promote their entry into target tissues 
is an important area of research. The purpose of this study is to evaluate the effects of a newly 
synthesized series of 4-isoxazolyl-1,4-dihydropyridines (IDHPs) that function as P-gp inhibitors 
and enhance the cytotoxicity of anthracenyl isoxazole amide (AIM) antitumor compounds when 
co-dosed together in vitro. 12 IDHPs were evaluated for their inhibition of P-gp. Two of these 
IDHPs 1A and 1K produced substantial P-gp inhibition and were selected for further 
investigation into their ability to increase the cytotoxicity of both known and novel anticancer 
agents. For the purposes of this study, a new modified MTT assay was developed to determine 
the change in cytotoxicity to P-gp expressing MDCK-MDR1+ cells and non-P-gp expressing 
MDCK-MDR1- cells before and after IDHP exposure. Results of this study indicate that some 
IDHPs compounds in our series produce substantial P-gp inhibition and can be used in vitro to 
increase the cytotoxicity of a new series of AIM antitumor agents. 
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INTRODUCTION 
 Brain cancer, and more specifically glioblastoma, is a devastating and fatal disease and 
despite extensive research, patient prognosis is overwhelmingly poor and treatment remains 
largely ineffective. One of the major challenges in the treatment of brain cancer is the 
development and delivery of effective anticancer agents that are capable of reaching their target 
within tumor cells of the brain and central nervous system (CNS). The first obstacle that needs to 
be overcome is gaining access to tumor cells in the brain by bypassing the blood-brain barrier 
(BBB). The BBB is comprised of endothelial cells that are joined together to form tight 
junctions; they create a physical barrier that separates the blood from the brain and protects the 
brain from toxins and exposure to other harmful chemicals (Hawkins and Davis, 2005). In regard 
to brain tumors, this barrier also limits entry of drugs and prevents these therapeutic agents from 
reaching the brain, drastically decreasing the effectiveness of these anticancer agents. 
Additionally, cells of the BBB also contain efflux transporters that further limit the entry of 
xenobiotics, environmental contaminants and anticancer therapeutic agents into the brain 
(Pardridge, 1999). One particular transporter, P-glycoprotein (P-gp, also commonly known as 
MDR1 and ABCB1), is highly expressed at the level of the BBB and has been widely studied as 
a contributing factor to multidrug resistance. Drug resistance attributed to P-gp limits the 
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effectiveness of many clinical anticancer agents, including taxanes, etoposide, anthracyclines, 
vinca-alkaloids, and topotecan (Tsuji, 1998). Because so many anticancer agents are substrates 
for P-gp and because P-gp so effectively exports these drugs before they can reach tumor cells in 
the brain, developing P-gp inhibitors to be used clinically to block this transporter is an important 
area of research. 
 The first P-gp inhibitor studied was verapamil—a calcium channel blocker used to treat 
hypertension that was found to also possess P-gp inhibition properties (Tsuruo et al., 1981). 
Since this discovery, many P-gp inhibitors have been developed and tested; however, aside from 
their ability to block the efflux functions of P-gp, few of these drugs have been examined for 
their ability to enhance drug delivery to the brain when dosed together with conventional 
chemotherapies (Avendano and Menendez, 2002; Pleban and Ecker, 2005; Agarwal et al., 2011). 
To this end, we have developed a series of 4-isoxazolyl-1,4-dihydropyridines (IDHPs) that 
function as P-gp inhibitors and enhance the cytotoxicity of a select anthracenyl isoxazole amide 
(AIM) antitumor compound when co-dosed together in vitro.  The series of IDHPs were 
synthesized after the discovery that many 4-aryl-1,4-dihydropyridines (DHPs) that bind the L-
type voltage gated calcium channel are also P-gp inhibitors (Yusa and Tsuruo, 1989; Vilpo et al., 
2000; Boer et al., 1994; Zhou et al., 2005a). While the IDHPs do exhibit calcium channel 
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binding, we found that replacement of the 4-aryl substituent with an isoxazole in this series of 
IDHPs resulted in good selectivity for P-gp beyond the selectivity for calcium channels that 
traditional DHPs exhibit (Hulubei et al., 2012). In this regard, our most active P-gp inhibitor 
(1K) contains a branched aryl group that is likely the structural feature leading to preferential 
binding to P-gp instead of adopting a conformation that would overwhelmingly favor calcium 
channel binding (Hulubei et al., 2012). 
 In this study, a series of IDHPs were examined to determine their ability to inhibit P-gp. 
Several parameters were assessed including IDHP cytotoxicity to P-gp expressing and non-P-gp 
expressing cells as well as to a SNB-19 human glioblastoma cell line. Once P-gp inhibition was 
determined, lead IDHPs were selected for further investigation into their ability to enhance the 
cytotoxicity of AIMs when the two agents were dosed together in vitro. The results of this study 
suggest that IDHPs produce potent P-gp inhibition and are minimally cytotoxic. In addition, 
IDHPs have the potential to be useful drugs to administer with anticancer therapies to increase 
the overall cytotoxicity and aid in the ability of these chemotherapeutic agents to better reach 
their targets within the brain. 
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MATERIALS AND METHODS 
Chemicals. IDHPs and AIM 1 were obtained from the University of Montana (Missoula, MT). 
IDHP and AIM 1 synthesis was performed by the Natale laboratory at the University of 
Montana. We are appreciative of the efforts of Scott A. Steiger and Matthew J. Weaver for their 
respective contributions to the synthesis of the IDHPs and AIM compounds.  
 
MDCK Cell Culture. MDR1 transfected MDCK MDR1+ (P-gp expressing) and parent MDCK 
MDR1- (non P-gp expressing) canine kidney epithelial cells were obtained from the National 
Cancer Institute (Bethesda, MD). Cells were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), glucose, L-glutamine, sodium 
pyruvate and penicillin/streptomycin (VWR International).  MDCK MDR1+ cells were 
additionally supplemented with 80 µg/mL colchicine to maintain integrity of the cell line. Cells 
were grown to confluence prior to inhibition assays and maintained at 37 °C under a humidified 
atmosphere containing 5% CO2.  
 
SNB-19 Cell Culture. SNB-19 human glioblastoma cells (American Type Cell Culture Cat No. 
CRL-2266) were grown in RPMI 1640 medium with L-glutamine and penicillin/streptomycin, 
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supplemented with 10% fetal bovine serum (FBS). Cell culture medium and supplements were 
obtained from Invitrogen (Carlsbad, CA). The cells were incubated at 37 °C under a humidified 
atmosphere containing 5% CO2 and allowed to achieve confluence prior to experimentation.  
 
Cell Viability Assay. Cell survival was measured by the [3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. MTT was obtained from Sigma-
Aldrich (St. Louis, MO). As previously described, cells were plated in 96-well plates at a density 
of 10,000 cells/mL and allowed to attach overnight (16 h). P-gp inhibitor or substrate solutions 
were applied in medium for 24 h, removed, and replaced with fresh medium, and the plates were 
incubated at 37°C under a humidified atmosphere containing 5% CO2 for 2−4 days. MTT (50 
µg) was added and the cells were incubated for another 4 h. Medium/MTT solutions were 
removed carefully by aspiration, the MTT formazan crystals were dissolved in 100 µL of 
DMSO, and absorbance was recorded on a spectrophotometer at 560 nm. IC50 values 
(concentration at which cell survival equals 50% of control) were determined from semilog plots 
of percent of control versus concentration. Average IC50 values are reported from triplicate 
results.  
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Cytotoxicity Following P-gp Inhibition Assay. MDCK MDR1-/+ cells were plated at a density of 
10,000cells/mL in 96 well plates and allowed to adhere overnight (16 h). As previously 
mentioned, colchicine was added to the MDCK-MDR1+ medium immediately before cells were 
plated. On the day of IDHP treatment, medium was aspirated from plates and replaced with 
medium containing 10-50 µM IDHP for a 1-h initial exposure. Following IDHP pre-treatment, 
AIM solutions containing IDHPs (to reach the desired final concentration of IDHP) were applied 
in medium for 24 h. Medium was then aspirated and fresh medium was applied and plates were 
incubated at 37 °C under a humidified atmosphere containing 5% CO2 for 24-48 hours. MTT (50 
µg) was added and the cells were incubated for another 4 h. Medium/MTT solutions were 
removed carefully by aspiration, the MTT formazan crystals were dissolved in 100 µL DMSO, 
and absorbance was determined on a plate reader at 560 nm.  IC50 values (concentration at which 
cell survival equals 50% of control) were determined from semi-log plots of percent of control 
vs. concentration. Data were analyzed as changes in AIMs IC50 before and after IDHP exposure 
in MDCK-MDR1- vs. MDCK-MDR1+ cells to determine the effect of IDHP pre-treatment on 
AIMs selective toxicity to MDCK-MDR1+ cells. 
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Statistics. All statistical analyses were performed using GraphPad Prism 4.0 for Macintosh 
(GraphPad Software, San Diego, CA). Student’s t-test was used to compare change in IC50 
values of each compound in MDCK-MDR1- vs MDCK-MDR1+ cell lines. ANOVA with post 
hoc Bonferroni test was used to compare effect of IDHP exposure on antitumor compound 
cytotoxicity across all groups. IC50 values were expressed as the mean +/- standard deviation 
(SD). Values p≤0.05 were determined to be significant. 
 
RESULTS 
AIM 1 is less cytotoxic to high P-gp expressing ADR-RES cell line compared to cell lines not 
expressing significant P-gp. Results from NCI-DTP 60 cell line screen (NCI data courtesy of 
Dr. Nicholas Natale, University of Montana) demonstrate AIM 1 was approximately 7-fold more 
toxic in non-resistant cell lines tested (Figure 4.1). Compared to double tailed AIMs, there was 
no difference in growth inhibition across all cell lines tested as compared to the ADR-RES 
(adriamycin-resistant) cell line for single tail AIMs (AIM 3 and AIM 5). Other double tail and 
single tail AIMs were examined and results were consistent with double tail AIMs showing 
substantial toxicity to cell lines that were not resistant compared to the ADR-RES cell line (data 
not shown). Data from NCI-DTP 60 cell line screen suggest double tail AIMs, including AIM 1, 
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are substrates for P-gp and are effluxed out of cells, resulting in the minimal cytotoxicity 
observed in ADR-RES cells compared to other cell lines tested. 
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Figure 4.1 
	  
 
AIM 1 
 
AIM 3 
 
AIM 5 
	  
 
AIM Mean GI50 (µM) ADR-RES GI50 (µM) 
1 2.0 14 
3 1.4 1.6 
5 1.8 1.9 
 
Figure 4.1. Double tail AIMs are less cytotoxic in ADR-RES cell line. NCI-DTP 60 cell line 
screen indicating GI50 values (concentration of drug that results in 50% growth inhibition) is 
reported. A larger GI50 value in ADR-RES cells compared to the mean GI50 value indicates AIM 
is sensitive to drug resistance and potentially a P-gp substrate. 
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IDHPs 1A and 1K produce substantial P-gp (MDR1) inhibition. Screening of IDHPs was 
performed by the Psychoactive Drug Screening Program (PDSP) of the National Institute of 
Mental Health (NIMH). Results from this screening demonstrated that all IDHPs produced P-gp 
inhibition of at least 10% (Figure 4.2). Of the IDHPs tested, two produced substantial P-gp 
inhibition; 1A produced 49% P-gp inhibition and 1K produced 61% P-gp inhibition. 1A and 1K 
were selected for further investigation. 
 
1A has cytotoxicity profile comparable to nifedipine. The DHP calcium channel antagonist 
nifedipine was selected as a control for these experiments. MTT results demonstrate that IDHP 
1A is similarly non-toxic to nifedipine with mean IC50 values >100 uM for a 24 hour exposure 
(Figure 4.3). IDHP 1K showed some cytotoxicity to both cell lines tested: mean IC50 value 25.48 
µM in MDCK-MDR1- cells and 20.98 µM in MDCK-MDR1+ cells. Due to concerns over the 
cytotoxicity of 1K, for co-dosing experiments evaluating the change in AIM cytotoxicity 
following IDHP exposure, cells were exposed to a non-toxic dose of IDHP 1K compared to 1A. 
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Figure 4.2 
 
	  
IDHP R1 R2 MDR-1 (% 
inhibition) 
1a CH3 C6H5 49 
1b CH3 o-MeO-C6H4 33 
1c CH3 2-MeO-5-Cl- 
C6H3 
15 
1d CH3 o-Cl-C6H4 11 
1e CH3 m-Cl-C6H4 27 
1f CH3 p-Cl-C6H4 12 
1g i-Pr C6H5 38 
1h C6H5CH2CH2 C6H5 28 
1i p-Biphenyl- 
CH2CH2 
CH3 19 
1j 1-naphthyl 
CH2CH2 
CH3 19 
1k m-Br- C6H5CH2 
(CH3)CH 
CH3 61 
1l 1-naphthyl 
CH2(CH3)CH 
CH3 38 
 
Figure 4.2. IDHPs produce P-gp (MDR-1) inhibition. All IDHPs in this series showed P-gp 
inhibition of at least 10%. Structure and percent MDR1 are indicated (adapted from Hulubei et 
al., 2012). 
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Figure 4.3 
	  
	  
	  
	  
 
 
Figure 4.3. Assessment of cytotoxicity of IDHPs against known P-gp inhibitor. Nifedipine, a 
well documented P-gp inhibitor, shows no measurable cytotoxicity to both MDCK-MDR1- and 
MDCK-MDR1+ cell lines. 1A also shows no measurable cytotoxicity. 1K is more cytotoxic to 
MDCK-MDR1+ cells but the difference is not statistically significant.  
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Doxorubicin, AIM 1, and AIM 3 are cytotoxic to MDCK-MDR1- non-P-gp expressing cells. 
Doxorubicin is a known P-gp substrate and was selected for viability assays as a comparison 
against the AIMs (Teodori et al., 2002). Doxorubicin was more cytotoxic in cells not expressing 
P-gp compared to cells that do express P-gp (Figure 4.4). When AIM 1 was evaluated by MTT, 
similar results were observed. AIM 1 mean IC50 value in MDCK-MDR1- cells was 3.46 µM. and 
in MDCK-MDR1+ cells the mean IC50 value increased significantly to 22.90 µM. AIM 3 mean 
IC50 value was also significantly higher in MDCK-MDR1+ cells. 
 
Exposure to IDHPs 1A and 1K significantly increases doxorubicin cytotoxicity in P-gp 
expressing cells. For these experiments, a modified MTT assay was developed to examine the 
effects of co-treatment with IDHPs on the cytotoxicity of P-gp substrates (Figure 4.5). 
Doxorubicin, a known P-gp substrate was once again used as a control. Exposure to 50 µM 
IDHP 1A significantly increased the cytotoxicity of doxorubicin in MDCK-MDR1+ cells. For 
evaluation of 1K, a lower dose was used due to the concerns over cytotoxicity. Exposure to 10 
µM IDHP 1K also significantly increased the cytotoxicity of doxorubicin in MDCK-MDR1+ 
cells.  
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Figure 4.4 
	  
	  
	  
	  
	  
Figure 4.4. Assessment of P-gp substrate doxorubicin cytotoxicity compared to AIMs. 
Histograms reveal results from MTT viability assays. Differences in IC50 values between 
MDCK-MDR1- cells (grey) compared to P-gp expressing MDCK-MDR1+ cells (black) are 
shown. * p≤0.05 compared to IC50 values from non-P-gp expressing MDCK-MDR1- cells. 
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Figure 4.5  
	  
	  	  	  	  	  	   	  
	  
Figure 4.5. Doxorubicin cytotoxicity after addition of IDHP P-gp inhibitors. Histograms 
reveal results from modified MTT viability assays following co-dosing with IDHP. IDHP effect 
on doxorubicin cytotoxicity is indicated. IC50 values in MDCK-MDR1- cells (grey) compared to 
P-gp expressing MDCK-MDR1+ cells (black) are shown. * p <0.05 from doxorubicin before 
IDHP pre-treatment. 
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Cytotoxicity of AIM 1 is increased following pre-treatment with IDHPs. Following exposure 
to 50 µM IDHP 1A the cytotoxicity of AIM 1 in MDCK-MDR1+ cells significantly increased 
from a mean IC50 of 22.90 µM to 2.80 µM (Figure 4.6). In both cell lines, following exposure to 
10 µM 1K, AIM 1 became significantly more cytotoxic.  
 
Cytotoxicity of AIM 3 was not increased following IDHP pre-treatment. In MDCK-MDR1+ 
cells, AIM 3 mean IC50 value is 6.35 µM. Following exposure to 50 µM IDHP 1A, AIM 3 mean 
IC50 value was reduced to 5.94 µM (Figure 4.7). This change is not statistically significant. 
When MDCK-MDR1+ cells were exposed to 10 µM IDHP 1K, the cytotoxicity of AIM 3 
decreased. Surprisingly, AIM 3 became significantly less toxic following pre-treatment with 1K 
in MDCK-MDR1+ cells.  
 
IDHPs increased cytotoxicity of AIM 1 in SNB-19 cells. Due to the extensive data collected in 
relation to AIM 1 in SNB-19 human glioblastoma cells (Chapters 2 and 3), modified MTT assays 
were performed to examine the effects of IDHP pre-treatment on AIM 1 cytotoxicity (Figure 
4.8). Following exposure to IDHPs 1A and 1K, AIM 1 became more cytotoxic in SNB-19 cells. 
Pre-treatment of 10 µM of IDHP 1K resulted in a statistically significant increase in AIM 1 
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cytotoxicity to SNB-19 cells. This effect is likely due to the inherent toxicity of 1K.  
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Figure 4.6 
	  
	  
Figure 4.6. AIM 1 cytotoxicity after addition of IDHP P-gp inhibitors. Histograms reveal 
results from modified MTT viability assays following co-dosing with IDHP. IDHP effect on 
AIM 1 cytotoxicity is indicated. IC50 values in MDCK-MDR1- cells (grey) compared to P-gp 
expressing MDCK-MDR1+ cells (black) are shown. * p<0.05, ** p <0.001, *** p≤0.0001.  
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Figure 4.7 
	  
	  
	  
Figure 4.7. Pre-treatment with IDHPs and effects on AIM 3 cytotoxicity. Histograms reveal 
results from modified MTT viability assays following co-dosing with IDHP. IDHP effect on 
cytotoxicity of AIM 3 is indicated. IC50 values in MDCK-MDR1- cells (grey) compared to P-gp 
expressing MDCK-MDR1+ cells (black) are shown. * p<0.05, ** p <0.001, *** p≤0.0001. 
*indicates a p <0.05 from AIM 3 before IDHP pre-treatment. 
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Figure 4.8 
 
	  
 
Figure 4.8. Effects of IDHPs on AIM 1 in SNB-19 cells. Pre-treatment of SNB-19 cells with 
IDHPs increases the cytotoxicity of AIM 1. Histogram details IC50 of AIM 1 with IDHP. * p 
<0.05. 
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AIM 3 is less cytotoxic to SNB-19 cells following IDHP exposure. As observed in MDCK-
MDR1- and MDCK-MDR1+ cells, pre-treatment of IDHPs resulted in a reduction of AIM 3 
cytotoxicity in SNB-19 cells (Figure 4.9). With the addition of both IDHPs 1A and 1K, AIM 3 
became significantly less toxic to SNB-19 cells, which was unexpected. 
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Figure 4.9 
 
 
 
 
Figure 4.9. Effects of IDHPs on AIM 3 in SNB-19 cells. Pre-treatment of SNB-19 cells with 
IDHPs decreases the cytotoxicity of AIM 3. Histogram details IC50 of AIM 1 with IDHP. * p 
<0.05, ** p<0.01. 
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DISCUSSION 
Results of this study demonstrate the potential to use IDHPs as P-gp inhibitors. The two 
IDHPs examined in this study, 1A and 1K, possess significant P-gp inhibition properties and 
increase the cytotoxicity of P-gp substrates, doxorubicin and AIM 1. NCI-60 cell line screening 
results strongly suggest AIM 1 is indeed a P-gp substrate and our results both in MDCK-MDR1+ 
cells and SNB-19 cells corroborate these findings. AIM 3, a single tail AIM, does not appear to 
act in the same manner as doxorubicin and AIM 1. When the results of the MTT assays with 
doxorubicin, AIM 1, and AIM 3 are examined closely, we can conclude that while AIM 3 is 
significantly more cytotoxic in MDCK- MDR1- cells, the extent to which this is true is much less 
than that of doxorubicin and AIM 1. MTT results considered together with the results of the 
NCI-60 cell line screening that show AIM 3 is less sensitive to the P-gp effects of ADR-RES 
cells, suggest that if AIM 3 is a P-gp substrate, it is functioning as a very weak P-gp substrate. 
Results with IDHP 1K, which PDSP data showed produced the most P-gp inhibition, are 
not straightforward. In cases with doxorubicin and AIM 1, 1K pre-treatment results in a 
significant increase in substrate cytotoxicity. However, when 1K is dosed with AIM 3, the 
cytotoxicity is decreased significantly in MDCK-MDR1+ cells and SNB-19 cells; we would 
expect the cytotoxicity to be unchanged before and after 1K exposure. In these cases, there may 
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be an interaction between 1K and AIM 3, which results in one drug outcompeting the other for 
an enzyme or binding site (non P-gp related). AIM 3 might also be inducing P-gp, leading to an 
overall decrease in the cytotoxicity of the compound (Matheny et al., 2001). This could result in 
AIM 3 not being able to achieve the cytotoxic effects that are seen before 1K exposure. 
IDHP exposure effects in SNB-19 cells are preliminary—P-gp expression was not 
calculated in these cells— but do support the data that suggest efflux transporters exist not only 
within endothelial cells of the BBB, but other CNS cells as well (Abe et al., 1995; Dallas et al., 
2006). While the modified MTT assay demonstrated a decrease in mean IC50 values when AIM 1 
was co-dosed with IDHP 1A, results were only significant following exposure to 1K. Baseline P-
gp expression was not evaluated in SNB-19 cells; however, the significant effects observed only 
with exposure to 1K with AIM 1 in SNB-19 cells could be due to an inherent high expression of 
P-gp in SNB-19 cells. That is, a more potent IDHP (such as 1K, which produces more P-gp 
inhibition than 1A) would be necessary to achieve significant increases in cytotoxicity compared 
to the cytotoxicity before IDHP exposure. 1K is also inherently more cytotoxic than 1A (as 
demonstrated by MTT viability assays) and this cytotoxicity could be contributing to the effects 
observed following treatment with 1K and AIM 1. 
 Results from this study demonstrate IDHPs are capable of increasing the cytotoxicity of 
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doxorubicin in P-gp expressing cell lines to a greater extent than other P-gp inhibitors reported in 
the literature (Dantzig et al., 2001). Pre-treatment with IDHPs also increases the cytotoxicity of 
AIM 1 significantly more efficiently than other anticancer agents being evaluated in conjunction 
with P-gp inhibitors (Zhou et al., 2005b). While the development of P-gp inhibitors is an active 
field, there have been several limiting factors to their use. First generation P-gp inhibitors such as 
cyclosporin A, quinidine, and reserpine inhibited P-gp but were somewhat non-specific for the 
transporter and less potent than later generation P-gp inhibitors (Bansal et al., 2009). In addition, 
doses required to achieve inhibition were often accompanied by significant toxicity. Second 
generation modulators such as biricodar and analogues of cyclosporin A had similar problems 
with not producing significant P-gp inhibition at tolerable doses. Issues with second generation 
inhibitors were compounded when it was discovered that many of these agents were also 
substrates for CYP3A4—competition between anticancer agents and these P-gp inhibitors for 
CYP 3A4 activity resulted in unpredictable pharmacokinetic interactions leading to toxic levels 
of anticancer drugs (Liscovitch and Lavie, 2002). Third generation P-gp inhibitors, such as 
tariquidar, have been improved to reduce the affinity to be metabolized by CYP34A, as well as 
increase the overall potency and activity for P-gp (Palmeira et al., 2012; Bansal et al., 2009). 
One of the biggest improvements that has been made with new P-gp inhibitors is their ability to 
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be dosed within the nanomolar range (Krishna and Mayer, 2000). While great strides have been 
made in the development of third generation P-gp inhibitors, results from our studies with IDHPs 
are still superior in the extent to which pre-treatment increases the cytotoxicity of known 
substrates; one of the highest reported values is a 13 fold increase in cytotoxicity of doxorubicin 
following P-gp inhibitor exposure (Dantzig et al., 2001). Our IDHPs exceed this value. 
 In vitro assays detailed in this study dosing at 10-50 µM IDHPs is an acceptable range for 
preliminary investigation. It is possible that effects would be replicated at doses even lower, but 
as results were significant with AIM 1 co-dosed with IDHPs, a dose response was not evaluated 
in this study. It is the ultimate goal of this research to continue the synthesis of IDHPs and 
develop increasingly potent P-gp inhibitors that are highly selective only for the P-gp efflux 
transporter. In the meantime, it is important to continue to evaluate the IDHPs to determine 
exactly how they interact with P-gp (to include a more detailed structure-activity analysis and 
identify IDHP activity as competitive or non-competitive inhibitors of P-gp) and how these 
effects can be accentuated to produce the most P-gp inhibition in the absence of undesirable or 
unpredictable toxicity. 
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ABSTRACT 
 A series of 7-amino- and 7-acetamidoquinoline-5,8-diones with aryl substituents at the 2-
position were synthesized, characterized, and evaluated as potential NAD(P)H:quinone 
oxidoreductase (NQO1)-directed antitumor agents. NQO1 is an important drug target in cancer 
research; it is upregulated in many solid tumors and is capable of bioactivating compounds to 
increase toxicity and selectivity to cancerous cells. Aside from reducing quinone substrates to 
potentially more active hydroquinone alkylating agents that target cancer cells, NQO1 also 
functions as a cytoprotective enzyme. Through the detoxification of quinones, NQO1 aids in 
reducing harmful exposure and regulates the health of the cellular environment. In the present 
study we utilized several techniques to assay potential NQO1 substrates. Results of metabolism 
studies demonstrated that 7-amino analogues were generally better substrates for NQO1 than 7-
amido analogues, as were compounds with smaller heteroaromatic substituents at the C-2 
position. Two compounds, 7-acetamido-2-(8′-quinolinyl)quinoline-5,8-dione (11) and 7-amino-
2-(2-pyridinyl)quinoline-5,8-dione (23), showed selective cytotoxicity toward the NQO1-
expressing MDA468-NQ16 breast cancer cells versus the NQO1-null MDA468-WT cells. For all 
other compounds tested, NQO1 protected against quinoline-5,8-dione cytotoxicity. Compound 
22 showed potent activity against human breast cancer cells expressing and not expressing 
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NQO1, with respective IC
50
 values of 190 nM and 140 nM and a low NQO1-mediated reduction 
rate, suggestive of a mode of action for 22 that differs from that of lavendamycin and involves an 
unidentified target(s). 
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INTRODUCTION 
 Lavendamycin is a quinolinequinone antibiotic with antitumor activity that was isolated 
from Streptomyces lavendulae (Balitz et al., 1982; Doyle et al., 1981). Lavendamycin is 
structurally related to streptonigrin, which was first isolated from Streptomyces flocculus (Rao 
and Cullen, 1959; Rao et al., 1963). Streptonigrin is known for its potent cytotoxic properties, 
antitumor activity, in vitro and in vivo antiviral properties, and potent, broad-spectrum 
antimicrobial properties. Although lavendamycin is not suitable for clinical use due to its 
toxicity, its analogues are less toxic and have potential as antitumor agents (Podeszwa et al., 
2007).  Recent findings suggest that some indolequinones and quinolinequinones are excellent 
substrates for the quinone reductase enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1) and 
are selectively cytotoxic to cancer cell lines that overexpress NQO1 (Hassani et al., 2005; Fryatt 
et al., 2004; Beall et al., 1998; Swann et al., 2001; Hassani et al., 2008; Cai et al., 2010). 
NQO1 is a ubiquitous flavoenzyme that catalyzes the two-electron reduction of quinones 
to hydroquinones, and it is highly expressed in many solid tumors (Colucci et al., 2008). The 
upregulation of NQO1 in cancer is a feature that can be exploited to target drugs that are reduced 
by NQO1 and that become active through metabolism by the enzyme. This forms the basis for 
the synthesis of novel quinolinequinones structurally related to lavendamycin as potential 
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NQO1-directed antitumor agents. The primary role of NQO1, however, is not necessarily the 
bioactivation of substrates, but rather the detoxification of potentially harmful quinones. Two-
electron reduction of quinones to hydroquinones results in bypass of formation of the highly 
reactive semiquinones from one-electron reduction. Formation of semiquinones, with one 
unpaired electron on the oxygen atom, can undergo redox cycling in the presence of molecular 
oxygen to generate additional reactive oxygen species (ROS) including superoxide, singlet 
oxygen, and hydroxyl radicals (Thor et al., 1982). Semiquinones can also reduce other 
compounds. For example, when iron is reduced by a semiquinone, hydroxyl radicals can be 
formed by way of the Fenton reaction. The resulting ROS generated from the reactive 
semiquinone are toxic to the cells—consequences of ROS accumulation include lipid 
peroxidation, enzyme inactivation, and modification of DNA (Lind et al., 1982). Conversely, the 
two electron reduction by NQO1 favors the formation of the stable hydroquinone that can be 
readily conjugated and excreted (Losito et al., 1967).  
In this study we utilize an efficient and direct approach from commercially available 
hydroxyquinolines that results in the synthesis of our series of 7-aminoquinoline quinones. 
Included in this study are metabolism and cytotoxicity studies on the quinoline-5,8-diones. 
Additionally, we report NMR spectra indicating the extent to which this series of quinones binds 
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Zn2+, as metal complexation is believed to be an important factor in NQO1-mediated reduction 
and the resulting toxicity of quinones. Results from this study provide important information as 
to the mechanisms by which this series of lavendamycin analogues function. 
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MATERIALS AND METHODS 
Chemicals. Synthetic chemistry of quinolinequinone derivatives was performed by Charles M. 
Keyari in the laboratory of Dr. Philippe Diaz at the University of Montana (Missoula, MT). 
 
Cell Culture. MDA-MB-468 (MDA468) human breast cancer cells and stably NQO1-transfected 
MDA468-NQ1632 were a gift from Dr. David Ross (University of Colorado, Denver, Denver, 
CO). MDA468 cells had no measurable NQO1 activiy whereas activity in MDA468-NQ16 cells 
was 1070 nmol·min−1(mg of total cell protein)−1, with dichlorophenolindophenol (DCPIP) as 
the standard electron acceptor. Cells were grown in RPMI 1640 medium with L-glutamine and 
penicillin/streptomycin, supplemented with 10% fetal bovine serum (FBS). Cell culture medium 
and supplements were obtained from Invitrogen (Carlsbad, CA). The cells were incubated at 37 
°C under a humidified atmosphere containing 5% CO2. 
 
Spectrophotometric Cytochrome c Assay. Quinolinequinone reduction was monitored by a 
spectrophotometric assay in which the rate of reduction of cytochrome c was quantified at 550 
nm. Briefly, the assay mixture contained cytochrome c (70 µM), reduced nicotinamide adenine 
dinucleotide (NADH; 1 mM), recombinant human NQO1 (0.1−10 µg) (gift from Dr. David Ross, 
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University of Colorado, Denver, Denver, CO), and quinonlinequinones (25 µM) in a final 
volume of 1 mL of Tris-HCl (25 mM, pH 7.4) containing 0.7 mg/mL bovine serumalbumin 
(BSA) and 0.1%Tween-20. Reactions were carried out at room temperature and started by the 
addition of NADH. Rates of reduction were calculated from the initial linear part of the reaction 
curve (0−30 s), and results were expressed in terms of micromoles of cytochrome c reduced per 
minute per milligram of NQO1 by use of a molar extinction coefficient of 21.1 mM−1·cm−1 for 
cytochrome c. All reactions were carried out at least in triplicate. 
 
Oxygen Consumption. Oxygen concentration was monitored with a MI-730 micro-oxygen 
electrode (Microelectrodes, Bedford, NH) with concentrations adjusted for temperature (25 °C). 
Assay mixtures contained 25 µM quinonlinequinones, 200 µM NADH, and 1 µg/mL NQO1 in a 
2 mL Tris-HCl/BSA/Tween (0.1%) buffer system. Reactions were started with NADH and 
measured over 3-min intervals at room temperature. All reactions were carried out in triplicate. 
 
Cell Viability Assay. Growth inhibition was determined by the MTT colorimetric assay. Cells 
were plated in 96-well plates at a density of 10,000 cells/mL and allowed to attach overnight (16 
h). Quinolinequinone solutions were applied in medium for 2 h, removed, and replaced with 
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fresh medium, and the plates were incubated at 37 °C under a humidified atmosphere containing 
5% CO2 for 3−5 days. MTT (50 µg) was added and the cells were incubated for another 4 h. 
Medium/MTT solutions were removed carefully by aspiration, the MTT formazan crystals were 
dissolved in 100 µL of DMSO, and absorbance was determined on a plate reader at 560 nm. IC50 
values (concentration at which cell survival equals 50% of control) were determined from 
semilog plots of percent of control versus concentration. Selectivity ratios were defined as IC50 
value for the MDA468 cell line divided by IC50 value for the MDA468-NQ16 cell line. 
 
RESULTS 
Parameters relating to NQO1 substrate specificity. For this study, a series of derivatives of 
lavendamycin were synthesized (Figure 5.1). Several parameters were assessed to determine the 
ability of each compound to be efficiently reduced by NQO1 (Table 5.1). First, quinolinequinone 
metabolism by recombinant human NQO1 was determined using a spectrophotometric assay 
with cytochrome c as the terminal electron acceptor. For this study, the larger the value the more 
efficiently the compound is reduced by NQO1, indicating good substrate specificity for the 
enzyme. Results of metabolism studies demonstrated that 7-amino analogues were generally 
better substrates for NQO1 than 7-amido analogues, as were compounds with smaller 
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heteroaromatic substituents at the C-2 position. Although unusual, higher rates for acetylated 
analogues have been observed in other series (Hassani et al., 2005; Cai et al., 2010). No clear 
trend in reduction rates was observed in regard to the aromatic substitutions at the C-2 position, 
other than that bulkier groups generally decreased reduction rates. Oxygen consumption, the 
measure of the ability of a hydroquinone to redox-cycle following reduction by NQO1, was also 
assessed for select compounds. The trend of oxygen consumption was similar to reduction rates 
for these compounds. In addition, reduction potential versus ferrocene was also measured. 
Reduction potential versus ferrocene is a measure of the electronic effects and a consequence of 
chemical reduction. Reduction rates by NQO1 are more suitable in determining the effect to 
which quinones can be reduced enzymatically by NQO1. 
 
Selective cytotoxicity of quinoline-5,8-diones. MTT cell viability assays were performed to 
determine selective toxicity of each compound to a NQO1 expressing (MDA468-NQ16) and 
non-NQO1 expressing (MDA468-WT) human breast cancer cell line (Table 5.2). Preferential 
cytotoxicity toward MDA468-NQ16 cells is reflected by a selectivity ratio of >1. Surprisingly, 
almost all compounds tested had a selectivity ratio of <1, indicating greater selectivity toward 
MDA-468-WT cells. 
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Figure 5.1 
 
Figure 5.1. Structures of lavendamycin and streptonigrin. Streptonigrin is structurally related 
to lavendamycin, however, toxicity of these compounds limits their use. The series of 
quinolinequinones detailed in this study are structurally similar to lavendamycin. 
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18 ! INTRODUCTION
19 Lavendamycin (Figure 1) is a quinolinequinone antibiotic with
20 antitumor activity "rst isolated from Streptomyces lavendulae by
21 Balitz et al. in 1982.1,2 It is structurally related to streptonigrin,
22 which was "rst isolated from Streptomyces !occulus.3,4 Strepton-
23 igrin is known for its potent cytotoxic properties, antitumor
24 activity, in vitro and in vivo antiviral properties, and potent,
25 broad-spectrum antimicrobial properties. Although lavendamy-
26 cin is not suitable for clinical use due to it toxicity, its nalogues
27 are less toxic and hence have potential as antitumor agents.5
28 Recent "ndings6!11 suggest that some indolequinones and
29quinolinequinones are excellent substrates for the quinone
30reductase enzyme NAD(P)H:quinone oxidoreductase 1
31(NQO1) and are selectively cytotoxic to cancer cell lines that
32overexpress NQO1. NQO1 is a ubiquitous #avoenzyme that
33catalyzes the two-electron reduction of quinones to hydro-
34quinones, and it is highly expressed in many solid tumors.12 This
35forms the basis for the synthesis of novel quinolinequinones
36structurally related to lavendamycin as potential NQO1-directed
37antitumor agents.
38Behforouz et al.13 "rst demonstrated that 7-aminoquinoline-
395,8-diones can be e$ciently prepared from commercially
40available 8-hydroxy-2-methylquinoline. Fryatt et al.7 also showed
41that, by starting with 6-methoxyquinoline, 6-methoxy-2-
42chloroquinoline-5,8-dione was prepared, and subsequent palla-
43dium(0)-catalyzed reaction with boronic acids gave novel
44quinolinequinones under re#ux for 24 h. Furthermore, in
452004,14 arylboronic acids were shown to be more reactive than
46their counterparts, the arylpinacolboronate esters, when reacted
47with indole bromides in Suzuki couplings under re#ux. The lower
48reactivity was attributed to steric factors in the arylpinacolbor-
49onate esters. Also, 3-arylindazoles have been synthesized by the
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Figure 1. Natural quinolinequinone antibiotics.
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Table 5.1 
 
Table 5.1. Reduction rates and oxygen consumption as a result of quinoline-5,8-dione 
metabolism by recombinant human NQO1. aSpectrophotometric assay with cytochrome c as 
terminal electron acceptor (550 nm). bOxygen concentration monitored via an oxygen electrode. 
cE1/2 values calculated as (Epc+Epa)/2 are average values from voltammograms recorded 
atpotential sweep rate of 50 mV/s. Epc = cathodic peak potential; Epa = anodic peak potential. dnr 
= nonreversible, anodic peak only. 
Table 2. Reduction Ratesa and Oxygen Consumptionb as a Result of Quinoline-5,8-Dione Metabolism by Recombinant Human
NQO1 and Electrochemical Reduction Potentials versus Ferrocenec,d
aSpectrophotometric assay with cytochrome c as terminal electron acceptor (550 nm). bOxygen concentration monitored via an oxygen electrode.
cE1/2 values calculated as (Epc+Epa)/2 are average values from voltammograms recorded atpotential sweep rate of 50 mV/s. Epc = cathodic peak
potential; Epa = anodic peak potential.
dnr = nonreversible, anodic peak only.
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm301689x | J. Med. Chem. XXXX, XXX, XXX!XXXD
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Table 5.2 
 
Table 5.2. Cytotoxicity of quinoline-5,8-diones toward MDA468-WT (NQO1-deficient) and 
MDA468-NQ16 (NQO1-rich) human breast cancer cell lines. IC50 values are mean 
representation +/- standard deviation (SD) from triplicate experiments. 
 
316 bovine serum albumin (BSA) and 0.1%Tween-20. Reactions were carried
317 out at room temperature and started by the addition of NADH. Rates
318 of reduction were calculated from the initial linear part of the reaction
319 curve (0!30 s), and results were expressed in terms of micromoles of
320 cytochrome c reduced per minute per milligram of NQO1 by use of a
321 molar extinction coe!cient of 21.1 mM!1·cm!1 for cytochrome c. All
322 reactions were carried out at least in triplicate.
323Oxygen Consumption. Oxygen concentration was monitored with
324a MI-730 micro-oxygen electrode (Microelectrodes, Bedford, NH) with
325concentrations adjusted for temperature (25 °C). Assay mixtures contained
32625 !M quinonlinequinones, 200 !M NADH, and 1 !g/mL NQO1 in a
3272 mL Tris-HCl/BSA/Tween (0.1%) bu"er system. Reactions were started
328with NADH and measured over 3-min intervals at room temperature. All
329reactions were carried out in triplicate.
Table 3. Cytotoxicity of Quinoline-5,8-diones towardMDA468-WT (NQO1-de!cient) andMDA468-NQ16 (NQO1-rich) Human
Breast Cancer Cell Lines
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm301689x | J. Med. Chem. XXXX, XXX, XXX!XXXH
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Metal complexation. For the purposes of this paper, two compounds were selected to highlight 
the differences in compound interactions with cationic metal. Compounds 19 and 22 were 
subjected to varying equivalents of Zn2+ and analyzed by NMR (Figure 5.2). Results of this 
experiment demonstrate that 19 does not efficiently bind Zn2+. In contrast, NMR spectra with 22 
indicates substantial proton shift with all equivalents of Zn2+ (Figure 5.3). Only one equivalent of 
Zn2+ was sufficient to produce a shift in protons, indicating that 22 complexes metal very 
efficiently compared to 19.  
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Figure 5.2 
 
Figure 5.2. NMR spectra of 19 with Zn2+. Aromatic proton region of NMR spectrum of 19 
upon addition of increasing equivalents of Zn(SO3CF3)2 in THF-d8. Note the change in δ of H-
2′ and H-3 upon addition of Zn2+. Equivalents of Zn2+: A = 0, B = 1, C = 2, D = 3, E = 4, F = 5, 
and G = 10. 
165 reported by Long and Harding,25 wher they d monstrated
166 that the 1:1 bipyridyl complex of streptonigrin was the major
167 complex formed at room temperature by perfoming an NMR
168 study in THF-d8 with addition of Zn
2+. Titration of compound
169 23 with Zn2+ in a mixture of dimethyl sulfoxide/methanol
170 (1:3) was monitored by a spectrophotometer as reported in
171 literature.26 A plot of !!355 against Zn2+ concentration gave a
172 moderate a!nity constant of 1.41! 104 M!1 for compound 23
173 binding with Zn2+.
174 ! RESULTS AND DISCUSSION
175 Quinolinequinone metabolism by recombinant human NQO1
176 was examined via a spectrophotometric assay that employs
177 cytochrome c as the terminal electron acceptor. Initial rates of
178 reduction (micromoles of cytochrome c reduced per minute per
179 milligram of NQO1) were calculated from the linear portion
180 (0!30 s) of the reaction graphs. The 7-acetamido-2-(2-pyridinyl)
181 compound 13 displayed the highest reduction rate by NQO1
182 (Table 2), although it was the only acetylated analogue with a
183 high reduction rate. In all other cases, 7-amino compounds had
184 much higher reduction rates than corresponding 7-acetamido
185 compounds with identical substituents at the quinoline
186 2-position. Although unusual, higher rates for acetylated
187 analogues have been observed in other series.6,11 With regard
188 to the aromatic substituents at the quinoline 2-position, no clear
189trend in reduction rates was observed except that bulkier groups
190generally decreased reduction rates. Oxygen consumption is a
191measure of the ability of the reduced quinone (hydroquinone) to
192redox-cycle following reduction by NQO1. This could lead to
193production of toxic reactive oxygen species and ultimately to cell
194death. Oxygen consumption was measured for select quinoline-
195quinones, and the trend, if not the magnitude, mirrored the
196reduction rates (Table 2).
197Cell survival wasmeasured by the [3-(4,5-dimethylthiazol-2-yl)-
1982,5-diphenyltetrazolium bromide (MTT) colorimetric assay. In
199previous work, we demonstrated that IC50 values generated from
200standard clonogenic assays and MTT assays were positively
201correlated, suggesting that the MTT assay is a reliable indicator
202of cytotoxicity.6 We utilized MDA-MB-468 human breast cancer
203cells stably transfected with human NQO1 cDNA (MDA468-
204NQ16) along with the nontransfected wild-type cells (MDA468)
205to compare the cytotoxicity of the quinolinequinones (Table 3).27
206Quinolinequinone cytotoxicity (IC50) to MDA468 cells was
207generally in the single-digit micromolar range following 2-h
208exposures, with some in the high nanomolar range (11, 13, and
20922). Surprisingly, selectivity ratios [IC50 (MDA468)/IC50
210(MDA468-NQ16)] were generally <1, meaning that the
211quinolinequinones were less cytotoxic to the NQO1-rich
212MDA468-NQ16 cells rather than more cytotoxic. This suggests
213that NQO1 was protective to the cells rather than functioning as
Figure 2. Aromatic proton region of NMR spectrum of 19 upon addition of increasing equivalents of Zn(SO3CF3)2 in THF-d8. Note the change in " of
H-2! and H-3 upon addition of Zn2+. Equiv lents of Zn2+: A = 0, B = 1, C = 2, D = 3, E = 4, F = 5, and G = 10.
Journal of Medicinal Chemistry Article
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Figure 5.3 
 
Figure 5.2. NMR spectra of 22 with Zn2+. Aromatic protons region NMR spectra of 22 upon 
addition of increasing equivalents of Zn(SO3CF3)2 in THF-d8. Equivalents of Zn2+: A = 0, B = 
1, C = 2, D = 3, E = 4, F = 5, and G = 10. 
 
 
214 an activating enzyme.27 Only two compounds (11 and 23) were
215 selectively cytotoxic to the MDA468-NQ16 cells. The reason for
216 the general absence of selective cytotoxicity with this particular
217 series of compounds is unclear, but it is consistent with NQO1’s
218 primary role as a detoxi!cation enzyme.27
219 Molecular docking of the quinolinequinones in the NQO1
220 active site was performed by use of Sybyl 8.1.1 and GOLD 5.1 for
221 scoring. Three goodNQO1 substrates (13, 20, and 24) and three
222 poor NQO1 substrates (9, 11, and 17) were docked and scored
223 with ChemPLP and ChemScore (Table 4). The highest scores
224 representing a good !t for the model were found for 20 and 24,
225 consistent with themetabolism data. The exception again was 13,
226 which scored the lowest but was the best substrate. Interatomic
227 distances between quinolinequinone carbonyl groups and "avin
228 adenine dinucleotide (FAD) atom N5 and His161 were shortest
229 for 20, but all were within a reasonable distance for hydride
230 transfer from FAD when the dynamic e#ects of the quinone!
231 enzyme interaction are considered. Figure 5 shows possible
232 docking conformations for 20 and 11 with NQO1. All
233 quinolinequinones orient with the quinone ring above the
234 FAD isoalloxazine ring as needed for hydride transfer.
235 The mechanism of action of lavendamycin and streptonigrin is
236 not clearly understood. However, previous studies demonstrated
237 that quinone moieties are reduced by NQO1 to the
238corresponding hydroquinones, which undergo autoxidation to
239produce activated oxygen species including not only semi-
240quinone derivatives but also superoxide and hydroxyl radicals.28
241In addition, both streptonigrin and lavendamycin chelate
242divalent cationic metal ions. This property might confer to
243streptonigrin and lavendamycin the ability to shuttle iron cations
244into the cells, which in turn can catalyze production of reactive
245oxygen species through a Fenton reaction. On the other hand,
246this chelation can result in depletion of intracellular cationic
247metals, which might result in cell death.29Generation of the
248semiquinone radical, after reduction of the quinone to the
249hydroquinone followed by autoxidation, results in a decrease of
250activity in nine compounds. The best NQO1 substrates are less
251active compounds (13, 20, and 24) in NQO1 expressing cells. In
252contrast, poor NQO1 substrates such as compound 22 or 11,
253exhibit the best activity in both cancer cells expressing NQO1
254and those not expressing NQO1. According to the NMR
255experiments, quinoline derivative 22 and compound 13 bind the
256Zn2+ more e$ciently than compound 19, and only 1 equiv of
257Zn2+ is enough to cause important chemical shift variations.
258Similar observations were made with compound 23, which was
259less cytotoxic than compound 22. Even though metal chelation
260by these compounds is still a plausible mechanism to explain their
261activity against breast cancer cells, another mode of action cannot
Figure 3. Aromatic protons region NMR spectra of 22 upon additio of increasing equivalents f Zn(SO3CF3)2 in THF-d8. Equivalents of Zn
2+: A = 0,
B = 1, C = 2, D = 3, E = 4, F = 5, and G = 10.
Journal of Medicinal Chemistry Article
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DISCUSSION 
 The purpose of this study was to design new lavendamycin derivatives that are NQO1 
substrates and possess selective toxicity toward NQO1 expressing cancer cells. Of all the 
quinolinequinones evaluated in this series, only two compounds 11 and 23, were selective for 
NQO1 expressing cells. Results from cytochrome c reduction rates by NQO1, however, showed 
that both compounds were not the best substrates in the series for the enzyme. To this end, 
almost all of the quinolinequinones were cytotoxic to the MDA468 cell lines in the single digit 
micromolar range, with selectivity ratios <1. These results are indicative of the compounds being 
selectively more cytotoxic to the non-NQO1 expressing cell line and suggest that NQO1 is 
cytoprotective in this case, rather than functioning to activate these quinones (Ross et al., 2000). 
Results from this study indicate that the best NQO1 substrates (13, 20, 24) were among the least 
active compounds in NQO1 expressing cells. In contrast, compounds that were poor NQO1 
substrates (22, 11) exhibit the best activity in both cell lines tested. The explanation for the 
overall absence of selective cytotoxicity to MDA468-NQ16 cells in this series of compounds is 
unclear, but it is consistent with the primary role of NQO1 as a detoxification enzyme.  
 To explain the results of this study, it is important to note that the mechanism of action of 
both lavendamycin and streptonigrin is not clearly understood. One feature that is necessary to 
the function of both streptonigrin and lavendamycin as NQO1 substrates is the ability to chelate 
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divalent cationic metal ions (Harding and Long, 1997). The precise mechanism for which metal 
complexation confers downstream cytotoxic toxic effects is poorly understood. With iron for 
example, complexation might lead to iron shuttling into cells, catalyzing the production of 
reactive oxygen species through a Fenton reaction. This chelation may also result in the 
depletion of intracellular cationic metals, leading to cell death (Budimir, 2011). The NMR data 
reported in this study indicate that compound 22 (as well as compounds 13 and 23; NMR spectra 
for these compounds not shown) binds Zn2+ more efficiently than compound 19. Compounds 13 
and 22 were also the most cytotoxic to NQO1 non-expressing cells with IC50 values of 
approximately 530 nM and 140 nM, respectively. As supported by NMR data, one possible 
explanation for this effect is that these two compounds bind metals more efficiently and are 
therefore better able to either generate ROS or shuttle iron into the cell, leading to cytotoxicity 
and eventual cell death. In addition, compound 23, which exhibits lower activity than compound 
13, an acetylated amino analogue, may be less active due to a tautomeric shift to an inactive 
quinoid. Acetylated analogues cannot undergo tautomeric shift. It has been proposed that metals 
assist tautomeric shift from an active quinone compound to an inactive quinoid that is 
isoelectronic with biologically inactive azastreptonigrin (Gibson et al., 1992). This tautomeric 
shift provides an explanation for the decrease in activity of compound 23.   
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 The most active compounds in this study 11, 13, and 22 are potential tridentate ligands 
for metals. Our results seem to indicate that these compounds exert toxic effects at least partially 
due to metal chelation. In our series of aryl-substituted quinolinequinones, the active molecules 
appear to be the quinone derivatives and not derivatives of hydroquinones or semiquinones. 
These data suggest a mode of action that differs from that of previously studied lavendamycin 
analogues that are activated by NQO1 reduction and may involve an unidentified target (Hassani 
et al., 2005; Hassani et al., 2008; Cai et al., 2010). Collectively, our data with this series of aryl-
substituted quinolinequinones derivatives represent a promising class of cytotoxic agents with 
potential novel therapeutic value. 
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CHAPTER 6: CONCLUSIONS 
 Cancer is a common, complex, and difficult to treat disease. Understanding the 
underlying biology of cancer is vital to the development of new anticancer agents. Cancer is 
challenging to cure due in part to the characteristics of tumor cells: sustained proliferative 
signaling, evasion of growth suppressors, resistance to apoptosis, replicative immortality, 
induced angiogenesis, and invasion and metastasis capacity (Hanahan and Weinberg, 2000). 
Drug resistance and undesirable systemic toxicity add additional complexity to effective cancer 
treatment. Despite these barriers, cancer drug discovery research is an active and dynamic field 
with new approaches being identified frequently. To this end, the research detailed in our studies 
is an important contribution to the field of anticancer drug discovery. The following sections 
highlight the conclusions of these studies and future directions to expand on our results.  
 
G-quadruplex ligand AIM 1 exerts effects on the mitochondria 
 Identification of G-quadruplex ligands capable of inhibiting telomerase was first reported 
in the literature in 1991 by Zahler and colleagues (Zahler et al., 1991). Since this discovery, G-
quadruplex DNA has been extensively studied as a drug target for telomerase inhibition in the 
context of cancer (Hemann et al., 1999; Han et al., 1999; Federoff et al., 1998; Ou et al., 2008). 
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To this end, we developed a series of anthracenyl isoxazole amides (AIMs) designed to bind to 
G-quadruplex DNA and inhibit telomerase. The first goal of this project was to identify which 
AIMs from the series were the most cytotoxic to SNB-19 human glioblastoma cells. In addition 
to determining relevant toxicities, fluorescent properties of the AIMs were examined by a series 
of LSC and confocal microscopy experiments. The inherent fluorescence of the AIMs was truly 
an advantage to all fluorescent microscopy experimentation that proceeded from this point and 
led to the identification of a possible alternate mechanism of action of AIM 1 in the 
mitochondria. Fluorescence was also a unique property to the AIMs that makes them distinctly 
different from other commercially available G-quadruplex ligands (Brooks and Hurley, 2010).  
 Following selection of AIM 1 as the lead compound, we demonstrated that AIM 1 binds 
telomeric G-quadruplex DNA and is localized to the mitochondria, and not the nucleus as 
originally expected. The discovery that AIM 1 was present in the mitochondria led to further 
investigation into the mitochondrial-specific effects that AIM 1 exerts, including activation of 
caspase-9 and apoptosis, decrease in mitochondrial membrane potential (ΔΨM), generation of 
mitochondrial superoxide, and facilitation of the export of hTERT from the nucleus. The 
presence of AIM 1 in the mitochondria as well as the induction of mitochondrial-apoptosis 
represents a novel mechanism for G-quadruplex ligands. We concluded using NMR 
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spectroscopy that AIM 1 is a G-quadruplex ligand; if AIM 1 is binding G-quadruplex DNA and 
is localized to the mitochondria (which we have shown by multiple fluorescent microscopy 
experiments), we hypothesize that AIM 1 is binding within mitochondrial DNA. Research 
suggests that G-quadruplex can form within mitochondrial DNA (Wanrooij et al., 2012; Capra et 
al., 2010; Ngo et al., 2013). The first step to testing this hypothesis is to isolate mitochondria and 
determine via NMR spectroscopy that AIM 1 binds to G-quadruplex structures within the 
mitochondrial DNA. Electron microscopy would also be necessary to visualize the location of 
AIM 1 bound to mitochondrial DNA. Conversely, it is possible that the mitochondrial effects 
detailed in this study are unrelated to G-quadruplex binding. In this case, AIM 1 could be 
functioning as a mitochondrial complex inhibitor, a potent generator of reactive oxygen species 
(ROS), or altering mitochondrial metabolism in some other way (Fulda et al., 2010). 
 
A new series of P-gp inhibitors effectively increase cytotoxicity of P-gp substrates 
 The second goal of this project was to assay a series of 4-isoxazolyl-1,4-dihydropyridines 
(IDHPs) that function as P-gp inhibitors to determine their contribution to enhanced cytotoxicity 
of the AIMs when co-dosed together in vitro. Because so many anticancer agents are substrates 
for P-gp and are therefore limited in their ability to reach intended targets, the development of P-
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gp inhibitors is an important area of research (Tsuji, 1998). Once it was determined that two of 
the IDHPs, 1A and 1K, produced substantial P-gp inhibition, the effect of co-dosing the IDHPs 
with the AIMs was examined. For these experiments, we developed a modified MTT assay that 
allowed for the determination of the effects of co-treatment of IDHPs with the AIMs. Results 
from these experiments indicated that IDHPs were superior to other dihydropyridine (DHP) P-gp 
inhibitors being reviewed by others; IDHPs increased the cytotoxicity of known P-gp substrate 
doxorubicin greater than these P-gp inhibitors being investigated (Dantzig et al., 2001).  Findings 
also demonstrate that AIM 1 is likely a P-gp substrate—a result that is not all together surprising, 
as many anticancer agents are P-gp substrates ((Loscher and Potschka, 2005). However, because 
AIM 1 was effectively administered with IDHPs and the resulting effect was increased 
cytotoxicity in the presence of high expression of P-gp, we have two conclusions. First, IDHPs 
represent a viable class of P-gp inhibitors and second, the P-gp substrate properties of AIM 1 can 
be overcome and does not limit its use in vitro. Understanding the mechanisms of drug resistance 
and continuing to develop strategies to overcome these effects is an important area of research to 
be expanded. In this way, continued synthesis of additional IDHPs is a viable component to drug 
discovery research. 
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Quinolinequinone lavendamycin derivatives as NQO1-directed antitumor agents 
 NQO1 is a bioreductive enzyme that is overexpressed in solid tumors and is well 
characterized in the literature (Lin et al., 1972; Ross et al., 1994; Workman, 1994; Colucci et al., 
2008). Based on previous research investigating the use of lavendamycin as a potent NQO1 
substrate, we developed a series of quinoline-5,8-diones structurally similar to lavendamycin 
(Podeszwa et al., 2007). The goal of this study was to determine the NQO1 substrate potential of 
this series of quinolinequinones and assess their corresponding antitumor potential. The first data 
that we collected on the quinolinequinones was reduction rates by NQO1. Surprisingly, we 
discovered that reduction rates varied substantially—compound 13 displayed the highest 
reduction rate by NQO1, although it was the only acetylated analogue in the series with such a 
high rate of reduction. In all other cases, it was the 7-amino compounds that possessed the 
highest rates of reduction compared to 7-acetamido counterparts. Bulkier groups at the C2 
position also appeared to reduce reduction rates. Also unexpected, we discovered that only two 
compounds (23 and 11) were preferentially more cytotoxic to NQO1 expressing cells as 
compared to non-NQO1 expressing counterparts. These two compounds were not among the 
compounds possessing the highest reduction rates by NQO1 and a correlation was not found 
between the two assays in regards to these compounds. 
	  
	  
  
173	  
 In an effort to explain the mechanisms of this series of quinolinequinones that lack 
specificity for NQO1 as bioreductive agents, we added NMR experiments investigating quinone-
metal complexation. The Zn2+ complexation studies were an important element to this 
investigation; research suggests that one feature that is necessary to the activity of both 
streptonigrin and lavendamycin is the ability to chelate divalent cationic metal ions (Harding and 
Long, 1997). We discovered that the ability to complex metal did appear to be an important 
component with our most active compounds and conclude that the activity can be explained at 
least in part by the capability to chelate metal. Collectively, in our series of aryl-substituted 
quinolinequinones, the active molecules appear to be the quinone derivatives and not derivatives 
of hydroquinones or semiquinones. These data suggest a mode of action that differs from that of 
previously studied lavendamycin analogues that are activated by NQO1 reduction (Hassani et al., 
2005; Hassani et al., 2008; Cai et al., 2010) and may involve an unidentified target. The data in 
this study represent a promising class of cytotoxic agents with potential novel therapeutic value. 
 This project involved three separate but related studies that fall under the category of 
anticancer drug discovery as a whole. Our investigation into the yet untapped extra-nuclear 
mechanisms and site of action of G-quadruplex ligands is an important contribution not only to 
G-quadruplex research but mitochondrial medicine for cancer as well. Our use of novel P-gp 
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inhibitors that are capable of increasing the cytotoxicity of P-gp substrates contributes not only to 
P-gp related research but adds to the understanding of how our AIMs function as antitumor 
agents as well. In regards to NQO1-directed antitumor pharmacology, we demonstrated that our 
lavendamycin analogues function in a manner that is different from lavendamycin itself and may 
involve another target. While this project focused on the general targeting of solid tumors, the 
type of tumor explicitly studied varied from brain cancer to breast cancer and encompassed 
multiple drug targets. Collectively the results of this study are expansive and offer much to the 
field of anticancer drug discovery. 
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ABSTRACT 
A series of 7-amino- and 7-acetamidoquinoline-5,8-diones with aryl substituents at the 2-
position were synthesized, characterized and evaluated as potential NAD(P)H:quinone 
oxidoreductase (NQO1)-directed antitumor agents. The synthesis of lavendamycin analogs is 
illustrated. Metabolism studies demonstrated that 7-amino- analogues were generally better 
substrates for NQO1 than 7-amido- analogues as were compounds with smaller heteroaromatic 
substituents at the C-2 position. Surprisingly, only two compounds, 7-acetamido-2-(8’-
quinolinyl)quinoline-5,8-dione (11) and 7-amino-2-(2-pyridinyl)quinoline-5,8-dione (23) 
showed selective cytotoxicity toward the NQO1-expressing MDA468-NQ16 breast cancer cells 
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versus the NQO1-null MDA468-WT cells. For all other compounds, NQO1 protected against 
quinoline-5,8-dione cytotoxicity. Compound 22 showed a potent activity against human breast 
cancer cells expressing or not expressing NQO1 with IC50 values of respectively 190 nM and 
140 nM and a low NQO1 mediated reduction rate, which suggests that the mode of action of 22 
differs from lavendamycin and involves an unidentified target(s). 
 
KEYWORDS: Lavendamycin, Suzuki coupling, microwave irradiation, palladium (0) catalysis, 
quinolinequinones, NQO1, antitumor, cytotoxicity 
 
INTRODUCTION 
Lavendamycin (Figure 1) is a quinolinequinone antibiotic with antitumor activity first isolated 
from Streptomyces lavendulae by Balitz et al in 1982.1-2 It is structurally related to Streptonigrin 
which was first isolated from Streptomyces flocculus.3-4 Streptonigrin is known for its potent 
cytotoxic properties, antitumor activity, and in vitro and in vivo antiviral properties and potent, 
broad spectrum antimicrobial properties. Although lavendamycin is not suitable for clinical use 
due to its toxicity, its analogs are less  
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Figure 1. Natural quinolinequinone antibiotics 
toxic and hence have potential as antitumor agents.5 Recent findings6-11  suggest that some 
indolequinones and quinolinequinones are excellent substrates for the quinone reductase enzyme, 
NAD(P)H:quinone oxidoreductase 1 (NQO1), and are selectively cytotoxic to cancer cell lines 
that overexpress NQO1. NQO1 is a ubiquitous flavoenzyme that catalyzes the 2-electron 
reduction of quinones to hydroquinones, and it is highly expressed in many solid tumors.12 This 
forms the basis for the synthesis of novel quinolinequinones structurally related to lavendamycin 
as potential NQO1-directed antitumor agents. 
Behforouz et al. (1996)13 first demonstrated that 7-aminoquinoline-5,8-diones can be 
efficiently prepared from commercially available 8-hydroxy-2-methylquinoline. Fryatt and co-
workers7 also showed that by starting with 6-methoxyquinoline, 6-methoxy-2-chloroquinoline-
5,8-dione was prepared and subsequent palladium(0) catalyzed reaction with boronic acids gave 
novel quinoline quinones under reflux for 24 hours. Further, in 2004, 14 arylboronic acids were 
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shown to be more reactive than their counterparts, the arylpinacolboronate esters when reacted 
with indole bromides in Suzuki couplings under reflux.  The lower reactivity was attributed to 
steric factors in the arylpinacolboronate esters. Also, 3-aryl-indazoles have been synthesized by 
the reaction of haloindazoles (3-bromoindazole and 3-iodoindazole) with aryl boronic acids 
under Pd(0) catalysis in Suzuki type cross couplings. 15 The reaction times ranged from 1 -18 
hours under reflux conditions.  In this present study we report a direct more efficient approach to 
7-aminoquinoline quinones starting from commercially available 7-amino-8-hydroxyquinoline 
under microwave conditions where the reaction times are shorter. Computational, metabolism 
and cytotoxicity studies on the quinoline-5,8-diones are also described. 
CHEMISTRY 
The synthesis commenced with the nitration of 5-chloro-8-hydroxyquinoline under 
HNO3/H2SO4  according to a procedure reported by Musser et al.16 to give the 5-chloro-7-nitro-
8-hydroxyquinoline (1) in good yield (79%). Hydrogenation under Pd/C-catalysis at 40-50 psi 
not only reduced the nitro group to the free amine but also removed the chloride to provide the 
desired 7-amino-8-hydroxyquinoline (2) in excellent yield (99%). A direct approach to the amino 
alcohol 2 involves the heating of a mixture of 8-hydroxyquinoline and N-methyl-N-
phenylhydrazine at 90°C, albeit very low yields were obtained. 17Our attempt to synthesize the 
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amino alcohol by heating in a microwave between 130-160°C did not improve the yield. 
Acetylation proceeded smoothly where both the amino and hydroxyl groups were protected. The 
resulting diacetylated product (3) was hydrolyzed in MeOH/H2O under reflux to form 7-
acetamido-8-hydroxyquinoline. Subsequent benzylation of the free hydroxyl was effected by 
reacting with BnBr/K2CO3 in DMF at 50°C for 24 hrs to give the 7-acetamido-8-
benzyloxyquinoline (4) in 90% yield. Oxidation using mCPBA in 1,2-dichloroethane at rt for 48 
hrs gave the N-oxide (5) in 82% yield.18 The key intermediate in the synthesis, the 2-chloro-7-
acetamido-8-benzyloxyquinoline (6), was obtained in 62% yield by refuxing the N-oxide with 
POCl3 in CHCl3.19 The high regioselectivity of the reaction can be rationalized in terms of sterics 
as well as formation of an oxyphosphorane adduct anion in a rapid concerted mechanism. 20 We 
also attempted refluxing the N-oxide 5 with SO2Cl2 as reported in literature,9 but only resulted in 
massive decomposition of the starting material. Deprotection of the benzyl group was effected 
with BCl3•SMe2 in CH2Cl2 and subsequent oxidation using Fremy’s salt (potassium 
nitrosodisulfonate-(KO3S)2NO) gave the 7-acetamido-2-chloro-quinoline-5,8-dione (8) in 71% 
yield. 7 The results are summarized in Scheme 1 below. 
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Scheme 1a 
 
After the successful formation of the quinolinequinone 8, the stage was now set for Suzuki 
coupling chemistry. This was accomplished by reaction with different boronic acids under Pd(0) 
catalysis in a microwave as illustrated in Table 1 below. Generally, the reactions were complete 
within 20-30 minutes in good yields except for the arylboronate ester where only 27% of the 
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product (16) was obtained. The mechanistic details of the reaction have been well studied in 
which case oxidative addition, transmetallation and reductive elimination being the most critical  
Table 1. Suzuki coupling products 
         
         R-X         Reaction conditions      R           Yield 
(%) 
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*Stille coupling reaction 
steps.21 Interestingly, the 7-amino-2-(2-pyridyl)quinoline-5,8-dione was prepared in 9 steps 
starting from 3-hydroxybenzoic acid where the key step was a *  Friedlander condensation of 2-
acetylpyridine and  2-amino-3-benzyloxy-4-bromobenzaldehyde to give the 8-benzyloxy-7-
bromo-2-(2’-pyridyl)quinoline.22 Although this seems an attractive strategy, the method lacks the 
flexibility needed to create a library of lavendamycin analogs. 
The final step in the synthesis involved the removal of the acetate protecting group which was 
effected by reaction with H2SO4-MeOH at rt. The Boc-protected derivatives were also subjected 
to TFA/CH2Cl2 at rt for 2 hrs to provide the 7-acetamido derivatives. 
ELECTROCHEMISTRY 
Eletrochemistry was performed to compare the electrochemical behavior of the 
quinolinequinones with their reduction rates by NQO1, and the data are shown in Table 2. 
Tetrahydrofuran was used as the solvent for all compounds except 15, which was run in DMSO. 
The compounds were run against a Ag/AgCl electrode cathodic and anodic peak potentials, Epc 
and Epa, respectively, were measured at a potential sweep rate of 50 mV/sec, and the midpoint of 
the peak potentials was used to determine E1/2 values, (Epc + Epa)/2. Unfortunately, many of the 
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analogues did not show reversible electrochemistry, and in some cases, there were multiple 
reduction peaks.  This makes interpretation of the numbers somewhat difficult, but some 
conclusions can be drawn. For instance, most of the acetylated quinolinequinones had a 
reduction peak between -1.08V and -1.18V, an indication that they are easier to reduce than the 
non-acetylated compounds due to the presence of this electron-withdrawing group. This is 
consistent with what we reported previously for lavendamycins. However, there was no 
correlation between reduction potentials and reduction rates by NQO1, in line with previous 
publications on this topic.6-8, 23, 24 This suggests that steric interactions are more likely to be 
predictive of substrate efficiency than reduction potentials. 
NMR SPECTROSCOPY AND SPECTROPHOTOMETRY 
Complexation of  zinc(II) triflate by compounds 19, 22 and 23 was studied using 1H NMR 
spectroscopy. No new peaks were observed in NMR spectra, indicating that free and complexed 
forms of zinc(II) triflate were in a rapid exchange relative to NMR timescale. The aromatic 
region of the NMR spectrum of compound 19 in THF-D8 at room temperature is shown below in 
Figure 2. 
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Figure 2. Aromatic proton region NMR spectra of 19 upon addition of increasing equivalent of 
Zn(SO3CF3)2 in [2H8]THF. Note the change in d   of H-2’ and H-3 on addition of Zn2+. 
Equivalents of Zn2+: A=0, B=1, C=2, D=3, E=4, F=5 and G=10. 
There was a small difference in chemical shifts of H-2’ (moving upfield) and H-3 (moving 
downfield) after addition of one equivalent zinc(II) triflate to the NMR solution (Table S1 and 
Figure 2) whereas the changes in d of the other protons were barely noticeable. The biggest 
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change in d of H-2’ (-0.04 ppm) and H-3’ (+0.07 ppm) occurs after addition of ten equivalents of 
Zn(SO3CF3)2. This suggests that weak binding occurs at low Zn2+ concentration. 
 
 
 
Figure 3. Aromatic protons region NMR spectra of 22 upon addition of increasing equivalent of 
Zn(SO3CF3)2 in [2H8]THF. Equivalents of Zn2+: A=0, B=1, C=2, D=3, E=4, F=5 and G=10. 
In contrast, addition of only one equivalent of Zn(SO3CF3)2 to compound 22 caused larger 
chemical shift variations of all the protons (Table S2 and Figure 3) Increasing the amount of Zn2+ 
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(2-10 equiv.) added to compound 22 made little or no difference in d afterwards (>0.01 ppm).  
This means that the quinoline derivative binds the Zn2+ more efficiently than compound 19 and 
only one equivalent of Zn2+ is enough to cause chemical shift variations. 
 
 
 
 
Figure 4. Aromatic proton region NMR spectra of 23 upon addition of increasing equivalent of 
Zn(SO3CF3)2 in [2H8]THF. Equivalents of Zn2+: A=0, B=1, C=2, D=3, E=4, F=5 and G=10. 
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Similar observations were made with compounds 23 (Table S3 and Figure 4) and 13 (Table S4). 
This is consistent with the results reported by Long and Harding25 where they demonstrated that 
the 1:1 bipyridyl complex of streptonigrin was the major complex formed at room temperature 
by perfoming an NMR study in [2H8]THF with addition of Zn2+. Titration of compound 23 with 
Zn2+ in a mixture of dimethylsulfoxide-methanol (1:3) was monitored by a spectrophotometer as 
reported in literature.26 A plot of Dλ355 against Zn2+ concentration gave a moderate affinity 
constant of 1.41×104 M-1 for compound 23 binding with Zn2+. 
RESULTS AND DISCUSSION 
Quinolinequinone metabolism by recombinant human NQO1 was examined using a 
spectrophotometric assay that employs cytochrome c as the terminal electron acceptor. Initial 
rates of reduction (µmol cytochrome c reduced/min/mg NQO1) were calculated from the linear 
portion (0-30 s) of the reaction graphs. The 7-acetamido-2-(2-pyridinyl) compound 13 displayed 
the highest reduction rate by NQO1 (Table 2), although it was the only acetylated analogue with 
a high reduction rate. In all other cases, 7-amino compounds had much higher reduction rates 
than corresponding 7-acetamido compounds with identical substituents at the quinoline-2-
position. Although unusual, higher rates for acetylated analogues have been observed in other 
series.6, 11 With regard to the aromatic substituents at the quinoline-2-position, no clear trend in 
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reduction rates was observed except that bulkier groups generally decreased reduction rates. 
Oxygen consumption is a measure of the ability of the reduced quinone (hydroquinone) to redox 
cycle following reduction by NQO1. This could lead to production of toxic reactive oxygen 
species and ultimately to cell death. Oxygen consumption was measured for select 
quinolinequinones, and the trend, if not the magnitude, mirrored the reduction rates. (Table 2). 
Table 2. Reduction ratesa and oxygen consumptionb as a result of quinoline-5,8-dione 
metabolism by recombinant human NQO1 and electrochemical reduction potentials vs 
ferrocenec. Reduction rates were determined by spectrophotometric cytochrome c assay and 
oxygen uptake by oxygen electrode. 
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No. 
 
 
R1 
 
 
R2 
Reduction rate by 
hNQO1 
(µmol cyt c reduced 
/min/mg NQO1 
Oxygen 
Consumption 
(µmol/min/mg 
NQO1) 
 
Reduction Potential 
(E1/2(V) vs Fc) 
 
9 
 
CH3CO  
 
4.5 +/- 0.5 
 
5.2 +/- 1.0 
 
-1.93 nrd 
 
10 
 
CH3CO  
 
25 +/- 4 
 
- 
 
-1.17, -1.92 nr 
 
11 
 
CH3CO 
 
 
7.0 +/- 0.3 
 
- 
 
 
-1.18, -1.68, -1.77 
 
13 
 
CH3CO  
 
480 +/- 200 
 
34 +/- 3 
 
-1.90 nr 
 
15 
 
CH3CO  
 
16 +/- 1 
 
- 
 
-1.08, -1.36, -1.58 
 
17 
 
CH3CO  
 
2.8 +/- 0.2 
 
- 
 
-1.10, -1.60, -1.94 
 
18 
 
CH3CO 
 
 
31 +/- 9 
 
- 
 
- 
 
19 
 
H  
 
78 +/- 7 
 
- 
 
- 
 
20 
 
H  
 
170 +/- 30 
 
- 
 
-1.99 nr 
 
21 
 
H  
 
80 +/- 8 
 
- 
 
-1.84 nr 
 
22 
 
H 
 
 
18 +/- 6 
 
- 
 
-1.53, -1.65 
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23 
 
H  
 
71 +/- 13 
 
- 
 
-1.85 nr 
 
24 
 
H  
 
120 +/- 10 
 
8.5 +/- 1.6 
 
- 
aSpectrophotometric assay using cytochrome c as terminal electron acceptor (550 nm). 
bOxygen concentration monitored using an oxygen electrode. cE1/2 values calculated as 
(Epc+Epa)/2 are average values from voltammograms recorded potential sweep rate of 50 mV/sec. 
Epc = cathodic peak potential; Epa = anodic peak potential.dnr = non-reversible, anodic peak only. 
 
Cell survival was measured using the MTT colorimetric assay. In previous work, we 
demonstrated that IC50 values generated from standard clonogenic assays and MTT assays were 
positively correlated suggesting that the MTT assay is a reliable indicator of cytotoxicity. 6 We 
utilized MDA-MB-468 human breast cancer cells stably transfected with human NQO1 cDNA 
(MDA468-NQ16) along with the non-transfected wild type cells (MDA468) to compare the 
cytotoxicity of the quinolinequinones (Table 3).27  
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Table 3. Cytotoxicity of quinoline-5,8-diones toward MDA468-WT (NQO1-deficient) and 
MDA468-NQ16 (NQO1-rich) human breast cancer cell lines. 
  
 
 
No. 
 
 
R1 
 
 
R2 
 
IC50 (µM) 
MDA468-WT 
 
IC50 (µM) 
MDA468-NQ16 
Selectivity Ratio 
IC50 (WT)/ 
IC50 NQ16 
 
9 
 
CH3CO  
 
1.7 +/- 0.8 
 
2.4 +/- 1.9 
 
0.73 
 
10 
 
CH3CO  
 
3.3 +/- 0.1 
 
6.3 +/- 0.2 
 
0.52 
 
11 
 
CH3CO 
 
 
0.80 +/- 0.33 
 
0.64 +/- 0.41 
 
1.2 
 
 
13 
 
CH3CO  
 
0.53 +/- 0.27 
 
2.2 +/- 0.5 
 
0.24 
 
17 
 
CH3CO  
 
7.4 +/- 5.0 
 
19.1 +/- 5.9 
 
0.39 
 
19 
 
H  
 
5.3 +/- 0.8 
 
17 +/- 5 
 
0.31 
 
20 
 
H  
 
5.6 +/- 1.3 
 
15 +/- 2 
 
0.37 
 
21 
 
H  
 
4.8 +/- 0.9 
 
10 +/- 1 
 
0.47 
 
22 
 
H 
 
 
0.14 +/- 0.02 
 
0.19 +/- 0.04 
 
0.75 
 
23 
 
H  
 
19 +/- 12 
 
5.3 +/- 2.1 
 
3.5 
 
24 
 
H  
 
4.5 +/- 1.9 
 
17 +/- 2 
 
0.26 
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Quinolinequinone cytotoxicity (IC50) to MDA468 cells was generally in the single digit 
micromolar range following 2-h exposures with some in the high nanomolar range (11, 13, 22). 
Surprisingly, selectivity ratios [IC50 (MDA468) / IC50 (MDA468-NQ16)] were generally <1 
meaning that the quinolinequinones were less cytotoxic to the NQO1-rich MDA468-NQ16 cells 
rather than more cytotoxic. This suggests that NQO1 was protective to the cells rather than 
functioning as an activating enzyme.27 Only two compounds (11, 23) were selectively cytotoxic 
to the MDA468-NQ16 cells. The reason for the general absence of selective cytotoxicity with 
this particular series of compounds is unclear, but it is consistent with NQO1’s primary role as a 
detoxification enzyme.27 
Molecular docking of the quinolinequinones in the NQO1 active site was performed using 
Sybyl 8.1.1 and GOLD 5.1 for scoring. Three good NQO1 substrates (13, 20, 24) and three poor 
NQO1 substrates (9, 11, 17) were docked and scored using ChemPLP and ChemScore (Table 4). 
The highest scores representing a good fit for the model were found for 20 and 24 consistent 
with the metabolism data. The exception again was 13, which scored the lowest, but was the best 
substrate. Interatomic distances between quinolinequinone carbonyl groups and FAD N5 and 
His161 were shortest for 20, but all were within a reasonable distance for hydride transfer from 
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FAD when the dynamic effects of the quinone-enzyme interaction are considered. Figure 5 
shows possible docking conformations for 20 and 11 with NQO1. All quinolinequinones orient 
with the quinone ring above the FAD isoalloxazine ring as needed for hydride transfer. 
The mechanism of action of lavendamycin and streptonigrin is not clearly understood. However 
previous studies demonstrated that quinone moieties are reduced by NQO1 to the corresponding 
hydroquinones which undergo auto-oxidation producing activated oxygen species including not 
only the semiquinone derivatives but also superoxide and hydroxyl radicals.28   In addition, both 
streptonigrin and lavendamycin chelate divalent cationic metal ions. This property might confer 
to streptonigrin and lavendamycin the ability to shuttle iron cations into the cells which in turn 
can catalyze production of reactive oxygen species through a Fenton reaction. On the other hand, 
this chelation can result in depletion of intracellular cationic metals which might result in cell 
death. 29Generation of the semiquinone radical, after reduction of the quinone to the 
hydroquinone followed by auto-oxidation, results in a decrease of activity in 9 compounds. The 
best NQO1 substrates are less active compounds (13, 20, 24) in NQO1 expressing cells. In 
contrast, poor NQO1 substrates such as compound 22 or 11, exhibit the best activity in both 
cancer cells expressing NQO1 and not expressing NQO1. According to the NMR experiments, 
the quinoline derivative 22 and compound 13 binds the Zn2+ more efficiently than compound 19; 
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and only one equivalent of Zn2+ is enough to cause important chemical shift variations. Similar 
observations were made with compound 23, which was less cytotoxic than compound 22. Even 
though metal chelation by these compounds is still a plausible mechanism to explain their 
activity against breast cancer cells, another mode of action cannot be discarded. Most active 
compounds (11, 13 and 22) are potential tridentate ligands for metals. Compound 23 exhibits 
lower activity than the corresponding acetylated amino analogue 13. It was proposed that metals 
can assist tautomeric shift from the active quinone analogues to the quinoid analogue which has 
an isoelectronic structure with the biologically inactive azastreptonigrin.24  This tautomeric shift 
can explain the decrease of activity of the amino derivative compared to the amido derivative. In 
our series of aryl substituted quinonequinolines the active molecule is the quinone derivatives 
and not the semiquinone derivatives. A similar mode of action than the bidentate metal ligands 
derivatives 8-hydroxyquinone is currently under investigation. 30, 31  
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Table 4. Computational parameters for selected quinoline-5,8-diones. 
 
 
No. 
 
R1 
 
R2 
 
ChemPLP 
 
ChemScore 
C=O8… 
NH5 ((Ǻ) 
C=O5… 
His161NE2 (Ǻ) 
 
9 
 
CH3CO  
 
63.2 
 
22.6 
 
3.9 
 
3.6 
 
11 
 
CH3CO 
 
 
63.8 
 
22.6 
 
4.7 
 
3.3 
 
 
13 
 
CH3CO  
 
57.6 
 
21.4 
 
4.3 
 
3.5 
 
17 
 
CH3CO  
 
63.8 
 
22.1 
 
4.2 
 
3.3 
 
20 
 
H  
 
72.8 
 
26.0 
 
3.6 
 
3.2 
 
24 
 
H  
 
67.3 
 
22.7 
 
4.1 
 
3.3 
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Figure 5. Quinolinequinones docked in NQO1 active site: 20, cyan; 11, magenta; FAD, green. 
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CONCLUSIONS 
A six step synthetic scheme led to good yields for quinolinequinone analogs of lavendamycin 
projected as NQO1-directed antitumor agents. Unexpectedly, ten of eleven analogs demonstrated 
excellent cytotoxicity (IC50 values of single digit micromolar or better) towards MDA468 breast 
cancer cells, but only two were selectively cytotoxic to NQO1-expressing MDA468-NQ16 cells. 
Compounds 22 and 11 are poor NQO1 substrates and exhibit the best activity against breast 
cancer cells. In our novel series of aryl substituted quinonequinolines the active molecule 
appears to be the quinone derivatives and not the semiquinone derivatives resulting from NQO1 
reduction, suggesting that the mode of action of this novel series differs from lavendamycin and 
involves an unidentified target. Quinolinequinone derivatives 11, 13 and 22 cytotoxicities (IC50) 
to MDA468 cells were in the high nanomolar range. Our results seem to indicate that compounds 
11, 13 and 22 effects could be also, at least partially, mediated by metal chelation. These aryl 
quinonequinoline derivatives represent a novel promising class of cytotoxic agents with a 
potential novel therapeutic value. 
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EXPERIMENTAL SECTION 
Cell Culture. MDA-MB-468 (MDA468) human breast cancer cells and stably NQO1-
transfected MDA468-NQ1632  were a gift from Dr. David Ross (University of Colorado-Denver, 
Denver, CO). MDA468 cells had no measurable NQO1 activiy whereas activity in MDA468-
NQ16 cells was 1070 nmol/min/mg total cell protein using dichlorophenolindophenol (DCPIP) 
as the standard electron acceptor. Cells were grown in RPMI 1640 medium with L-glutamine 
and penicillin/streptomycin, and supplemented with 10% fetal bovine serum (FBS). Cell culture 
medium and supplements were obtained from Invitrogen (Carlsbad, CA). The cells were 
incubated at 37 °C under a humidified atmosphere containing 5% CO2. 
Spectrophotometric cytochrome c assay. Quinolinequinone reduction was monitored using a 
spectrophotometric assay in which the rate of reduction of cytochrome c was quantified at 550 
nm.  Briefly, the assay mixture contained cytochrome c (70 µM), NADH (1 mM), recombinant 
human NQO1 (0.1-10 µg) (gift from Dr. David Ross, University of Colorado-Denver, Denver, 
CO) and quinonlinequinones (25 µM) in a final volume of 1 mL Tris-HCl (25 mM, pH 7.4) 
containing 0.7 mg/mL BSA and 0.1% Tween-20.  Reactions were carried out at room 
temperature and started by the addition of NADH.  Rates of reduction were calculated from the 
initial linear part of the reaction curve (0-30 s) and results were expressed in terms of µmol of 
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cytochrome c reduced/min/mg of NQO1 using a molar extinction coefficient of 21.1 mM-1 cm-1 
for cytochrome c.  All reactions were carried out at least in triplicate. 
Oxygen Consumption. Oxygen concentration was monitored using a MI-730 Micro-Oxygen 
Electrode (Microelectrodes, Bedford, NH) with concentrations adjusted for temperature (25 °C). 
Assay mixtures contained 25 µM quinonlinequinones, 200 µM NADH and 1 µg/mL NQO1 in a 
2 mL Tris-Hcl-BSA/Tween (0.1%) buffer system. Reactions were started with NADH and 
measured over 3 minute intervals at room temperature. All reactions were carried out in 
triplicate.  
Electrochemistry. Cyclic Voltammagrams were collected for 10 analogues using a BAS CV-
50W electrochemical analyzer using a standard 3 electrode cell.  Experiments were performed 
using an Ag/AgCl reference electrode, a glossy carbon working electrode and a platinum wire 
auxiliary electrode.  The reported potentials are referenced by the Ferrocene (0/+) couple in the 
solvent used, primarily THF, which occurs at +.60V vs. Ag/AgCl.  The compounds were run at 
concentrations of 1mM in THF, except compound 15 which was run in DMSO, with a.1M 
concentration of tetrabutylammonium hexafluorophosphate as a supporting electrolyte.  All 
samples were purged and run under an Ar atmosphere during the course of the experiment, and 
the electrodes were washed and wiped down between each sample.  Each CV was collected at a 
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sweep rate of 50mV/s in the potential range of 0V to -2V at room temperature of 21°C. 
NMR spectroscopy. One-dimensional 1H NMR spectra were recorded at room temperature on 
Bruker Avance IIITM spectrometer (The Woodlands, Texas) at 400 MHz using a 5-mm probe 
and a simple pulse-acquire sequence. Acquisition parameters consisted of spectral width of 4000 
Hz with an acquisition time 3.98 s, number of scans of 128, and relaxation delay of 1 s. 
Complexes were prepared in a mixture of CDCl3 and THF-D8. 
Cell Viability Assay. Growth inhibition was determined using the MTT colorimetric assay.  
Cells were plated in 96-well plates at a density of 10,000 cells/mL and allowed to attach 
overnight (16 h).  Quinolinequinone solutions were applied in medium for 2 hours, removed and 
replaced with fresh medium, and the plates were incubated at 37 °C under a humidified 
atmosphere containing 5% CO2 for 3-5 days.  MTT (50 µg) was added and the cells were 
incubated for another 4 hours. Medium/MTT solutions were removed carefully by aspiration, the 
MTT formazan crystals were dissolved in 100 µL DMSO, and absorbance was determined on a 
plate reader at 560 nm.  IC50 values (concentration at which cell survival equals 50% of control) 
were determined from semi-log plots of percent of control vs. concentration.  Selectivity ratios 
were defined as the IC50 value for the MDA468 cell line divided by the IC50 value for the 
MDA468-NQ16 cell line. 
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Molecular Modeling. For docking purposes, the crystallographic coordinates of the human 
NQO1 complex with 3-(hydroxymethyl)-5-(2-methylaziridin-1-yl)-1-methyl-2-phenylindole-4,7-
dione (25) were obtained from the Brookhaven Database (PDB code 1H6933 and resolution 
1.86Ǻ) and was edited accordingly to provide a monomer of the protein. The protein complex 
was then minimized within Sybyl 7.3 (Tripos Ltd., St Louis) while holding all heavy atoms 
stationary. The ligand was then removed to leave the receptor complex which was used for the 
subsequent docking studies. For preparation of ligand structures, fragments from Sybyl 8.1.1 
were used to construct the compounds and all symmetric compounds were prepared as 
monoanionic ligands. Ligands were subject to 1000 iterations of energy minimization using the 
Powell method with MMFF94s force field standard method. For computational docking, the 
GOLD 5.1 software was used in combination with the ChemPLP34 scoring function (rescoring 
with ChemScore.35 The active site was defined as being any volume within 8Ǻ of the quinone 
scaffold of 25 in its crystal pose in 1H69. Each GA run comprised using the default parameters 
of: 100000 genetic operations on an initial population of 100 members divided into five 
subpopulations with weights for crossover, mutation, and migration being set to 95, 95, and 10, 
respectively. GOLD allows a user-definable number of GA runs per ligand, each of which starts 
from a different orientation. For these experiments, the number of GA runs was set to 10, and 
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scoring of the docked poses was performed with the ChemPLP scoring function using 
ChemScore rescore. Each GOLD run was saved and the strongest scoring binding pose of each 
ligand (subject to a rmsd default distance threshold of 1.5Ǻ) was compared to that of the 
reference ligand position observed in the crystal structure. The best output pose (orientations) of 
the ligands generated were analyzed based on its ChemPLP/ChemScore score, feasibility of 
hydride transfer process and H-bonding to the enzyme. The best pose(s) were visualized using 
PyMOL Molecular Graphics System version 1.3. 
Chemistry. All moisture sensitive reactions were performed in an inert, dry atmosphere of argon 
in flame dried glassware. Air sensitive liquids were transferred via syringe or cannula through 
rubber septa. Reagent grade solvents were used for extraction and flash chromatography. THF 
was distilled from Na/benzophenone under argon; dichloromethane (CH2Cl2) and chloroform 
(CHCl3) were distilled from CaH2 under argon. All other reagents and solvents which were 
purchased from commercial sources, were used directly without further purification. The 
progress of reactions was checked by analytical thin-layer chromatography (Sorbent 
Technologies, Silica G TLC plates w/UV 254). The plates were visualized first with UV 
illumination followed by charring with ninhydrin (0.3% ninhydrin (w/v), 97:3 EtOH-AcOH). 
Flash column chromatography was performed using prepacked Biotage SNAP cartridges on a 
	  
	  
  
206	  
Biotage Isolera One instrument. Microwave reactions were performed using a Biotage Initiator 
instrument. The solvent compositions reported for all chromatographic separations are on a 
volume/volume (v/v) basis. 1HNMR spectra were recorded at 400 or 500 MHz and are reported 
in parts per million (ppm) on the δ scale relative to tetramethylsilane as an internal standard. 
13CNMR spectra were recorded at 100 or 125 MHz and are reported in parts per million (ppm) 
on the δ scale relative to CDCl3 (δ 77.00). Melting points were determined on a Stuart melting 
point apparatus from Bibby Scientific Limited and are uncorrected. High Resolution mass 
spectrometry (HRMS) was performed on a Waters/Micromass LCT-TOF instrument. All 
compounds were more than 95% pure. 
5-chloro-8-hydroxy-7-nitroquinoline (1). This compound was prepared according to the literature 
12 procedure to yield a yellow solid, 4.40 g (79%). M.p. 198-200°C, [lit.12, m.p. 192-194°C]; 1H 
NMR (500 MHz, DMSO) δ 9.09 (dd, J = 4.2, 0.5 Hz, 1H), 8.58 (dd, J = 8.5, 0.8 Hz, 1H), 8.18 (s, 
1H), 7.94 (dd, J = 8.5, 4.3 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 150.5, 150.1, 139.9, 133.6, 
132.3, 128.5, 125.9, 122.0, 117.9. HRMS (TOF MS ES+) for C9H6ClN2O3+ (MH+) calcd. 
225.0067, found 225.0055. 
7-Amino-8-hydroxyquinoline (2). Compound 1 (2.4 g, 10.69 mmol) was placed in a 
hydrogenation apparatus equipped with a magnetic stir bar and methanol added. Pd/C (150 mg) 
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in a small amount of MeOH (60 mL) was added and stirring commenced. H2 gas was introduced 
at a pressure of 40-50 psi and reacted at rt overnight. TLC showed full conversion. The black 
solution was filtered using a celite pad and concentrated under reduced pressure to yield 2 as a 
black oil, 99% yield. 1H NMR (500 MHz, CDCl3) δ 8.66 (dd, J = 4.4, 1.6 Hz, 1H), 8.03 (dd, J = 
8.2, 1.6 Hz, 1H), 7.24 (d, J = 8.7 Hz, 1H), 7.17 (dd, J = 8.2, 4.4 Hz, 1H), 7.10 (d, J = 8.7 Hz, 
1H). 13C NMR (126 MHz, CDCl3) δ 148.0, 137.9, 136.6, 136.1, 132.1, 122.4, 119.3, 118.5, 
117.7. HRMS (TOF MS ES+) for C9H9N2O+ (MH+) calcd. 161.0715, found 161.0707. 
7-acetamido-8-acetyloxyquinoline (3). Compound 2 (330 mg, 2.06 mmol) was dissolved in dried 
THF (10 mL) and DIEA added with stirring. AcCl (176 µL) in 1mL THF was added drop wise 
while stirring and reacted at rt for 2 hrs. Then concentrated under reduced pressure followed by 
redissolving in CH2Cl2 (20 mL) and water (10 mL). The two layers were allowed to partition and 
extracted 2x 20 mL CH2Cl2. The combined organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure. Then purified on a Biotage SNAP cartridge (25 g) at a flow 
rate of 25 mL/min to yield an orange solid, 382 mg (76%); m.p. 151-153°C; 1H NMR (500 MHz, 
CDCl3) δ 8.85 (dd, J = 4.1, 1.3 Hz, 1H), 8.49 (d, J = 9.1 Hz, 1H), 8.13 (dd, J = 8.3, 1.5 Hz, 1H), 
7.70 (d, J = 9.1 Hz, 1H), 7.67 (s, 1H), 7.36 (dd, J = 8.2, 4.2 Hz, 1H), 2.56 (s, 1H), 2.04 (s, 1H); 
13C NMR (126 MHz, CDCl3) δ 169.7, 168.5, 150.6, 140.7, 135.8, 134.9, 130.8, 125.8, 125.6, 
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121.3, 120.6, 24.5, 21.0; HRMS (TOF MS ES+) for C13H13N2O3+ (MH+) calcd. 245.0926, found 
245.0923. 
7-acetamido-8-benzyloxyquinoline (4). To a solution of 3 (1.2 g, 4.91 mmol) in MeOH (100 mL) 
was added water (10 mL) and the reaction stirred under reflux for 1 hr. The black solution was 
concentrated and in vacuo and flash chromatographed on a KP-Sil 100 g Biotage SNAP cartridge 
using MeOH: DCM as the solvent (0-5% MeOH). A white solid (0.9 g) obtained and used for the 
next step directly. Rf= 0.11 (5% MeOH:CH2Cl2).  
To a solution of 7-acetamido-8-hydroxyquinoline (2.27 g, 11.23 mmol) in 40 mL DMF was 
added K2CO3 (2.33 g, 16.80 mmol) and BnBr (2 mL, 16.80 mmol) respectively. The reaction 
was stirred at 50°C for 24 hrs after which TLC showed almost all the starting material was 
consumed. The reaction mixture was diluted with 30 mL CH2Cl2, filtered with a pad of celite and 
concentrated under reduced pressure. The residue was loaded onto a 100 g Biotage SNAP 
cartridge by dissolving in a small amount of CH2Cl2 and eluted with EtOAc:heptane gradient (0-
50%). Yield 2.95 g (90%) of a yellow oil was obtained.  Rf= 0.50 (60% EtOAc:heptane). 1H 
NMR (500 MHz, CDCl3) δ 8.95 (dd, J = 4.2, 1.7 Hz, 1H), 8.58 (d, J = 9.0 Hz, 1H), 8.14 (dd, J = 
8.3, 1.7 Hz, 1H), 7.77 (s, 1H), 7.57 (d, J = 9.0 Hz, 1H), 7.40 – 7.35 (m, 6H), 5.49 (s, 2H), 1.93 (s, 
4H). 13C NMR (126 MHz, CDCl3) δ 168.3, 150.0, 142.0, 141.0, 137.4, 136.2, 132.0, 128.9, 
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128.8, 128.8, 126.0, 124.0, 120.0, 120.0, 77.3, 24.6. HRMS (TOF MS ES+) for C18H17N2O2+ 
(MH+) calcd. 293.1290, found 293.1264. 
7-acetamido-8-(benzyloxy)quinoline-1-oxide (5). The starting material (4) (428 mg, 1.46 mmol) 
was dissolved in 4.3 mL 1,2-dichloroethane with stirring. The mCPBA (340 mg, 1.76 mmol) was 
added (0.5 M) and the reaction stirred at rt for 48 hrs. TLC showed almost all the starting 
material was consumed. The precipitated mCPBA was filtered and washed with 5 mL 1, 2-
dichloroethane. The filtrate was concentrated under reduced pressure and flash chromatographed 
on a KP-sil 100 g Biotage SNAP cartridge using a 5% MeOH: DCM gradient at a flow rate of 25 
mL/min to yield a yellow solid, 373 mg (82%). M.p. 145-147°C; Rf 0.24 (5%MeOH:DCM). 1H 
NMR (500 MHz, DMSO) δ 9.45 (s, 1H), 8.46 (d, J = 6.1 Hz, 1H), 8.20 (d, J = 8.9 Hz, 1H), 7.81 
(d, J = 8.3 Hz, 1H), 7.77 (d, J = 9.0 Hz, 1H), 7.58 – 7.50 (2H), 7.40 – 7.30 (aromatic, 4H). 13C 
NMR (126 MHz, DMSO) δ 168.9, 139.8, 138.1, 137.1, 136.4, 133.3, 129.8, 129.1, 128.1, 128.0, 
124.7, 124.4, 120.8, 77.7, 23.8. HRMS (TOF MS ES+) for C18H17N2O3+ (MH+) calcd. 309.1239, 
found 309.1227. 
7-acetamido-8-benzyloxy-2-chloroquinoline (6). Phosphoryl chloride (280 µL, 3.0 mmol) in 
CHCl3 (1.0 mL) was added to a stirred solution of the oxide 5 (770 mg, 2.50 mmol) in 21 mL 
CHCl3 and stirred for 15 min. The mixture was then refluxed for 2 hrs, cooled and poured into 
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ice (50 g) and the pH adjusted to 12 with NaOH (aq.). The aq. layer was extracted with 2 x 50 
mL CH2Cl2, washed with 2 x 20 mL H2O, dried over MgSO4, filtered and concentrated under 
reduced pressure to yield a brown oil. Then purified on a HP-Sil 25 g Biotage SNAP cartridge 
using EtOAc:heptane gradient (0-50%) as the solvent. Yield 504 mg (62%) of an off-white solid 
was obtained.  Rf= 0.58 (60% EtOAc:heptane); M.P. 92-94°C; 1H NMR (500 MHz, CDCl3) δ 
8.60 (d, J = 9.0 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.81 (s, 1H), 7.54 (d, J = 9.0 Hz, 1H), 7.45 – 
7.35 (m, 1H), 7.32 (d, J = 8.5 Hz, 1H), 5.48 (s, 1H), 1.96 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 
168.4, 150.5, 141.4, 140.3, 139.0, 137.2, 133.0, 128.9, 128.8, 128.8, 124.3, 123.3, 121.1, 120.1, 
77.4, 24.7. HRMS (TOF MS ES+) for C18H16ClN2O2+ (MH+) calcd. 327.0900, found 327.0936. 
7-acetamido-2-chloro-8-hydroxyquinoline (7). To a solution of 6 (330 mg, 1.01 mmol) in 
CH2Cl2 (10.1 mL) under an Ar atmosphere was added BCl3•SMe2 (10.1 mL) via a syringe and 
stirred at rt overnight. TLC showed the reaction was complete. The reaction was then quenched 
with saturated NaHCO3(aq.) and extracted with 2x20 mL CH2Cl2. The organic layers were 
combined, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was 
purified on 50 g KP-Sil Biotage SNAP cartridge using a MeOH: CH2Cl2 gradient (0-5% MeOH) 
at a flow rate of 25 mL/minute to give a yellow solid, 198 mg (82%). M.P. 176-178°C; Rf= 0.50 
(5%  MeOH:CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 8.60 (d, J = 9.0 Hz, 1H), 8.05 (d, J = 8.5 
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Hz, 1H), 7.82 (brs, 1H), 7.72 (s, 1H), 7.35 (d, J = 9.0 Hz, 1H), 7.30 (d, J = 8.5 Hz, 1H), 2.29 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 168.6, 149.7, 138.9, 138.2, 137.1, 124.4, 123.3, 121.5, 
121.3, 118.0, 24.9. HRMS (TOF MS ES+) for C11H10ClN2O2+ (MH+) calcd. 237.0431, found 
237.0424. 
7-Acetamido-2-chloroquinoline-5,8-dione (8). To a solution of 7 (300 mg, 1.27 mmol) in acetone 
(30 mL) was added a solution of Fremy’s salt  in NaH2PO4 buffer (0.3 M, 30 mL) and the 
mixture stirred at rt for 1 hr. A further solution of Fremy’s salt in the buffer (0.3M, 30 mL) was 
added and stirring continued for 2 hrs. The acetone was removed under reduced pressure and the 
residue extracted with 2 x 50 mL CH2Cl2. The CH2Cl2 phases were combined, dried over MgSO4 
and concentrated under reduced pressure. The residue was purified on a 25 g HP-Sil Biotage 
SNAp cartridge using EtOAc:heptanes gradient (0-60%) to obtain a yellow solid, 225 mg (71% 
over 2 steps); m.p. 224-226°C (decomposes into a black mass), Rf= 0.49 (60% EtOAc:heptane). 
1H NMR (500 MHz, CDCl3) δ 8.41 (s, 1H), 8.39 (d, J = 8.2 Hz, 1H), 7.97 (s, 1H), 7.74 (d, J = 
8.2 Hz, 1H), 2.34 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 183.4, 178.1, 169.5, 156.7, 145.9, 
140.4, 137.2, 129.9, 128.0, 116.3, 25.1. HRMS (TOF MS ES+) for  C11H8ClN2O3+ (MH+) calcd. 
251.0223, found 250.0203. 
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General procedure for Suzuki coupling under microwave conditions. The 7-acetamido-2-
chloroquinoline-5,8-dione 8 (21 mg, 0.08 mmol)  was dissolved in 4 mL dimethoxyethane 
(DME) and degassed under reduced pressure. The palladium (0) catalyst, Pd(PPh3)4 (10 mg, 
0084 mmol) was added and the solution degassed further. The mixture was stirred under Ar 
atmosphere for 10 minutes. Na2CO3 solution (0.2 mL, 2.0 M) was added followed by the boronic 
acid (0.126 mmol). The mixture was then heated using a Biotage microwave initiator at 110-
140°C for 20 minutes. After cooling, TLC showed all the starting material was consumed. The 
reaction mixture was poured into DCM and washed with 2 x 10 mL water. Then dried over 
MgSO4, filtered and concentrated under reduced pressure. The residue was purified on HP-Sil 25 
g Biotage SNAP cartridge using EtOAc:heptane gradient (0-50%) at a flow rate of 20 mL/min. 
For very polar products, MeOH:CH2Cl2 (0-10%MeOH) was used as solvent for purification. 
7-acetamido-2-(4-(trifluoromethyl)phenyl)quinoline-5,8-dione (9). Yield 21 mg (70%) of a 
yellow solid was obtained.  Rf= 0.47 (50% EtOAc:heptane); m.p. 250°C(decomposes);  1H NMR 
(500 MHz, CDCl3) δ 8.53 (d, J = 8.2 Hz, 1H), 8.45 (s, 1H), 8.27 (d, J = 8.1 Hz, 2H), 8.17 (d, J = 
8.2 Hz, 1H), 7.99 (s, 1H), 7.80 (d, J = 8.2 Hz, 2H), 2.35 (s, 4H).13C NMR (126 MHz, CDCl3) δ 
184.1, 179.1, 169.5, 160.1, 146.1, 140.6, 135.7, 128.3, 128.0, 126.0, 126.0, 126.0, 125.3, 116.5, 
25.2; HRMS (TOF MS ES+) for  C18H12F3N2O3+(MH+) calcd. 361.0800, found 361.0834. 
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7-acetamido-2-(3-pyridinyl))quinoline-5,8-dione (10). Yield 21 mg (41%) of a yellow solid 
obtained, Rf= 0.19 (5% MeOH:DCM); m.p. >300°C(decomposes); 1H NMR (500 MHz, CDCl3) 
δ 9.29 (s, 1H), 8.72 (d, J = 3.9 Hz, 1H), 8.56 (d, J = 8.2 Hz, 1H),8.55 (m, 1H), 8.21 (d, J = 8.2 
Hz, 1H), 8.00 (s, 1H), 7.56 (dd, J = 8.0, 4.9 Hz, 1H), 2.35 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 184.2, 179.0, 170.4, 158.9, 150.7, 148.1, 146.1, 140.9, 135.7, 135.7, 128.1, 125.3, 116.6, 24.6 ; 
HRMS (TOF MS ES+) for  C16H12N3O3+MH+) calcd. 294.0879, found 294.0914. 7-amino-2-(3-
pyridinyl)quinoline-5,8-dione: 6 mg (12%) of a red solid was obtained.  Rf= 0.13 (5% 
MeOH:DCM); m.p. 195-197°C (decomposes, turns black); 1H NMR (500 MHz, CDCl3) δ 9.29 
(d, J = 1.7 Hz, 1H), 8.67 (dd, J = 4.9, 1.4 Hz, 1H), 8.58 (ddd, J = 8.0, 2.2, 1.7 Hz, 1H), 8.52 (d, J 
= 8.2 Hz, 1H), 8.22 (d, J = 8.2 Hz, 1H), 7.59 (ddd, J = 8.0, 4.9, 0.7 Hz, 1H), 6.07 (s, 1H). 13C 
NMR (126 MHz, CDCl3) δ 181.9, 179.8, 157.0, 150.4, 149.6, 147.6, 146.3, 135.4, 135.0, 133.5, 
129.4, 124.7, 123.8, 102.1.  HRMS (TOF MS ES+) for   C14H10N3O2+MH+) calcd. 252.0773, 
found  252.0795. 
7-acetamido-2-(8’-quinolinyl)quinoline-5,8-dione (11). Yield 31 mg (51%) of a yellow solid was 
obtained. Rf= 0.25 (70% EtOAc:heptane), crystallized from MeOH/CH2Cl2; m.p. 295°C 
(decomposes); 1H NMR (500 MHz, CDCl3) δ 8.93 (dd, J = 4.2, 1.8 Hz, 1H), 8.53 (d, J = 8.1 Hz, 
1H), 8.48 (d, J = 8.1 Hz, 1H), 8.34 (dd, J = 8.3, 1.8 Hz, 1H), 8.22 (dd, J = 7.2, 1.4 Hz, 1H), 8.04 
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(dd, J = 8.2, 1.4 Hz, 1H), 8.00 (s, 1H), 7.76 (dd, J = 8.1, 7.3 Hz, 1H), 7.54 (dd, J = 8.3, 4.2 Hz, 
1H), 2.34 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 184.8, 179.1, 170.9, 161.9, 150.5, 145.7, 145.1, 
140.9, 136.7, 136.5, 133.3, 131.9, 131.7, 130.2, 128.4, 127.6, 126.3, 121.4, 116.5, 24.2. HRMS 
(TOF MS ES+) C20H14N3O3+ (MH+) calcd. 344.1035, found  344.1022. 
7-acetamido-2-(2-(1-tert-butoxycarbonylindolyl))quinoline-5,8-dione (12). Yield 63mg (67%) of 
an orange was obtained. Rf= 0.40 (50% EtOAc:heptane); m.p. 191-193°C (decomposes); 1H 
NMR (500 MHz, CDCl3) δ 8.47 (s, 1H), 8.45 (d, J = 8.1 Hz, 1H), 8.15 (d, J = 8.4 Hz, 1H), 7.97 
(s, 1H), 7.89 (d, J = 8.1 Hz, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.40 (t, J = 7.8 Hz, 1H), 7.27 (dd, J = 
9.1, 5.9 Hz, 1H), 6.98 (s, 1H), 2.33 (s, 3H), 1.41 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 184.2, 
179.0, 169.6, 157.4, 149.7, 145.3, 140.4, 138.1, 137.5, 134.2, 128.6, 127.9, 127.6, 126.0, 123.3, 
121.5, 116.5, 115.2, 114.0, 84.2, 27.8, 25.1.  HRMS (TOF MS ES+) C24H22N3O5+(MH+) calcd. 
432.1559, found 432.1568. 
7-acetamido-2-(2-pyridinyl)quinoline-5,8-dione (13). Yield 37 mg (71%) of a yellow solid was 
obtained. Rf= 0.19 (5% MeOH:CH2Cl2), crystallized from MeOH/CH2Cl2; m.p. 255-258°C 
(decomposes); 1H NMR (500 MHz, DMSO) δ 10.08 (s, 1H), 8.78 (ddd, J = 4.8, 1.6, 0.8 Hz, 1H), 
8.53 (d, J = 7.9 Hz, 1H), 8.46 (d, J = 8.2 Hz, 1H), 8.08 (td, J = 7.7, 1.8 Hz, 1H), 7.77 (s, 1H), 
7.58 (ddd, J = 7.5, 4.7, 1.1 Hz, 1H), 2.28 (s, 3H). 13C NMR (126 MHz, DMSO) δ 184.6, 178.4, 
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171.5, 158.6, 153.6, 149.8, 146.4, 142.5, 137.8, 135.0, 128.5, 125.5, 124.6, 121.7, 115.3, 24.7. 
HRMS (TOF MS ES+) C16H12N3O3+ (MH+) calcd. 294.0879, found   294.0914. 
7-acetamido-2-(2-(1-tert-butoxycarbonylpyrrolyl))quinoline-5,8-dione (14). Yield 36 mg (53%) 
of a yellow solid was obtained. Rf= 0.30 (50% EtOAc:heptane); m.p. 191-193°C (decomposes), 
recrystallized from methanol; 1H NMR (500 MHz, CDCl3) δ 8.42 (s, 1H), 8.39 (d, J = 8.2 Hz, 
1H), 7.95 (s, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.42 (dd, J = 3.2, 1.7 Hz, 1H), 6.64 (dd, J = 3.4, 1.7 
Hz, 1H), 6.29 (t, J = 3.3 Hz, 1H), 2.32 (s, 3H), 1.43 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 
184.3, 179.2, 169.5, 156.9, 148.8, 145.3, 140.3, 134.0, 132.5, 128.0, 127.3, 125.5, 118.6, 116.4, 
111.2, 84.4, 27.7, 25.1. HRMS (TOF MS ES+) C20H20N3O5+ (MH+) calcd. 382.1403, found 
382.1381. 
7-acetamido-2-(4-pyrazolyl))quinoline-5,8-dione (15). Yield 31 mg (42%) of a brown solid was 
obtained. Rf= 0.33 (5% MeOH:CH2Cl2); m.p. 270°C (decomposes), recrystallized from 
methanol; 1H NMR (500 MHz, DMSO) δ 13.34 (s, 1H), 9.97 (s, 1H), 8.55 (s, 1H), 8.25 (d, J = 
8.2 Hz, 1H), 8.21 (s, 1H), 8.11 (d, J = 8.2 Hz, 1H), 7.69 (s, 1H), 2.26 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 184.6, 178.6, 171.4, 156.1, 146.6, 142.1, 134.2, 126.1, 123.8, 121.2, 115.1, 24.6. 
HRMS (TOF MS ES+) C14H11N4O3+ (MH+) calcd. 283.0831, found 283.0846. 
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7-acetamido-2-(3-(2-acetamido-pyridinyl))quinoline-5,8-dione (16). The quinone 8 (71 mg, 0.28 
mmol) was dissolved in 2 mL 1,4-dioxane and degassed under reduced pressure. PdCl2(dppf) (20 
mg), K3PO4 (238 mg) and the boronate were added and the solution degassed further. The 
mixture was stirred under Ar atmosphere for 10 minutes. The mixture was then heated heated 
using a Biotage microwave initiator at 120°C for 30 minutes. After cooling, the reaction mixture 
was poured into CH2Cl2 and washed with 2 x 10 mL water and extracted 2x 30 mL DCM. The 
combined organic phases were dried over MgSO4, filtered and concentrated under reduced 
pressure. The residue was purified on a HP-Sil 25 g Biotage SNAP cartridge using 
MeOH:CH2Cl2 gradient (0-5%) at a flow rate of 20 mL/min. Yield 23mg (23%) of a brown solid 
was obtained. Rf= 0.32 (5% MeOH:CH2Cl2); m.p. 249°C (decomposes); 1H NMR (500 MHz, 
DMSO) δ 10.82 (s, 1H), 10.04 (s, 1H), 9.17 (d, J = 2.5 Hz, 1H), 8.60 (dd, J = 8.8, 2.5 Hz, 1H), 
8.45 (d, J = 8.3 Hz, 1H), 8.38 (d, J = 8.2 Hz, 1H), 8.27 (d, J = 8.8 Hz, 1H), 7.75 (s, 1H), 2.28 (s, 
3H), 2.14 (s, 3H). 13C NMR (126 MHz, DMSO) δ 184.6, 178.5, 171.5, 169.7, 157.4, 153.6, 
147.3, 146.6, 142.4, 137.0, 134.8, 128.0, 127.2, 124.1, 115.3, 113.0, 24.7, 24.0. HRMS (TOF 
MS ES+) C18H15N4O4+ (MH+) calcd. 351.1093, found 351.1064. 
7-acetamido-2-(2-indolyl)quinoline-5,8-dione (17). The starting material 12 (39 mg, 0.09 mmol)  
was dissolved in 2.5 mL CH2Cl2 and cooled to 0°C using an ice bath. Trifluoroacetic acid (140 
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mL) was the added dropwise and reacted at rt for 2 hrs. TLC showed full conversion.  Then 
quenched with sat. NaHCO3 (10 mL) and extracted 2x20 mL CH2Cl2.  The organic layers were 
combined, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was 
purified on a HP-Sil 25 g Biotage SNAP cartridge using EtOAc:heptane gradient (0-70%) at a 
flow rate of 20 mL/min. Yield 17 mg (59%) of a red solid was obtained after recrystallization 
from MeOH. M.p. 185°C, decomposes; Rf= 0.38 (70% EtOAc:heptane). 1H NMR (500 MHz, 
CDCl3) δ 8.35 (d, J = 8.3 Hz, 1H), 8.14 (d, J = 8.3 Hz, 1H), 7.92 (s, 1H), 7.67 (d, J = 8.0 Hz, 
1H), 7.49 (d, J = 8.3 Hz, 1H), 7.29 (t, J = 7.6 Hz, 1H), 7.23 (s, 1H), 7.13 (t, J = 7.4 Hz, 1H), 2.34 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 184.2, 180.4, 170.5, 154.7, 145.4, 140.3, 137.8, 134.7, 
134.4, 128.3, 126.6, 124.4, 124.4, 121.5, 120.2, 117.0, 111.7, 104.4, 24.4. HRMS (TOF MS 
ES+) C19H14N3O3+ (MH+) calcd. 332.1035, found 332.1030. 
7-acetamido-2-(2-(pyrrolyl))quinoline-5,8-dione (18). The starting material 14 (30 mg, 0.08 
mmol)  was dissolved in 3 mL CH2Cl2 and cooled to 0°C using an ice bath. Trifluoroacetic acid 
(150 µL) was the added dropwise and reacted at rt for 2 hrs. TLC showed full conversion.  Then 
quenched with sat. NaHCO3 (10 mL) and extracted 2x20 mL CH2Cl2.  The organic layers were 
combined, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was 
purified on a HP-Sil 25 g Biotage SNAP cartridge using EtOAc:heptane gradient (0-50%) at a 
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flow rate of 20 mL/min. Yield 21 mg (93%) of a red solid was obtained after recrystallization 
from MeOH. M.P. 255°C, decomposes. Rf= 0.11 (50% EtOAc:heptane). 1H NMR (500 MHz, 
DMSO) δ 11.65 (s, 1H), 9.95 (s, 1H), 8.20 (d, J = 8.4 Hz, 1H), 8.05 (d, J = 8.4 Hz, 1H), 7.69 (s, 
1H), 7.07 – 7.04 (m, 2H), 6.28 – 6.22 (m, 1H), 2.27 (s, 3H). 13C NMR (126 MHz, DMSO) δ 
184.6, 178.7, 171.4, 154.0, 146.6, 141.9, 133.9, 130.1, 125.3, 123.8, 121.8, 115.2, 111.9, 110.4, 
24.7. HRMS (TOF MS ES+) C15H12N3O3+ (MH+) calcd. 282.0879, found 282.0909. 
General procedure for removal of the acetate group with MeOH-H2SO4. To the starting material 
(0.1 mmol) in a 20 mL vial was added 175mL of H2SO4 in 3.0 mL MeOH and stirred at rt for 3 
hrs. The red solution was then neutralized with 5 mL 5% NaHCO3 (aq.) and extracted with 5 X 
10 mL CH2Cl2. The combined organic extracts were dried over MgSO4, filtered and concentrated 
under reduced pressure. Then purified on a HP-Sil 25 g Biotage SNAP cartridge using 
EtOAc:heptanes (0-70%) or MeOH:CH2Cl2 gradient (0-5%) at a flow rate of 20 mL/min.  
7-Amino-2-(4-(trifluoromethyl)phenyl)quinoline-5,8-dione (19). The general procedure was used 
to obtain 6.0 mg (67%) of a red solid; Rf= 0.38 (60% EtOAc:heptane); m.p. 151-153°C 
(decomposes, turns black); 1H NMR (500 MHz, CDCl3) δ 8.28 (d, J = 8.2 Hz, 1H), 8.05 (d, J = 
8.2 Hz, 2H), 7.95 (d, J = 8.2 Hz, 1H), 7.58 (d, J = 8.3 Hz, 2H), 5.84 (s, 1H). 13C NMR (126 
MHz, CDCl3) δ 182.2, 180.1, 158.7, 150.3, 146.3, 140.6, 135.1, 129.4, 127.7, 125.5, 125.5, 
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125.1, 105.8, 102.4. HRMS (TOF MS ES+) C16H10F3N2O2+ (MH+) calcd. 319.0694, found 
319.0666. 
7-amino-2-(3-pyridinyl)quinoline-5,8-dione (20). The general procedure was used to obtain 10 
mg (83%) of a red solid.  Rf= 0.16 (5% MeOH:CH2Cl2); m.p. 195-197°C (decomposes, turns 
black). 1H NMR (500 MHz, CDCl3) δ 9.29 (d, J = 1.7 Hz, 1H), 8.67 (dd, J = 4.9, 1.4 Hz, 1H), 
8.58 (ddd, J = 8.0, 2.2, 1.7 Hz, 1H), 8.52 (d, J = 8.2 Hz, 1H), 8.22 (d, J = 8.2 Hz, 1H), 7.59 (ddd, 
J = 8.0, 4.9, 0.7 Hz, 1H), 6.07 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 181.9, 179.8, 157.0, 150.4, 
149.6, 147.6, 146.3, 135.4, 135.0, 133.5, 129.4, 124.7, 123.8, 102.1. HRMS (TOF MS ES+) for   
C14H10N3O2+MH+) calcd. 252.0773, found 252.0795. 
7-amino-2-(2-indolyl)quinoline-5,8-dione (21). The general procedure was used to obtain 19 mg 
(63%) of a dark-brown solid.  Rf= 0.22 (70% EtOAc:heptane); m.p. 235°C decomposes. 1H 
NMR (500 MHz, CDCl3) δ 8.33 (d, J = 8.3 Hz, 1H), 8.10 (d, J = 8.3 Hz, 1H), 7.67 (d, J = 8.0 
Hz, 1H), 7.49 (d, J = 8.2 Hz, 1H), 7.39 (s, 1H), 7.27 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 7.19 (s, 1H), 
7.12 (td, J = 7.5, 0.8 Hz, 1H), 6.01 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 182.6, 181.6, 153.6, 
149.5, 145.9, 137.6, 135.0, 134.2, 128.3, 128.0, 124.1, 124.0, 121.3, 120.0, 111.7, 103.5, 102.9. 
HRMS (TOF MS ES+) for  C17H12N3O2+ (MH+) calcd. 290.0930, found 290.0900. 
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7-amino-2-(8-quinolinyl)quinoline-5,8-dione (22). The general procedure was used to obtain 55 
mg (71%) of a brown solid.  Rf= 0.29 (5% MeOH:CH2Cl2); m.p. 243-245°C, recrystallized from 
MeOH. 1H NMR (500 MHz, CD3OD) δ 8.92 (dd, J = 4.2, 1.8 Hz, 1H), 8.49 (d, J = 8.1 Hz, 1H), 
8.40 (d, J = 8.1 Hz, 1H), 8.33 (dd, J = 8.3, 1.8 Hz, 1H), 8.21 (dd, J = 7.2, 1.5 Hz, 1H), 8.02 (dd, J 
= 8.2, 1.4 Hz, 1H), 7.75 (dd, J = 8.1, 7.3 Hz, 1H), 7.53 (dd, J = 8.3, 4.2 Hz, 1H), 6.06 (s, 1H). 13C 
NMR (126 MHz, CDCl3) δ 182.8, 180.1, 160.5, 150.3, 150.2, 146.2, 145.2, 136.7, 136.7, 133.2, 
131.6, 131.5, 129.8, 129.1, 128.4, 126.3, 121.2, 102.4. HRMS (TOF MS ES+) for  C18H12N3O2+ 
(MH+) calcd. 302.0930, found 302.0939. 
7-amino-2-(2-pyridinyl)quinoline-5,8-dione (23). The general procedure was used to obtain 16 
mg (76%) of a red solid.  Rf= 0.25 (20% MeOH:CH2Cl2), recrystallized from MeOH. 1H NMR 
(500 MHz, DMSO) δ 8.75 (d, J = 4.1 Hz, 1H), 8.72 (d, J = 8.2 Hz, 1H), 8.50 (d, J = 7.9 Hz, 1H), 
8.40 (d, J = 8.1 Hz, 1H), 8.05 (t, J = 7.7 Hz, 1H), 7.58 – 7.53 (m, 1H), 5.89 (s, 1H). HRMS (TOF 
MS ES+) for C14H10N3O2+ (MH+) calcd. 252.0773 found 252.0749. 
7-Amino-2-(2-pyrrolyl)quinoline-5,8-dione (24). The general procedure was used to obtain 11 
mg (78%) of a red solid.  Rf= 0.37 (5% MeOH:CH2Cl2); m.p. 230°C (decomposes), 
recrystallized from MeOH. 1H NMR (500 MHz, CDCl3) δ 8.23 (d, J = 8.4 Hz, 1H), 7.84 (d, J = 
8.4 Hz, 1H), 7.06 (dd, J = 2.5, 1.3 Hz, 1H), 6.91 (dd, J = 3.7, 1.3 Hz, 1H), 6.32 (dd, J = 3.7, 2.6 
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Hz, 1H), 5.97 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 183.0, 181.7, 153.5, 149.4, 145.7, 133.9, 
129.9, 126.6, 122.7, 122.3, 110.8, 110.3, 102.5. HRMS (TOF MS ES+) for C13H10N3O2+ (MH+) 
calc. 240.0773, found 240.0779. 
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Abstract— A critical comparison of methods to prepare sterically hindered 3-aryl isoxazoles containing fused aromatic rings 
using the nitrile oxide cycloaddition (NOC) reveal that modification of the method of Bode, Hachisu, Matsuura and Suzuki 
(BHMS), utilizing either triethyl amine as base or sodium enolates of the diketone, ketoester and ketoamide dipolarophiles, 
respectively was the method of choice for this transformation.© 2013 Elsevier Science. All rights reserved 
 
Isoxazoles continue to be of interest for both their biological activities and synthetic utility.1-4 
The synthesis of aryl-isoxazoles is also the subject of on-going improvements.1,5-7 In connection 
with our studies on aryl isoxazole amides (AIMs)8-9 we have reported lead compounds which 
possess (1) useful antitumor activity and  (2) photophysical properties which are of potential 
diagnostic use as "tumor paint".10   
Figure 1. Structure, Symyx radar graph, and Laser Scanning Cytometry of NSC 728558. 
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An illustration of the application of AIMs is shown in Figure 1. AIM NSC 728558 has exhibited 
a mid-graph mean point of -5.71-5.75 (log scale, which translate to single digit micromolar) for 
tumor cell line growth inhibition (GI50) against the full panel in the NCI60 cell line antitumor 
screening protocol,8 and as a benchmark for comparison clinically used agents 5-
fluorodeoxyuridine, bleomycin and rubidazone gave values of -4.7, -5.2 and -5.8 respectively in 
the same standard assay.  The calculated physical property data for NSC 728558 fall within or 
close to values with useful bioavailability (radar graph, Symyx Draw v3.1; top right panel). 
Laser Scanning Cytometry shows that NSC 728558 does in fact permeate human glioma SNB-19 
cells (the AIM is blue) and is localized within the nucleus. Surgical resection of many cancers, 
especially brain tumors or gliomas, have a poor success rate because of the difficulty of judging 
the border between cancerous and healthy tissue. Fluorescent agents with antitumor activity such 
as the AIMs hold promise for improvements in visualizing tumors during surgery.10b,c 
We required both improvements in the efficiency of the preparation of the isoxazole and 
concomitant economy of scale to prepare amounts of material sufficient to expand the scope of 
our investigations toward in vivo studies.  
Isoxazoles prepared via nitrile oxide cycloaddition (NOC)11 are most often prepared by 
dehydration of α-methylene nitro precursors,5 or chlorination/dehalogenation of oximes1,6,7 to 
form the nitrile oxide 1.  
 
Among the unsymmetrical dipolarophiles 2 which usually give rise to regioselective 
cycloaddition are enamines. 
 
 
 
 
 
 
 
First pioneered by Stork and McMurry,12 the use of enamines in the NOC works well for 
aliphatic and aromatic nitrile oxides on mole scales.1 We have employed modifications of this 
synthesis in the preparation of isoxazole-oxazolines,13 antihypertensive 4-isoxazolyl-1,4-
dihydropyridines,14 and we  have championed the reaction as a learning tool for aspiring 
chemists.15 Our previous reports in the AIM series have used enamines as dipolarophiles,16 while 
for most cases modest yields in the range of 30-40% overall of 3 were obtained, sufficient 
R
C
N+
O-
R' R"
O O
R
N
O
R'
O
R"
1
2
3
	  
	  
  
230	  
quantities of material were isolated for pharmacology studies. Upon scale-up however, we have 
observed a consistent diseconomy of scale using enamines and nitrile oxides derived from fused 
ring aromatics, to the extent that even a ten-fold increase in scale  (from ca. 10 to 100 mM) 
produced only marginally more desired product, and purified yields plummeted to 10-20%. We 
have found this is especially a limitation when using nitrile oxides derived from fused aromatic 
systems. Careful examination of the reaction by-products after chromatographic isolation and 
characterization by LC-MS revealed that as the stability of aryl nitrile oxides 1 increases17,16b 
their consequent reactivity to dipolarophiles slows, with concomitant increases in amine trapping  
of the nitrile oxide/oximidoyl chloride to give 7, as well as self-condensation of the nitrile oxide 
to yield 8 as shown in Scheme 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We therefore examined the methodology of Bode, Hachisu, Matsuura and Suzuki (BHMS), 
which use either the sodium enolates of ketoesters,6 or tertiary amines as base.7 The use of 
sodium enolates in the NOC was pioneered by Renzi and Dal Piaz,20 and recently applied in 2,6-
disubstituted aryl cases for the preparation of growth hormone secretagogue receptor 
antagonists.21 The BHMS procedure has been used to prepare particularly hindered 
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unsymmetrical 2,6-disubstituted aryl examples, including examples which appear to exist as 
atropisomers,7 which recommended its application to our examples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The comparison was especially dramatic for the anthryl isoxazole cases, shown in Table 2. 
Excellent yields were obtained for anthryl isoxazoles 3j, 10-chloro analog 3k, and 10-bromo 
analog 3m. The yields with the enamine procedures were 35-4516 and 10-20%, for 3j and 3k, 
respectively. Table 2, Entry 3 illustrates the direct synthesis of a fused aromatic containing a C-4 
tertiary amide, which is an uncommon example of a ketamide used as dipolarophile in the 
NOC.22 The ketamide was prepared from diketene and pyrrolidine,18 and cycloaddition provided 
the C-4 amide in synthetically reasonable yield. The sluggish reactivity we previously reported 
for nucleophilic addition to the C-4 ester of the 3-anthryl-isoxazole is exemplified by (1) slow 
hydrolysis rates (i.e., 60 h using refluxing aqueous LiOH)9 and (2) the observation that n-BuLi 
deprotonates the C-5 methyl at -78oC without noticeable addition to the C-4 ester.19 The C-4 
functionalization prior to the NOC stage is a definite advantage for the preparation of AIMs, and 
will be the subject of further study. 
 
R Ar
H3C
CO2Et
N
O
4. R = -CHO
5. R = -CHNOH
1. R = C N+ O-
NH2OH
NCS
NO
CH3 Ar
CO2Et
3b. Ar = 2-Naphthyl 30-40%
3g. Ar = 2-MeO-Naphthyl 35%
3k. Ar= 10-Cl--anthr-9-yl 10-20%
N
O
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+
N
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Scheme 1. Synthesis of the isoxazoles used for the present study.
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In summary, we have found that the BHMS protocol produced superior results, especially in 
sterically encumbered examples containing fused ring aromatic nitrile oxides and that these 
conditions represent the methodology of choice when standard enamine methodology fails. We 
will report on the chemical and pharmacological application of these novel isoxazoles in due 
course. 
 
Experimental  
 
General: All reactions were performed under inert atmosphere. Purification was carried out by 
column chromatography. Chemicals were purchased from TCI or Aldrich Chemical Company, 
all commercial reagents are routinely examined for purity by NMR and TLC, and recrystallized 
or distilled as appropriate. Solvents were reagent grade. Melting points were determined in open 
capillary tubes on a Melt-Temp apparatus and are uncorrected. NMR spectra were obtained using 
either a Varian 400 MHz Unity Plus or a Varian NMR systems 500 MHz spectrometer, in 
deuteriochloroform unless otherwise noted. Infrared spectra were obtained on a thermo-Nicolet 
633 FT-IR spectrometer.  
 Chemical shifts (δ) are reported using CHCl3 (7.26 ppm for 1H), CDCl3 (77 ppm for 13C) as 
references. High resolution mass spectra (HRMS) were obtained using a Micromass electrospray 
ionization (ESI)/time-of-flight mass spectrometry (LCTOF). Mass spectrometer samples were 
introduced using a Waters model 2690 separations module HPLC fitted with a C-18 reversed 
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phase column (2.1 mm i.d., 5 cm). Elemental analyses for C, H, and N were performed by 
Midwest Microlab, Indianapolis, IN. All reactions were monitored by Thin Layer 
Chromatography (TLC). Purification was performed by flash column chromatography, and 
analytical samples were prepared by PTLC. Analytical LCMS (UV at 254 nm) and NMR were 
used to establish the purity of targeted compounds. All compounds that were evalauted in 
biochemical and biophysical assays had >95% purity as determined by 1H NMR and LCMS NSC 
728558 was prepared from 3k as previously described.8,9 
 
1-(Pyrrolidin-1-yl)butane-1,3-dione.18 Pyrolidine (0.539 g, 7.5 mmol) is dissolved in 10 mL of 
anhydrous DCM and diketene (0.925 g, 11.00 mmol) is added. The mixture is stirred at ambient 
temperature for 2.5 h, followed by removal of the solvent under vacuum to afford (1.163 g, 99%) 
as red brown liquid. 1H NMR (500 MHz, CDCl3): δ 3.46 (t, J = 6.62 Hz, 2H), 3.45 (s, 2H), 3.); 
13C NMR (125 MHz, CDCl3): δ 202.6, 165.0, 88.8, 51.3, 47.2, 45.9, 30.4, 26.0, 24.4; IR cm-1; 
mass calculated for C8H13NO2 155.0946, found m/z 156.1902 (M +1, 100%). 
 
NOC: sodium enolate method. 
(3-(Anthracen-9-yl)-5-methylisoxazol-4-yl)(pyrrolidin-1-yl)methanone, 3l. To a solution of 
sodium ethoxide, prepared from 0.199 g of Na in 44.2 mL of absolute EtOH, was added 1-
(Pyrrolidin-1-yl)butane-1,3-butane-1,3-dione (1.015 g, 6.54 mmol), and  9-
anthrahydroximinoylchloride, (1.06, 4.105 mmol) successively and the resulting red solution was 
stirred under Ar atmosphere for 4h at ambient temperature. The red-brown solution was 
extracted with ethyl acetate (4 x 20 mL), washed with DI water (2 x 50 mL) and brine (50 mL), 
and dried over anhydrous Na2SO4. Filtration and concentration afforded the desired product 3l as 
red-brown oil (1.40 g, 95%), which was further purified by silica column flash chromatography 
(Hexanes: EtOAc; 10:1), and PTLC to afford 3l as off white solid (0.7375 g, 50 %). 
 
NOC: triethyl amine method. Synthesis of 1-(5-methyl-3-(2-methylnaphthalene-1-
yl)isoxazol-4- yl)ethanone, 3a. To 2,4-pentanedione (0.42 g, 4.11 mmol)  in absolute ethanol 
(21ml) at ambient temperature was added triethylamine (0.47 g, 4.584 mmol) followed by 
addition of nitrile oxide (0.6 g, 3.28 mmol). The temperature was raised to 53oC and the mixture 
stirred under Ar atmosphere for 72 h. The pale yellow solution was extracted with chloroform (4 
x 20 mL), washed with DI water (2 x 50 mL) and brine (50 mL), dried over anhydrous Na2SO4. 
Filtration, concentration and silica column flash chromatography (Hexanes: EtOAc: DCM; 
5:1:1) afforded the desired product 3a (0.289 g, 40 %): 
 
	  
	  
  
234	  
Analytical data for 3-fused aryl isoxazole products. 
1-(5-Methyl-3-(2-methylnaphthalene-1-yl)isoxazol-4-yl)ethanone, 3a. Oil, TLC SiO2 hexane-
DCM-EtOAc 4:1:1	  Rf 0.77.	  1H NMR (500 MHz, CDCl3) δ 7.80-7.75 (m, 2H), 7.38-7.32 (m, 4H), 
2.76 (s, 3H), 2.26 (s, 3H), 1.56 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 192.3, 175.7, 159.6, 
135.3, 132.3, 131.4, 129.5, 127.8, 126.8, 125.2, 124.0, 117.5, 28.6, 19.8, 13.6; HRMS Calc'd for 
C17H16NO2 266.1181; Found: 266.1193. 
 
Ethyl 3-(2-methylnaphthalen-1-yl)-5-methylisoxazole-4-carboxylate, 3b. Oil, TLC SiO2 
hexane-DCM-EtOAc 4:1:1	  Rf 0.6. 1H-NMR (CDCl3) d 7.826 (d, 2H); 7.25-7.398(m, 4H); 3.87 
(q, 2H); 2.841 (s, 3H); 2.303 (s, 3H); 0.651 (t, 3H). 13C NMR (125 MHz, CDCl3) δ 175.7, 161.4, 
160.7, 135.0, 132.5, 131.4, 128.9, 127.9, 127.7, 126.2, 124.8, 124.6, 124.5, 110.1, 59.9, 20.1, 
13.2, 13.0. HRMS calc'd for C18H18NO3: 296.1287; Found: 296.1297.  
 
Phenyl (5-methyl-3-(2-methylnaphthalen-1-yl)isoxazol-4-yl)methanone, 3c. Oil, TLC SiO2 
hexane-DCM-EtOAc 4:1:1	  Rf 0.79	  1H NMR (500 MHz, CDCl3): δ 7.65 (d, J = 7.90, 1H), 7.60 
(d, J = 8.50 Hz, 1H), 7.55 (d, J = 8.00 Hz, 1H), 7.37 (t, J = 6.60 Hz, 1H), 7.33 (m, 3H), 7.16 (m, 
2H), 6.94 (t, J = 8.00 Hz, 2H), 3.38 (s, 3H), 2.64 (s, 3H); 13C NMR (125 MHz, CDCl3): δ  189.8, 
173.7, 171.0, 160.3, 137.1, 135.5, 132.4, 132.3, 131.4, 129.3, 129.2, 128.1, 128.0, 127.9, 127.8, 
127.5, 125.0, 124.5, 124.4, 123.6, 117.8, 20.4, 14.0; HRMS Calc'd for C22H18NO2: 328.1338; 
Found: 328.1370.  
 
6,6-Dimethyl-3-(2-methylnaphthalen-1-yl)-6,7-dihydrobenzo[d]isoxazol-4(5H)-one 3d. Oil, 
TLC SiO2 hexane-DCM-EtOAc 4:1:1 Rf 0.71. 1H NMR (500 MHz, CDCl3) δ 7.87 (d, J = 8.3, 
1H), 7.84 (d, J = 8.3, 1H), 7.36-7.43 (m, 4H), 3.01 (s, 2H), 2.40 (d, J = 8.3, 2H), 2.31 (s, 3H), 
1.22 (s, 3H), 1.19 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 190.8, 180.9, 171.1, 157.9, 135.6, 
132.3, 131.7, 129.7, 129.6, 128.4, 128.2, 128.1, 128.0, 125.2, 125.0, 124.5, 124.3, 122.9, 52.4, 
37.0, 35.5, 28.6, 28.5, 28.1, 28.0, 21.0, 14.2. HRMS Calc'd for C20H20NO2: 306.1494; Found: 
306.1516.   
 
1-(3-(2-methoxynaphthalene-1-yl)-5-methylisoxazol-4-yl)ethanone, 3e. Oil, TLC SiO2 
hexane-DCM-EtOAc 4:1:1 Rf 0.53.  1H NMR (500 MHz, CDCl3) δ 8.01 (d, J = 9.30 Hz, 1H), 
7.84 (d, J = 7.80 Hz, 1H), 7.48 (d, J = 8.30 Hz, 1H), 7.44 (t, J = 8.30 Hz, 1H), 7.39 (d, J = 7.90 
Hz, 1H), 7.36 (d, J = 8.80 Hz, 1H), 3.90 (s, 3H), 2.81 (s, 3H), 1.76 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 193.2, 175.4, 157.7, 155.3, 133.3, 132.1, 128.7, 128.1, 127.8, 124.2, 123.9, 118.3, 
112.6, 111.4, 56.4, 28.8, 14.0. HRMS Calc'd for M+H, C17H16NO3 282.1130; Found: 282.1150 
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(M +1, 100%). Anal Calc'd for C17H15NO3: C, 72.58; H, 5.37; N, 4.98. Found: C, 71.81; H, 5.52; 
N, 4.56. 
 
Methyl 3-(2-methoxynaphthalene-1-yl)-5-methylisoxazole-4-carboxylate, 3f. Oil, TLC SiO2 
hexane-DCM-EtOAc 4:1:1 Rf 0.56. 1H NMR (500 MHz, CDCl3): δ 7.96 (d, J = 9.05 Hz, 1H), 
7.82 (d, J = 9.99 Hz, 1H), 7.55 (d, J = 9.99 Hz, 1H), 7.40 (t, J = 9.99 Hz, 1H), 7.35 (t, J = 9.99 
Hz, 2H), 3.86 (s, 3H), 3.54 (s, 3H), 2.81 (s, 3H); 13C NMR (500 MHz, CDCl3): δ 175.1, 162.1, 
158.5, 155.3, 133.0, 131.3, 128.6, 127.9, 127.0, 124.0, 123.6, 112.6, 111.4, 110.4, 56.4, 51.3, 
13.3; IR cm-1; HRMS Calc'd for C17H16NO4: 298.1079; Found 298.1111. Anal. Calc'd for 
C17H15NO4: C, 68.68; H, 5.09; N, 4.71. Found: C, 66.81; H, 5.00; N, 4.53. 
  
Ethyl 3-(2-methoxynaphthalen-1-yl)-5-methylisoxazole-4-carboxylate, 3g, as yellow solid 
(1.8 g, 60 %): mp 103-104oC; 1H NMR (500 MHz, CDCl3): δ 7.96 (d, J = 8.99 Hz, 1H), 7.81 (d, 
J = 8.07 Hz, 1H), 7.50 (d, J = 8.55 Hz, 1H), 7.39 (dd, J = 11.00, 6.84 Hz 1H), 7.34 (d, J = 9.05 
Hz, 2H), 3.96 (q, J = 7.06 Hz, 2H), 3.88 (s, 3H), 2.82 (s, 3H), 0.79 (t, J = 7.06 Hz, 3H); 13C 
NMR (125 MHz, CDCl3): δ 175.3, 161.9, 158.6, 155.3, 133.3, 131.3, 128.6, 127.9, 127.1, 124.1, 
123.7, 112.7, 111.8, 110.6, 60.1, 56.5, 13.5, 13.3; ESI-MS Calculated for C18H17NO4+H m/z 
312.1428 (M +1, 100 %). Anal Calc'd for C18H17NO4: C, 69.44; H, 5.50; N, 4.50. Found: C, 
69.58; H, 5.47; N, 4.54. 
 
Phenyl (3-(2-methoxynaphthalen-1-yl)-5-methylisoxazol-4-yl) methanone, 3h. mp 141-142 
oC; 1H NMR (500 MHz, CDCl3): δ 8.06 (d, J = 8.50, 1H), 7.73 (d, J = 8.80 Hz, 2H), 7.51 (t, J = 
8.40 Hz, 1H), 7.44 (d, J = 8.30 Hz, 2H), 7.36 (t, J = 7.55 Hz, 1H), 6.96 (t, J = 7.80 Hz, 2H), 6.90 
(d, J = 9.30  Hz, 1H), 3.61 (s, 3H), 2.69 (s, 3H); 13C NMR (125 MHz, CDCl3): δ  189.8, 173.2, 
157.8, 154.5, 137.1, 132.7, 132.4, 131.7, 128.7, 128.5, 128.0, 127.7, 127.5, 124.2, 117.6, 111.6, 
78.1 55.5, 29.7; ESI-MS for C22H17NO3+Hm/z 344.1008 (M +1, 100%).  
6,6-dimethyl-3-(2-methoxynaphthalen-1-yl)--6,7-dihydrobenzo[d]isoxazol-4(5H)-one, 3i. 
Oil, TLC SiO2 hexane-DCM-EtOAc 4:1:1 Rf 0.46. 1H NMR (500 MHz, CDCl3) δ 7.96 (d, J = 
9.1, 1H), δ 7.81 (d, J = 7.8 Hz, 1H), 7.69 (d, J = 8.6 Hz, 1H), 7.43 (dt, J = 9.8 Hz, 1.5 Hz, 1H), 
7.36 (dd, J = 6.8 Hz, 1.3 Hz, 1H), 7.34 (d, J = 9.3 Hz, 2H), 3.85 (s, 3H), 2.90 (s, 2H), 2.36 (q, J = 
14.7 Hz, 2H), 1.17 (s, 3H), 1.14 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 190.7, 180.2, 155.7, 
155.4, 132.6, 131.7, 131.6, 128.6, 128.1, 128.0, 127.9, 127.8, 127.6, 127.2, 126.9, 123.9, 123.7, 
123.4, 115.2, 112.9, 112.8, 112.6, 109.9, 56.4, 56.2, 52.3, 36.7, 35.1, 28.3, 28.0. HRMS 
Calculated for C20H20NO3 322.1443; Found: 322.1458. 
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Ethyl 3-(anthracen-9-yl)-5-methylisoxazole-4-carboxylate, 3j. mp 121-122oC; TLC SiO2 
hexane-EtOAc 10:1, Rf 0.30. 1H NMR (500 MHz, CDCl3): δ 8.58 (s, 1H), 8.05 (d, J = 8.31 Hz, 
2H), 7.65 (d, J = 8.55 Hz, 2H), 7.40-7.49 (m, 4H), 3.71 (q, J = 7.21 Hz, 2H), 2.93 (s, 3H), 0.32 
(t, J = 7.10 Hz, 3H); 13C NMR (500 MHz, CDCl3): 176.2, 161.5, 160.5, 131.0, 130.8, 128.7, 
128.5, 126.3, 125.4, 125.2, 122.7, 111.4, 60.1, 13.5, 12.8, spectral data are in accord with those 
reported previously.16a ESI-MS for C21H17NO3+H m/z 332.1441 (M +1, 100%). 
 
Ethyl 3-(10-chloroanthracen-9-yl)-5-methylisoxazole-4-carboxylate, 3k. mp 123-124oC, lit. 
mp 119-120.16b TLC SiO2 hexane-EtOAc 10:1, Rf 0.28.	  1H NMR (500 MHz, CDCl3): δ 8.59 (d, J 
= 8.80 Hz, 2H), 7.53 - 7.60 (m, 4H), 7.43 (d, J = 8.80 Hz, 2H), 3.72 (q, J = 7.1 Hz, 2H), 2.93 (s, 
3H), 0.39 (t, J = 7.1 Hz, 3H); 13C NMR (500 MHz, CDCl3): 177.3, 161.3, 161.2, 134.1, 131.1, 
128.3, 126.7, 125.9, 125.1, 122.6, 111.5, 60.2, 13.2; ESI-MS for C21H16ClNO3+H m/Z 366.0886 
(M +1, 95%). 
   
[3-(Anthracen-9-yl)-5-methylisoxazol-4-yl](pyrrolidin-1-yl)methanone, 3l. mp	   	   194-5oC.	   1H 
NMR (500 MHz, CDCl3): δ 8.54 (s, 1H), 7.99 (d, J = 9.29 Hz, 2H), 7.95 (d, J = 10.0 Hz, 2H), 
7.48-7.45 (m, 4H), 3.10 (t, J = 6.87 Hz, 2H), 2.73 (s, 3H), 2.60 (t, J = 6.61 Hz, 2H),  1.42 (pentet, 
J = 6.85 Hz, 2H), 1.29 (pentet, J = 6.60 Hz, 2H); 13C NMR (125 MHz, CDCl3): δ 170.1, 161.3, 
158.3, 131.0, 130.5, 129.4, 128.5, 126.9, 126.7, 125.8, 125.3, 125.0, 121.9, 116.5, 47.7, 45.3, 
25.6, 23.7, 12.4; ESI-MS for C23H20N2O2+H, m/z 357.0757 [M +1, (100)]. Anal Calc'd for 
C23H20N2O2: C, 77.51; H, 5.66; N, 7.86. Found: C, 77.37; H, 5.45; N, 7.99.   
 
Methyl 3-(10-bromoanthracen-9-yl)-5-methylisoxazole-4-carboxylate, 3m. Rf=0.45 
Hex:EtOAc:DCM 4:1:11H NMR (500 MHz, CDCl3): 8.63-8.60 (d,2H), 7.62-7.59 (m,4H), 7.47-
7.43 (m,2H), 3.32 (s,3H), 2.93 (s,3H). 13C NMR (125 MHz, CDCl3): 176.08, 163.32, 161.53, 
131.12, 129.90, 127.96, 126.88, 126.39, 125.60, 123.12, 51.35, 13.42. HRMS Calc'd for M+H 
C20H14NO379Br+H, m/z 396.0227; Found: 396.0235. 
	  
Laser Scanning Cytometry Methods: SNB-19 human glioblastoma cells (American Type Cell 
Culture Cat No. CRL-2266) were plated at a density of 2000 cells/mL on cover slips in RPMI 
medium (with L-glutamine and penicillin/streptomycin and supplemented with 10% fetal bovine 
serum).  Cell culture medium and supplements were obtained from VWR (West Chester, PA).  
The cells were incubated at 37 °C under a humidified atmosphere containing 5% CO2 and 
allowed to adhere. Medium was aspirated and replaced with 1 µM NSC 728558 for 24-h 
exposure. Drug was removed and cells were washed twice with phosphate buffered saline (PBS). 
	  
	  
  
237	  
Cells were fixed in 4% paraformaldehye (15 min, 21 °C) and washed once with PBS. Following 
two additional washes, slides were inverted to microscope slides and sealed using FluorSave 
Reagent (Calbiochem). Images were generated from scans from a CompuCyte iCys Laser 
Scanning Cytometer.  (CompuCyte, Westwood, MA).  Cells were scanned with a 405 nm 30 
mW Diode laser.  Fluorescent signals were measured in photo-multiplier detectors following a 
440/30 Band-pass (BP) filter to detect NSC 728558 presence.  Light absorption was also 
measured to produce a differential interference contrast (DIC)-like image for cell morphology.  
Each signal was given a pseudo-color and overlaid to produce images.   
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